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IMMUNE EVASION BY DIVISION OF LABOR:  
THE TROPHIC LIFE CYCLE STAGE OF PNEUMOCYSTIS MURINA SUPPRESSES  
INNATE IMMUNITY TO THIS OPPORTUNISTIC, FUNGAL PATHOGEN 
 
Pneumocystis species are opportunistic fungal pathogens that cause severe 
pneumonia in immunocompromised hosts, including AIDS patients. Pneumocystis 
species have a biphasic life cycle consisting of single-nucleated trophic forms and ascus-
like cysts. Both stages live within the host, and, thus, must contend with threats from the 
host immune system. The cyst cell wall β-glucans have been shown to stimulate immune 
responses in lung epithelial cells, dendritic cells and alveolar macrophages. Little is 
known about how the trophic life forms, which do not have a fungal cell wall, interact 
with immune cells. In this study, the immune response to the life cycle stages of 
Pneumocystis murina was evaluated. 
Here, we report differences in the immune response of immunocompetent mice to 
the trophic and cystic life cycle stages of P. murina. Upon infection with purified trophic 
forms, wild-type adult mice developed a delayed innate and adaptive immune response 
compared to inoculation with the normal mixture of trophic forms and cysts. Cysts, but 
not trophic forms, stimulated Th1-type responses in the lungs of infected mice. 
Surprisingly, trophic forms are sufficient to generate protective adaptive 
responses, leading to clearance in immunocompetent mice. We report that CD4+ T cells 
primed in the presence of trophic forms are sufficient to mediate clearance of trophic 
forms and cysts. In addition, primary infection with trophic forms is sufficient to prime B 
cell memory responses capable of clearing a secondary infection with Pneumocystis 
following CD4+ T cell depletion. While trophic forms are sufficient for initiation of 
adaptive immune responses in immunocompetent mice, infection of 
immunocompromised RAG2-/- mice with trophic forms in the absence of cysts does not 
lead to the severe weight loss and infiltration of innate immune cells associated with the 
development of Pneumocystis pneumonia. 
Dendritic cells screen the alveolar spaces for pathogens, and are in a prime 
position to initiate the immune response against lung pathogens, including Pneumocystis. 
Our data demonstrate that trophic forms broadly dampen the ability of dendritic cells to 
respond to pathogen-associated molecular patterns. Bone marrow-derived dendritic cells 
were stimulated with trophic forms, a mixture of trophic forms and cysts, and various 
 
 
other inflammatory materials, including β-glucan. Trophic forms inhibited multiple 
components involved in antigen presentation by dendritic cells, including secretion of 
inflammatory cytokines and expression of MHC class II and costimulatory molecules on 
the cell surface. Furthermore, trophic forms suppressed or failed to induce the expression 
of multiple genes related to activation and maturation in dendritic cells. Dendritic cells 
silenced by trophic forms are unable to induce CD4+ T cell responses. These data suggest 
that immune evasion by trophic forms is dependent on the suppression of innate 
responses, and the development of adaptive immunity represents a “point of no return” at 
which the trophic forms are no longer able to escape clearance. 
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Chapter 1: Introduction 
 
I. Overview 
Pneumocystis species are opportunistic fungal pathogens that cause severe 
pneumonia in immunocompromised hosts, including HIV/AIDS patients. Clearance of 
Pneumocystis organisms is dependent on effective CD4+ T cell, B cell and macrophage 
responses (1-4). Failure to clear Pneumocystis organisms leads to severe alveolar damage 
due to an exaggerated inflammatory immune response (5). In spite of a reduced incidence 
of Pneumocystis pneumonia (PcP) in HIV-infected individuals due to improved highly 
active antiretroviral therapy (HAART), the mortality rate for patients with PcP has not 
improved (6). Additional studies are required to inform novel approaches to reduce 
morbidity and mortality due to Pneumocystis pneumonia. 
Outbreaks of PcP were first described in malnourished or premature infants in 
orphanages following the second world war (7). Evidence suggests that 
immunocompetent individuals of all ages are capable of mounting protective immune 
responses to Pneumocystis jirovecii that prevent progression to pneumonia. Most children 
encounter this opportunistic fungus at a young age, as indicated by the presence of 
specific antibodies in the serum of 85% of individuals by three years of age (8). Previous 
work from our lab has shown that the neonatal mouse immune response to Pneumocystis 
murina is delayed due in part to an anti-inflammatory lung environment (9-12). The 
neonatal lung environment is characterized by anti-inflammatory mediators, including 
transforming growth factor beta 1 (TGF-β1) and interleukin-10 (IL-10), and immature 
immune cells (9-12). Neonatal alveolar macrophages and T cells adoptively transferred to 
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an adult lung environment are competent to resolve P. murina pneumonia in mice (9, 12). 
In addition, neonatal alveolar macrophages are deficient in nuclear factor kappa B (NF-
κB) translocation following stimulation with Pneumocystis organisms (9). Neonatal 
alveolar CD11c+ cells demonstrate delayed trafficking to the draining lymph nodes (11). 
Together, these data indicate that both the neonatal lung environment and intrinsic 
immune cell deficits contribute to the delayed clearance of P. murina in neonatal mice. 
Pneumocystis species have a biphasic life cycle (Fig 1.1 and Fig 1.2). Trophic 
forms are proposed to undergo asexual reproduction, whereas cysts are formed by sexual 
reproduction (13). Trophic forms are single-nucleated organisms that are typically found 
in clusters surrounded by a biofilm-like substance consisting of a conglomeration of 
DNA, β-glucan, and other sugars (14). Cysts are ascus-like structures that consist of 
multiple nuclei surrounded by a fungal cell wall. β-1,3 glucan and β-1,6 glucan serve as 
the structural components of the cyst wall (15, 16). β-glucan is not detected on the 
surface of trophic forms (15, 17). Both stages express surface glycoproteins and 
mannoproteins that may serve as pathogen-associated molecular patterns (PAMPs) that 
could interact with receptors on phagocytic cells (18-20). Neither life form produces the 
classical fungal components ergosterol, chitin or α-glucans (21, 22). 
Dendritic cells are the principal antigen presenting cells in the lung. However, their 
role in initiating the adaptive response to Pneumocystis species has been understudied. 
Previous work has demonstrated that dendritic cells respond to β-glucans derived from 
the Pneumocystis cell wall (23). Dendritic cells activated by Pneumocystis cell wall-
derived β-glucans increase costimulatory molecule expression and drive T cell 
polarization towards a T helper 1 (Th1) -type response, as characterized by the production 
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of the proinflammatory cytokine interferon gamma (IFNγ) (23). The mechanism for 
dendritic cell recognition of Pneumocystis trophic forms, which do not express β-glucans, 
is unknown. 
An improved understanding of innate immune interactions with the cystic and 
trophic life cycle stages has the potential to inform future treatment of Pneumocystis 
pneumonia. Recently, it was reported that treatment of mice with the β-1,3-D-glucan 
synthase inhibitor anidulafungin resulted in depletion of P. murina cysts (24). The mice 
were able to control the remaining trophic burden in the absence of an excessive 
inflammatory response, however, the details of how trophic forms are recognized and 
cleared are not known. 
This dissertation examines the role of the life cycle stages of P. murina in shaping 
the immune response to this fungal pathogen. The work herein demonstrates that 
infection with the cyst stage provokes proinflammatory immune responses, including the 
early recruitment of innate and effector immune cells into the lungs. Conversely, the 
trophic life cycle stage inhibits critical components of the dendritic cell response to 
infection, including cytokine expression, proinflammatory signaling, and antigen 
presentation. The rapid establishment of a trophic population may be critical for this 
fungal pathogen to avoid preemptive clearance of the transmitted cyst stage. 
 
II. Populations at risk 
Severely immunocompromised patients are at risk for Pneumocystis infection that 
progresses to pneumonia. The history of Pneumocystis is closely tied to the expansion of 
susceptible populations in the past century. Early observations by Carlos Chagas in 1909 
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and by Antonio Carini in 1910 identified the cyst stage of Pneumocystis in association 
with Trypanosoma species ((25, 26), reviewed in (27)). The organisms were recognized 
as a separate species, Pneumocystis carini, by Pierre and Mme Delanoë in 1912 (27, 28). 
However, Pneumocystis was not associated with human disease until 1942, when M.G. 
van der Meer and S.L. Brug identified the organism in two infants and one young adult 
(27, 29). In 1951, Josef Vanek demonstrated that Pneumocystis was the causative agent 
of an epidemic of interstitial plasma cell pneumonia in preterm or malnourished infants in 
orphanages (27, 30). Otto Jírovec reported additional cases of PcP in neonates in 1952 
(27, 31). Sporadic reports of PcP followed, including a handful of cases in the United 
States in the 1950s (7). The disease was most commonly associated with premature, 
malnourished, or otherwise immunocompromised infants 6 weeks to 4 months of age (7). 
The development of chemotherapy and immunosuppressive drug treatments 
expanded the populations at risk for PcP. Long-term cortisone therapy has been reported 
in association with PcP since the 1960s (32). A report from 1968 in which an adult male 
who had received radiotherapy, cytotoxic agents, and steroids for chronic lymphatic 
leukemia was diagnosed with PcP illustrates the potential complexity of such cases (33). 
Early surveys of infection in bone marrow transplant patients identified Pneumocystis as 
an organism of concern (34). 
Pneumocystis continued to be a sporadic cause of disease in severely 
immunocompromised patients through the 1970s. However, in the early 1980s, an 
increase in the incidence of PcP in young, homosexual men alarmed the medical 
community (35). The HIV/AIDS epidemic resulted in a new pool of 
immunocompromised patients susceptible to PcP. The development of HAART has 
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significantly reduced the incidence of PcP in HIV patients. A dramatic 80% reduction in 
the incidence of PcP among HIV/AIDS patients in the United States and Canada was 
observed from 2004 to 2010 (36). These improvements are attributed to improved 
management of HIV/AIDS with HAART, including improved CD4+ T cell counts and 
lower viral titer (36). Despite improved management of HIV/AIDS, P. jirovecii remains 
the most common opportunistic infection associated with the disease (36). The risk 
remains significant among individuals who are unaware of their HIV-positive status or 
lack access to HAART (36). 
The development of novel immunosuppressive therapies continues to expand the 
range of populations at risk for PcP. The rise of the use of biologics in the treatment of 
cancer and autoimmune disease has been associated with increased risk of PcP. Examples 
include anti-CD20 antibody therapy for non-Hodgkin’s lymphoma (37, 38), and anti-
tumor necrosis factor alpha (TNFα) antibody therapy for rheumatoid arthritis (39) or 
Crohn’s disease (40). 
P. jirovecii may serve as a co-factor in other diseases. Colonization has been 
correlated with chronic obstructive pulmonary disease (COPD) (41, 42). It has been 
proposed that Pneumocystis may fuel lung inflammation, including recruitment of Th1 T 
cells (43), and promote the progression of COPD (44). The presence of Pneumocystis 
organisms has also been correlated with sudden infant death syndrome (SIDS) in some 
studies (45, 46). However, the correlation does not appear to be absolute, and it is 
unlikely that P. jirovecii is a direct cause of SIDS (47). Rather, colonization may 
contribute to SIDS by promoting excess mucus production in the lungs of infants (48). 
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Mortality due to PcP may range from as low as 10-20% in mild-to-moderate cases 
(49) to 65% in patients requiring artificial ventilation (50). Factors associated with death 
due to PcP include older age of the patient, time to diagnosis, and the need for oxygen 
therapy or invasive mechanical ventilation (51). The death rate in patients with AIDS 
diagnosis or solid organ transplant is lower than that of patients with other immune 
deficiencies (51). This may be partially attributed to a decreased time to diagnosis in 
these patients (51). 
 
III. Pneumocystis biology 
Pneumocystis species are members of the fungal phylum Ascomycota. The genus 
was originally described as a single species, Pneumocystis carinii. However, the 
discovery that individual host species were infected with unique species of Pneumocystis 
promoted changes in the taxonomy (52). The name Pneumocystis carinii is now reserved 
for one of the two species that infects rats. The human pathogen was renamed 
Pneumocystis jirovecii, while the species that infects mice was named Pneumocystis 
murina (52-54). Additional Pneumocystis species have been identified in host species as 
diverse as rabbits (P. oryctolagi), dogs, horses, bats, and chickens (55-59). While a single 
host species may be infected with multiple species of Pneumocystis (see P. carinii and P. 
wakefieldiae in rats), a given Pneumocystis species does not infect multiple host species 
(60, 61). 
The factors that determine the strict host restrictions of Pneumocystis species are 
unknown. However, recent genome analysis of P. jirovecii, P. carinii, and P. murina 
suggest that these species evolved in close association with their respective hosts (21). 
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The sizes of the genomes were remarkably reduced compared to other extracellular fungi, 
with notable losses in ribosomal RNA genes, transcription factors, nutrient transporters, 
and metabolic pathways. Conversely, the number of genes encoding peptidases is 
expanded in Pneumocystis species compared to related fungi, and the genes encoding 
proteins related to endocytosis and the proteasome are preserved. These data suggest that 
Pneumocystis species have made significant adaptations to acquire nutrients from their 
respective hosts. 
Pneumocystis species have a biphasic life cycle consisting of trophic forms and 
cysts (Fig 1.1, Fig 1.2 and reviewed in (62)). The trophic forms were formerly known as 
trophozoites, with the newer name reflecting their fungal, rather than protozoan identity. 
Trophic forms are single-nucleated organisms that may replicate asexually by binary 
fission. Trophic forms are also proposed to undergo conjugation to form a diploid pre-
cyst (or sporocyte), which then undergoes multiple rounds of sexual reproduction to form 
the cyst life cycle stage. Comparative genomics suggest sexual reproduction in 
Pneumocystis involves a single mating type (primary homothallism) rather that multiple 
mating types (heterothallism) or mating type switching (secondary homothallism) (63).  
Trophic forms may be found in clusters surrounded by a biofilm-like substance 
consisting of a conglomeration of DNA, β-glucan, and other sugars (14). It has been 
proposed that previously-lysed cysts provided the bulk of this biofilm-like substance. 
Trophic forms lack a fungal cell wall, and do not express β-glucan (15). Ultrastructural 
studies revealed that the trophic forms tightly adhere to the luminal surface of alveolar 
epithelial cells via microprotusions or invaginations of the trophic plasma membrane 
(64). Attachment is mediated by host cell fibronectin and other extracellular matrix 
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components, and does not involve fusion of host-Pneumocystis cell membranes or 
invasion of the host cell (64-66). 
The cyst stage of the species is more properly termed an ascus; however, this 
nomenclature is not yet the norm within the field. A mature cyst contains eight daughter 
spores, which are believed to develop into trophic forms upon lysis of the cysts. The cyst 
is surrounded by a fungal cell wall, with β-1,3 glucan and β-1,6 glucan serving as the 
major structural components (15, 16). Recent evidence indicates that cysts are the 
transmittable life cycle stage of Pneumocystis species (17). 
Both the trophic forms and cysts express surface glycoproteins and mannoproteins 
that may serve as PAMPs that could interact with receptors on phagocytic cells (18-20). 
Ten antigenic glycoproteins common to both lifeforms were identified in the cell wall 
fractions of P. carinii trophic forms and cysts separated by counterflow centrifugal 
elutriation and sequential microfiltration (20). Gas chromatography-mass spectrometry 
(GC-MS) demonstrated that all ten glycoproteins contained some degree of mannose, 
glucose, galactose, and N-acetylglucosamine (GlcNAc), while some contained traces of 
fucose. As a whole, the glycoproteins on the cysts contained more mannose, while the 
trophic glycoproteins contained more xylose. 
Neither life cycle stage produces the classical fungal components ergosterol, chitin 
or α-glucans (21, 22). While capable of de novo cholesterol synthesis, Pneumocystis 
species also use cholesterol scavenged from the host cell (67). It has recently been 
demonstrated that Pneumocystis species lack the enzymes required for the addition of 
outer chain N-mannans to the N- and O-linked glycan core structure (21). Tandem mass 
spectrometry confirmed that Pneumocystis cell wall proteins were glycosylated with 
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chains of mannose no longer than nine residues, with the majority comprised of six 
residues (21). Hyper-mannosylation is required for optimal C-type lectin receptor 
recognition of C. albicans, prompting Ma, et al. to propose that the lack of outer chain N-
mannans may permit Pneumocystis organisms to escape detection by the immune system 
(21, 68, 69). 
Transmission of Pneumocystis species occurs by the airborne route (70). It was 
initially hypothesized that suppression of the immune system would permit reactivation 
of a latent, subclinical infection in previously healthy adults. However, more recent 
evidence suggests that transient, subclinical infections in healthy hosts serve as a 
reservoir for Pneumocystis organisms that may be transmitted to susceptible 
immunocompromised hosts. Immunocompetent adult mice cohoused with P. murina-
infected severe combined immunodeficiency (SCID) mice develop a subclinical infection 
that resolves in 5 to 6 weeks (71). Studies in mice infected with P. murina demonstrated 
that a healthy host may transmit the organisms to both healthy and immunocompromised 
hosts (72-74). 
Clusters of PcP cases have been observed in both inpatient and outpatient facilities 
caring for immunocompromised patients. Several studies suggest nosocomial 
transmission of P. jirovecii in outbreaks of PcP in kidney transplant recipients (reviewed 
in (75)). Such outbreaks were often caused by a predominant or a single Pneumocystis 
strain, as confirmed by genotyping by comparison of the internal transcribed spacer (ITS) 
regions 1 and 2 or by multilocus sequence typing (MLST). The genotypes of reference 
samples were different that the strains associated with such outbreaks. One such cluster 
was identified at a nephrology outpatient clinic in which transplant patients shared a 
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common waiting room, suggesting that minimal patient-to-patient contact is sufficient for 
transmission (76).  
Exposure to P. jirovecii appears to be extremely common, with the first encounter 
occurring early in life. In a study of 74 healthy Chilean infants, P. jirovecii DNA was 
detected in the nasopharyngeal aspirates of 32% of the participants, and seroconversion 
developed in 85% of the infants by 20 months of age (77). Genotyping of P. jirovecii has 
demonstrated that the organisms may be transmitted from healthy, colonized caretakers to 
infants (78). Such evidence suggests that healthy hosts may serve as an infectious 
reservoir in the community. An environmental reservoir has not yet been identified. The 
severely constricted genome of Pneumocystis, as well as the lack of interspecies 
transmission, suggest that replication of P. jirovecii outside of the human host is unlikely. 
 
IV. Treatment of Pneumocystis jirovecii infection 
The first choice treatment for PcP is trimethoprim-sulphamethoxazole (TMP-SMX) 
(79, 80). Unfortunately, allergic responses to the sulfa component or other adverse effects 
may demand the use of alternative therapies (80). Pentamidine is a second-line therapy 
for severe PcP, but may also have serious side effects, including nephrotoxicity. 
Clindamycin in combination with primaquine or trimethoprim with dapsone are used as 
alternative therapies in patients who are unable to tolerate TMP-SMX and/or pentamidine 
(79). Atovaquone may also be used to treat less severe cases of PcP (79). Corticosteroids 
are given in addition to antifungals to reduce the damage due to lung inflammation in 
moderate to severe cases of PcP (79). Pneumocystis species do not produce ergosterols, 
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therefore, drugs that interfere with ergosterol synthesis, including azole antifungals, are 
not effective (22). 
Prophylaxis for PcP is recommended for HIV/AIDS patients with fewer than 200 
CD4+ T cells/µL or patients with oropharyngeal candidiasis (20, 80). TMP-SMX is the 
preferred prophylactic agent for PcP, and provides additional protection against 
toxoplasmosis and certain bacterial infections (80, 81). Dapsone or atovaquone may be 
used in patients who are unable to tolerate TMP-SMX, including those with sulfa allergy 
(20, 80). Prophylaxis may be discontinued in patients receiving HAART if their viral 
load is below the limit of detection and their CD4+ T cell count is greater than 200 
cells/µL for more than three months (80). Prophylaxis is also recommended for certain 
patients with cancer (including acute lymphocytic leukemia), patients with certain 
primary immunodeficiency, patients undergoing prolonged or strong glucocorticoid 
usage, and patients undergoing solid organ transplant or hematopoietic stem cell 
transplant (82). 
Recently, it was reported that treatment of immune-reconstituted mice with the β-
1,3-D-glucan synthase inhibitor anidulafungin results in depletion of Pneumocystis 
murina cysts, and the remaining trophic burden stimulate a much reduced inflammatory 
response (24). Anidulafungin belongs to a drug class known as the echinocandins, which 
have been used in combination with other antifungals, including TMP-SMX, in the 
treatment of PcP in human patients (83). Linke et al., propose that depletion of 
Pneumocystis cysts by echinocandins would reduce inflammation-induced lung damage 
in patients, especially in patients undergoing immune-reconstitution syndrome (24). 
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V. Host response to Pneumocystis 
A. Immune response in immunocompetent hosts 
The diverse range of immunocompromised states associated with the development 
of PcP illustrate the range of immune processes that are critical for the clearance of 
Pneumocystis. The clearance of the normal mixture of Pneumocystis organisms (i.e., 
trophic forms and cysts) from the lungs requires the participation of innate and adaptive 
immune cells, including macrophages, CD4+ T cells, and B cells (1-4). The alveolar 
epithelium provides a thin barrier for gas exchange between the lung alveoli and lung 
capillaries. The lung immune response to infection must be carefully controlled to avoid 
excessive thickening of the epithelium due to inflammation, edema, and recruitment of 
immune cells. 
 
i. Dendritic cells 
Dendritic cells are the principal antigen presenting cells in the lung, and are critical 
for optimal B cell and T cell activation in response to pathogens (reviewed in (84)). 
Immature lung dendritic cells reside in the alveolar interstitium, where they project their 
dendritic extensions through the epithelial-tight junctions into the alveolar spaces. 
Encounters with antigen promote a complex maturation process that prepares the 
dendritic cell to serve as an antigen-presenting cell. Unlike macrophages, which remain 
in the periphery in response to infection, activated dendritic cells migrate to the draining 
lymph nodes to present antigen to lymphocytes. The involvement of dendritic cells is 
critical to the recruitment of T and B cells into the airway lumen, particularly as these 
spaces are largely free of lymphocytes prior to infection.  
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While the interaction between dendritic cells and Pneumocystis organisms has been 
understudied, the scarce pertinent publications suggest a complex and unusual 
relationship. Macagno et al. found that human monocyte-derived dendritic cells 
stimulated in vitro with a ratio of two P. carinii organisms per DC failed to increase 
surface expression of the activation marker CD83, and only minimally increased 
expression of MHC class II, CD40, CD80 and CD86 compared to cells stimulated with 
lipopolysaccharide (LPS) (85). However, the authors suggest that the DCs were sensitive 
to P. carinii, as they observed aggregation of the DCs during co-culture. These data 
prompted the authors to speculate that Pneumocystis organisms may actively suppress the 
maturation process of DCs, and other host-derived factors, particularly cytokines, may be 
critical for the activation of DCs during infection. 
Kobayashi et al. demonstrated that phagocytosis of a mixed population of P. murina 
organisms by murine bone marrow-derived dendritic cells (BMDCs) was partially 
inhibited by the addition of mannan, implying that mannose-binding C-type lectin 
receptors such as mannose receptor or dectin-2 may recognize Pneumocystis organisms 
(86). Co-culture of murine BMDCs with a ratio of 10 P. murina organisms per BMDC 
failed to induce various markers of activation, including production of proinflammatory 
cytokines (IL-12p40, TNFα, IL-6) and surface expression of major histocompatibility 
(MHC) class II, CD40, CD54, CD80, and CD86 (86). P. murina-pulsed BMDCs were 
sufficient to induce P. murina-specific proliferation of CD4+ T cells in vitro (86). For this 
experiment, Zheng et al. employed CD4+ T cells isolated from the spleens of mice treated 
3 days prior with P. murina-pulsed BMDCs (86). Likewise, P. murina-pulsed BMDCs 
promoted production of P. murina-specific immunoglobulin G (IgG) in vivo (86, 87). 
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Despite suboptimal activation, dendritic cells stimulated with a mixture of P. murina 
trophic forms and cysts appear to serve as effective antigen-presenting cells to CD4+ T 
cells and B cells. 
While stimulation with a mixed population of intact Pneumocystis organisms 
appears to poorly stimulate dendritic cell responses, Carmona et al. demonstrated that 
human dendritic cells respond strongly to β-glucans derived from the Pneumocystis cyst 
cell wall (23, 88). DCs activated by cyst cell wall-derived β-glucans display increased 
costimulatory molecule expression (CD40, CD80, CD86) and drive T cell polarization 
towards a Th1/Th17-type response (23, 88). In addition, the DCs express CCR7, a 
chemokine receptor that directs migration to the draining lymph nodes (23). Intriguingly, 
human dendritic cells stimulated with Pneumocystis β-glucans produce the 
proinflammatory cytokines TNFα and IL-1β (23). The mechanism for dendritic cell 
recognition of Pneumocystis trophic forms, which do not express β-glucans, is unknown. 
 
ii. Macrophages 
Alveolar macrophages are the primary phagocyte involved in the clearance of 
Pneumocystis organisms. Alveolar macrophages bind Pneumocystis organisms in vitro, 
and traffic the fungi to the phagolysosomes for degradation (2, 89-91). Alveolar 
macrophages phagocytose Pneumocystis organisms using pattern recognition receptors 
(PRRs) including mannose receptor and the β-glucan receptor dectin-1(92, 93). 
Opsonized organisms may be also be phagocytosed by the receptors FcγRII and FcγRIII 
(93).  
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The role of reactive oxygen species in the killing of Pneumocystis organisms is 
unclear. Rat alveolar macrophages stimulated with P. carinii release NO2- and H2O2 in 
vitro (94, 95). H2O2 appears to be partially responsible for the killing of Pneumocystis 
within the phagosome (93). However, Pneumocystis organisms may have mechanisms for 
evasion of direct killing by reactive oxygen species, as stimulation with the fungus 
impairs the dimerization (and thus the activation) of iNOS (96). 
In addition to direct killing of Pneumocystis organisms, alveolar macrophages also 
contribute to the inflammatory environment of the lungs by releasing proinflammatory 
cytokines to promote adaptive responses. Recognition of Pneumocystis organisms by 
human alveolar macrophages triggers the production of proinflammatory cytokines 
associated with classically activated macrophages, including IL-1β, IL-6, IL-8 and TNF-α 
(97, 98). However, a proportion of macrophages in the lungs of mice infected with P. 
murina display characteristics of alternatively activated cells, including increased 
expression of mannose receptor, CD23, CCR7, and arginase (99). Polarization of 
macrophages towards the alternatively activated phenotype results in improved clearance 
of Pneumocystis organisms and decreased immunopathogenesis (100, 101). 
Alveolar macrophages are not sufficient for clearance of Pneumocystis in the 
absence of T helper cells (102). Intriguingly, Pneumocystis infection promotes expression 
of reactive oxygen species and the proinflammatory cytokines interferon gamma (IFNγ), 
TNFα, and IL-12 in the lungs of T cell-deficient mice (102). This suggests that alveolar 
macrophages may be dependent on additional cues from CD4+ T cells to mediate 
clearance of Pneumocystis. 
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iii. Alveolar epithelial cells 
Alveolar epithelial cells, or pneumocytes, compose a thin barrier between the 
alveolar lumen and lung capillaries. The integrity of this barrier is essential to effective 
gas exchange. Pneumocystis trophic forms bind intimately to type I alveolar epithelial 
cells (64). This interaction is a risky endeavor for the trophic forms, as alveolar epithelial 
cells are capable of producing proinflammatory cytokines. Rat alveolar epithelial cells 
stimulated with Pneumocystis cell wall β-glucans produce macrophage inflammatory 
protein-2 (MIP2) and TNFα (103-105). Alveolar epithelial cells do not express the β-
glucan receptor dectin-1. Rather, the production of cytokines in response to Pneumocystis 
β-glucan is dependent on NF-κB-dependent signaling pathways initiated by 
glycosphingolipids (105). Further work demonstrated that human airway epithelial cells 
stimulated with Pneumocystis cell wall β-glucans produce IL-8 in glycosphingolipid-
dependent mechanism triggered by an increase in calcium influx (106).  
Stimulation of human alveolar epithelial cells with mixed Pneumocystis organisms 
also induces expression of the proinflammatory cytokine IL-6 (107). Surprisingly, pre-
incubation of the cells with IL-6 promoted the production of fibronectin, and led to 
increased Pneumocystis attachment (107). These data suggest that trophic forms may 
manipulate the immune response with alveolar epithelial cells to promote fungal growth. 
 
iv. T lymphocytes 
The susceptibility of HIV/AIDS patients to PcP highlights the critical role of CD4+ 
T cells in the immune response to this fungus. A CD4+ T cell count below 200 cells/µl is 
associated with an increased risk for PcP in this population (20). Transfer of CD4+ T cells 
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from P. murina infected immunocompetent mice into SCID mice is sufficient to mediate 
clearance of infection (108). Effective costimulation of CD4+ T cells is required for 
control of Pneumocystis infection, as loss of CD40 ligand or the costimulatory receptor 
CD28 results in acute infection in mice (109, 110). While Th17 responses are critical for 
control of many fungal infections, including candidemia, a mixed T helper response is 
observed in response to Pneumocystis infection. This mixed response appears to be 
largely redundant, as Th1-, Th2-, and Th17-type responses have all been associated with 
clearance of P. murina organisms (24, 111-115).  
The role of CD8+ T cells in the response to Pneumocystis is less clear. In the 
immune reconstitution model, depletion of CD8+ T cells did not hinder clearance of 
Pneumocystis infection, but instead led to a prolonged CD4+ T cell response with an 
increased frequency of Th1 CD4+ T cells compared to the untreated, infected controls 
(116). In contrast, transfer of CD8+ T cells from P. murina infected immunocompetent 
mice into immunocompromised mice led to increased lung damage rather than control of 
infection (116, 117). These negative inflammatory effects are associated with CD8+ T 
cell-dependent TNFα-mediated effects on lung parenchyma cells (117, 118). In contrast, 
IFNγ production by CD8+ T cells is associated with protective responses against 
Pneumocystis (119). While CD8+ T cells are not normally sufficient to mediate clearance 
of infection, overexpression of IFNγ in the lungs of mice depleted of CD4+ T cells led to 
clearance of P. murina organisms and increased proliferation of IFNγ-expressing CD8+ T 
cells (119). 
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v. B lymphocytes 
B cells are required for the clearance of Pneumocystis organisms (3, 4). B cells are 
capable of playing multiple roles within the immune response, including antigen-
presentation to T cells and production of antibody and proinflammatory cytokines. The 
immune response to Pneumocystis incorporates each of these functions to a varying 
degree of importance. 
Antibody-mediated opsonization enhances phagocytosis of Pneumocystis organisms 
by alveolar macrophages, and mediates clearance of Pneumocystis organisms in vivo (3, 
93, 112, 120). Clearance is delayed in the absence of antibody class switching, indicating 
that P. murina-specific IgG enhances, but is not required for, control of Pneumocystis 
infection (3). In the absence of CD4+ T cells, a memory humoral response is sufficient to 
clear Pneumocystis organisms during a secondary infection (121, 122). This response 
requires the participation of CD8+ T cells and alveolar macrophages, which phagocytose 
antibody-coated organisms (122). P. murina-specific antibody composed of isotypes 
produced by either Th1- or Th2-like responses are sufficient for mediating clearance of 
secondary infection (IgG1 or IgG2a/IgG2b/IgG3, respectively) (112). 
B cells are required for the generation of protective effector and memory CD4+ T 
cell responses to Pneumocystis (3, 123, 124). B cells expressing both MHC class II and 
Pneumocystis-specific B cell receptor are required for effective priming of CD4+ T cells 
and clearance of Pneumocystis infection (123, 124). Production of TNFα by B cells in the 
draining lymph nodes is essential for CD4+ T cell expansion and clearance of P. murina, 
and anti-TNFα therapy for rheumatoid arthritis and Crohn’s disease is associated with an 
increased risk for PcP (39, 40, 125). 
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It has recently become apparent that B cells participate in the suppression of 
systemic inflammation due to Pneumocystis infection in the lungs (126). In the absence 
of type I interferon signaling and B cells, systemic inflammation due to Pneumocystis 
infection in the lungs leads to bone marrow failure due to increased turnover of maturing 
cells and decreased bone marrow progenitor function (126). The protective contribution 
of B cells is mediated in part by the expression of IL-10 and IL-27 (126). Increased 
systemic inflammation and bone marrow dysfunction has been observed in patients with 
chronic pulmonary diseases and HIV/AIDS (127-130). Hoyt et al propose that 
Pneumocystis infection may be a comorbidity factor for damage due to systemic 
inflammation in these patients, particularly as these populations are at an increased risk 
for PcP (126). 
 
vi. Summary of protective responses in immunocompetent hosts 
Dendritic cells, macrophages, and alveolar epithelial cells serve as early sentinels of 
Pneumocystis infection. Upon encountering antigen, dendritic cells undergo maturation 
and travel to the draining lymph nodes to present antigen to lymphocytes. CD4+ T cells 
and B cells are recruited to the lungs, where they may serve as helper cells that direct the 
killing of Pneumocystis by other immune cells, including macrophages. However, the 
exact mechanisms of macrophage killing of Pneumocystis organisms are unclear. 
 
B. Neonatal response to Pneumocystis 
While malnourished, premature, or otherwise immunocompromised infants are at 
risk for PcP, evidence suggests that immunocompetent individuals of all ages are capable 
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of mounting protective immune responses to Pneumocystis jirovecii. However, the 
neonatal immune response to Pneumocystis is delayed during the first three weeks of 
infection (9-12).  
The delayed clearance of P. murina in neonatal mice may be partially attributed to 
the tolerogenic phenotype of the neonatal lung. The neonatal lung environment is 
characterized by decreased expression of granulocyte-macrophage colony-stimulating 
factor (GM-CSF) and increased expression of anti-inflammatory mediators, including 
TGF-β-1 and IL-10, and immature immune cells (9-12, 131). Neonatal alveolar 
macrophages and T cells adoptively transferred into the immunogenic environment of 
adult lungs are competent to resolve P. murina infection without delayed kinetics (9, 12). 
Treatment of neonatal mice with exogenous GM-CSF and IL-4 promotes enhanced 
clearance of Pneumocystis organisms amidst increased expression of proinflammatory 
cytokines in the lungs (131). 
The immature phenotype of neonatal immune cells also contributes to delayed 
immune responses to Pneumocystis infection compared to adults. Ex vivo experiments 
demonstrate that neonatal alveolar macrophages are deficient in NF-κB translocation 
following stimulation with Pneumocystis organisms (9). In addition, neonatal alveolar 
CD11c+ cells demonstrate delayed trafficking to the draining lymph nodes (11). 
Together, these data indicate that both the neonatal lung environment and intrinsic 
immune cell deficits contribute to the delayed clearance of P. murina in neonatal mice. 
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C. Immunopathogenesis due to Pneumocystis 
Pneumocystis infection causes asymptomatic or subclinical infections in healthy 
hosts. The severely reduced genome of Pneumocystis species and the lack of an 
environmental reservoir strongly suggest that the organisms have evolved to live as 
obligate commensals within the healthy host (21).  
It is possible that Pneumocystis organisms contribute to mild damage to the 
structure of the alveoli, as binding of Pneumocystis carinii organisms to type I alveolar 
epithelial cells leads to cell necrosis and increased permeability of the alveolar-capillary 
membrane (132). However, the bulk of the lung damage that occurs during PcP is 
associated with rampant, non-productive inflammation in immunocompromised hosts 
(133, 134). Severe lung damage during PcP is more closely correlated with inflammation 
and increased recruitment and proliferation of immune cells within the lungs, rather than 
the fungal burden (5, 134, 135). The recruitment of neutrophils is correlated with a poor 
prognosis in humans with PcP (134, 136, 137), but animal studies suggest neither 
neutrophils nor reactive oxygen species directly cause lung damage (138). Rather, 
damage appears to be strongly related to the adaptive immune response, especially CD8+ 
T cells (134, 135). Respiratory impairment is attributed to direct damage to the alveoli, as 
well as impaired gas exchange due to accumulation of immune cells in the alveolar 
spaces. Fungal growth can contribute to impaired gas exchange in the later stages of PcP, 
especially in mice that lack adaptive immune cells (139). 
Myeloid-derived suppressor cells (MDSCs) accumulate in the alveolar spaces of 
immunocompromised mice and rats with PcP (140). Recent evidence suggests that 
MDSCs may contribute to pathogenesis and impede fungal clearance by suppressing key 
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effector cells. MDSCs isolated from the lungs of immunocompromised rodents with PcP 
suppress CD4+ T cell proliferation ex vivo (140). Alveolar macrophages co-cultured with 
MDSCs from mice with PcP exhibited reduced phagocytic capacity (141). In addition, 
MDSCs may directly contribute to lung injury, as adoptive transfer of MDSCs from 
rodents with PcP to healthy hosts resulted in increased lung albumin and lactate 
dehydrogenase (LDH) (140). 
The restoration of the immune system in previously immunocompromised patients 
increases the risk for lung damage due to PcP. Bone marrow transplant patients are at 
increased risk for PcP following engraftment and the restoration of the inflammatory 
capacity of immune cells (142). Initiation of HAART in HIV/AIDs patients may provoke 
an overexuberant return of inflammatory responses, known as immune reconstitution 
inflammatory syndrome (IRIS). IRIS increases the risk for lung damage associated with 
PcP, and is associated with a population of rapidly expanding CD8+ T cells (135). 
Corticosteroids are given in addition to antifungals to reduce the damage due to lung 
inflammation in moderate to severe cases of PcP (79). 
 
D. Recognition of fungal pathogens by the immune system 
i. Role of PRR and PAMPs in fungal immunity 
Pattern recognition receptors (PRRs) expressed by cells of the innate immune 
system are responsible for detecting pathogen-associated molecular patterns (PAMPs) 
and initiating anti-microbial mechanisms including phagocytosis, production of reactive 
oxygen species, and the release of inflammatory cytokines. Conserved fungal cell wall 
PAMPs include β-glucans, α-glucans, chitin, and mannoproteins. The major classes of 
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pattern recognition receptors involved in recognition of fungal pathogens include the toll-
like receptors (TLR), the C-type lectin receptors (CLR), and Nod-like receptors (NLR) 
(143). Toll-like receptors are type I transmembrane proteins with cytosolic Toll-IL-1 
receptor (TIR) domains that trigger downstream signaling cascades (144). TLR1, TLR2, 
TLR4 and TLR6 are commonly implicated in the response to fungal pathogens, including 
Candida albicans, Aspergillus fumigatus, and Cryptococcus neoformans (145).  
CLRs are transmembrane proteins with at least one C-type lectin-like domain 
capable of binding carbohydrate (144). Dectin-1 is a CLR expressed on macrophages and 
dendritic cells that is highly specific for β-1,3-glucans (146, 147). The cytoplasmic tail of 
dectin-1 contains a single tyrosine-based activation-like motif, or “hemi-ITAM” (148). 
Activation of dectin-1 triggers phagocytosis and Syk-and CARD9/Bcl10/MALT1-
dependent signaling cascade resulting in production of reactive oxygen species (ROS), 
the NF-κB- or NFAT-mediated production of inflammatory cytokines, and the 
upregulation of costimulatory molecules on dendritic cells (149). β-glucan has been 
shown to stimulate NLRP3 inflammasome-mediated production of the inflammatory 
cytokine IL-1β (26). These responses promote the polarization of Th1 and Th17 cells, the 
effector responses of cytotoxic CD8+ T cells, and antibody production (149, 150). Other 
C-type lectin receptors that may play a role in fungal immunity by targeting mannose, 
fucose, glycolipids or chitin include mannose receptor, DC-SIGN, SIGNR1, SIGNR3, 
dectin-2, mincle, langerin, LSECtin, Mgl1, Mgl2, and DEC-205 (Fig 1.3 and (151)). 
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ii. Synergistic interactions between PRR: 
Synergistic interactions between pattern recognition receptors may further influence 
the initiation of the innate immune response. Dectin-1 and TLR2 are recruited to 
phagosomes containing unopsonized zymosan, a Saccharomyces cerevisiae cell wall 
preparation consisting of β-glucans, mannans, mannoproteins and chitin (147). TLR2 
activation in the absence of dectin-1 is insufficient to induce phagocytosis or the 
production of ROS in response to zymosan, but does result in the production of 
inflammatory cytokines (147). Dectin-1 enhances TLR2-mediated production of 
inflammatory cytokines in response to zymosan by sustaining the degradation of IκB, 
which increases NF-κB nuclear translocation (147, 152). TLR2 activation does not play a 
direct role in the tyrosine phosphorylation of dectin-1, and direct physical contact 
between the receptors is not believed to occur (147). Both dectin-1-mediated Syk 
signaling and the TLR adaptor molecule MyD88 are required for this synergistic effect, 
suggesting that signal integration is responsible (152). Similar collaboration has been 
observed between dectin-1 and TLR4, TLR5, TLR7, and TLR9 (152).  
Other pattern recognition receptors may collaborate to shape the innate immune 
response. For example, the association of dectin-1 with the carbohydrate binding receptor 
galectin-3 has been shown to enhance the TNF-α response to Candida albicans (153). 
Similarly, the association of dectin-1 with DC-SIGN, a C-type lectin receptor that binds 
mannose, enhances the pro-inflammatory arachidonic acid cascade in dendritic cells 
(154). 
While dectin-1 is capable of binding soluble β-glucan, activation of downstream 
signaling is dependent on the recognition of immobilized, particulate β-glucan (147, 148). 
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This recognition causes dectin-1 to cluster in synapse-like structures that exclude 
regulatory tyrosine phosphatases CD45 and CD148 (148). This “phagocytic synapse” 
forms prior to internalization of particulate β-glucan and likely facilitates downstream 
signaling (148). It is not known whether other PRR are specifically clustered at the site of 
contact with particulate β-glucan, but the previously demonstrated physical association 
between dectin-1 and DC-SIGN or galectin-3 suggests that the formation of the synapse 
may facilitate homologous and heterologous receptor crosstalk (153, 154). Collaboration 
between PRRs may allow innate immune cells to differentiate between situations where a 
complex inflammatory response is warranted (i.e., a microbe expressing multiple 
PAMPs), and situations where tolerance is more ideal (i.e., inhalation of fungal 
allergens). 
 
iii. Innate recognition of Pneumocystis: 
The Pneumocystis cyst wall is predominately composed of β-1,3-glucan with side 
chains of β-1,6- and β-1,4-linked glucose residues (155). Dendritic cells have been shown 
to respond to β-glucans derived from the P. carinii cyst wall through dectin-1 (23). 
Dendritic cells activated by cyst wall-derived β-glucans increase costimulatory molecule 
expression and drive CD4+ T cell activation towards a proinflammatory Th1/Th17 
response in a dectin-1-dependent manner (23, 88). 
The mechanism for dendritic cell recognition of the trophic life cycle stage, which 
expresses glycoproteins but not β-glucans, is unclear. Recently, treatment of rats with the 
β-1,3-D-glucan synthase inhibitor echinocandin resulted in depletion of P. carinii cysts 
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(24). The rats were able to clear the remaining trophic forms in the absence of an 
excessive inflammatory response.  
TLR2 and the β-glucan receptor dectin-1 are required for the generation of an 
effective response to Pneumocystis (69, 156). This suggests that collaboration of TLR2 
and dectin-1 may play a role in the induction of the robust response to Pneumocystis 
cysts. β-glucan derived from Pneumocystis promotes the formation of dectin-1-containing 
lipid rafts at plasma membrane of dendritic cells. Lipid rafts are glycosphingolipid-
enriched microdomains that promote signaling via the clustering of receptors with ITAM 
domains. This rearrangement of the plasma membrane is likely analogous to the 
“phagocytic synapse” previously observed in macrophages (148). Glycosphingolipid 
cluster formation in human dendritic cells stimulated with cyst cell wall-derived β-glucan 
promotes classical NFκB activation and expression of the Th17-type cytokine, IL-23 (88). 
Other C-type lectin receptors may play a role in immunity to Pneumocystis by 
targeting mannose, fucose, or glycolipids (20, 151). Among these, mannose receptor has 
been the most rigorously studied in the context of Pneumocystis infection. Mannose 
receptor, a C-type lectin receptor with carbohydrate recognition domains capable of 
binding mannose, fucose and GlcNAc, binds the antigenic glycoprotein A (gpA, or major 
surface glycoprotein, MSG) on the cell wall of Pneumocystis organisms, triggering 
phagocytosis, ROS production, NFκB translocation, and production of IL-1, IL-6, IL-8, 
and TNF-α (92, 97, 98, 157). 
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iv. CLR-mediated suppression of immune responses 
Recently, it has become evident that signaling via C-type lectin receptors is highly 
context-specific, and, in certain situations, engagement of C-type lectin receptors may 
lead to suppression of proinflammatory immune responses. This phenomenon may reflect 
the capacity of C-type lectin receptors to shape the balance between tolerance and 
inflammation based on the composition, density, and architecture of the ligand. For 
example, arabinogalactan isolated from the dust of traditional farms is protective against 
allergy responses. It was recently demonstrated that arabinogalactan interacts with 
mannose receptor and DC-SIGN on human dendritic cells and inhibits NF-κB activation 
following stimulation with the TLR4 ligand LPS (158). High-molecular-weight or 
complex β-glucans such as curdlan promote dectin-1-mediated proinflammatory 
signaling, while the low-molecular-weight, soluble glucan laminarin acts as an antagonist 
of dectin-1.  
Recent evidence suggests that fungal pathogens may manipulate interactions with 
C-type lectin receptors to suppress proinflammatory responses. Engagement of the C-
type lectin receptor mincle by the fungal skin pathogen Fonsecaea monophora was 
shown to suppress the proinflammatory Th1- and Th17-type immune responses induced 
by dectin-1-mediated signaling (159). Opposing roles for dectin-2 and mincle have been 
observed in the recognition of Fonsecaea pedrosoi (160).  
Hyper-mannose glycosylation is required for optimal C-type lectin receptor 
recognition of C. albicans (68, 69). The lack of outer chain N-mannans may permit 
Pneumocystis organisms to escape detection by the immune system (21). While mannose 
receptor is associated with proinflammatory responses to Pneumocystis (92, 98, 157), 
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Zhang et al. demonstrated that blockage or knockdown of mannose receptor on rat 
alveolar macrophages resulted in elevated TNFα production in response to unopsonized 
mixed Pneumocystis organisms (161). In the absence of a strong proinflammatory signal 
from the cysts (β-glucan), the interaction of weakly mannosylated proteins on the surface 
of trophic forms with a C-type lectin receptor such as mincle or mannose receptor may 
suppress proinflammatory responses. 
 
VI. Current limitations in Pneumocystis research 
Despite repeated effort, a long term culture system for Pneumocystis organisms has 
not yet been developed. In the absence of an in vitro culture system, predictions have 
been made about the life cycle and reproduction of Pneumocystis species based on 
methods such as genome analysis, ultrastructural imaging of fungi from host lung 
isolates, and complementation of probable genes in related fungi including 
Saccharomyces cerevisiae. Recent genomic studies of P. jirovecii, P. murina, and P. 
carinii suggest that Pneumocystis species are obligate extracellular parasites that must 
scavenge nutrients, including amino acids, from their hosts (21, 162-164). In addition, the 
stable environment of the host lung may have permitted Pneumocystis species to lose 
genes involved in pH sensing, osmotic and oxidative stress responses (21). Such 
information will likely be critical to the success of future attempts to devise in vitro 
culture systems for Pneumocystis organisms. 
The inability of P. jirovecii to live outside of a human host has limited research on 
this medically important parasite and opportunistic pathogen. Rat and mouse models have 
driven critical advances in understanding the immune responses to P. carinii and P. 
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murina, respectively. The transmission of Pneumocystis organisms and the progression of 
disease, including the development of interstitial pneumonia, in immunocompromised 
rodents appear to be homologous to that experienced in humans. Patients with specific 
immunodeficiencies, including defects in immune cell populations, signaling pathways, 
and cytokines, have provided evidence regarding the components of the immune response 
that are essential for clearance of Pneumocystis organisms. These observations have been 
substantiated by a large body of research exploring the immune response to Pneumocystis 
in rodent models. In addition, rhesus macaques have been used in studies that explore 
Pneumocystis and simian immunodeficiency virus (SIV) co-infection or the development 
of vaccines against Pneumocystis. 
Currently, there is no reliable method for isolation of pure P. murina cyst 
organisms, though enrichment of P. carinii cysts from the lungs of infected rats via 
counterflow centrifugal elutriation has been reported (20). Cysts are relatively rare in the 
lungs of infected hosts (approximately 10% of the fungal lung burden), and the lungs of 
an infected mouse may contain only a tenth of the Pneumocystis organisms found in the 
lungs of an infected rat. The scarcity of cysts relative to trophic forms, in the context of 
the lower fungal burden in the lungs of mice compared to rats, may explain our inability 
to isolate pure cysts from mice. 
Several additional factors have likely contributed to this inability to isolate cysts, 
regardless of host species, including considerable overlap between the sizes of trophic 
forms and cysts, and the lack of unique surface markers. Our attempts to isolate 
organisms using density gradients or recombinant His-tagged murine dectin-1 (R&D 
Systems, Minneapolis, MN) were unsuccessful (unpublished data). In addition, De 
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Stefano et al demonstrate that there is a high degree of conservation in the surface 
glycoproteins expressed by trophic forms and cysts (20). We have found a similar degree 
of conservation in the lectin-staining profile of trophic forms and cysts (Zhan Ye, 
unpublished). Our attempts to isolate the organisms by lectin-binding resulted in a slight 
enrichment of cysts, but insufficient yield (Zhan Ye, unpublished).  
 
VII. Project Overview 
Prior research in the field has overwhelmingly focused on the immune response to 
infection with a mixture of the trophic and cystic life cycle stages. Certainly, such studies 
provide valuable information, as the typical immune response to Pneumocystis organisms 
is shaped in the context of infection with both trophic forms and cysts. However, such 
studies do not provide a nuanced understanding of the distinct roles of the trophic and 
cystic life cycle stages in the development of the immune response to Pneumocystis 
infection. Here, our goal was to explore the biology of the immune response to these life 
cycle stages. In addition to providing answers to basic research questions, these efforts 
may provide critical insights for vaccine development or identification of new drug 
targets. 
There is not a reliable method for isolation of pure P. murina cyst organisms. For 
this project, we have employed three general tools for modeling the exposure of the 
immune system to Pneumocystis lifeforms: 1) isolation of purified trophic forms, 2) 
depletion of cysts, and 3) substitution of the cyst form with materials that are homologous 
to cystic PAMPs. 
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We are able to employ differential centrifugation to isolate a population of purified 
trophic forms from the standard mixed population isolated from infected RAG2-/- mice. 
We routinely recover enriched trophic forms with ratios of at least 100 trophic organisms 
per cyst, in contrast to the standard mixture of 10 trophic forms per cyst found in infected 
mice. Differential centrifugation removes less than 10% of the trophic forms from the 
mixed population, and therefore has a negligible effect on the proportions of trophic 
forms and cysts that remain in the mixture. 
Trophic forms encyst in vivo. In this report, we use the β-1,3-D-glucan synthase 
inhibitor anidulafungin to analyze the in vivo immune response to infection with trophic 
forms in the absence of cysts. Treatment with anidulafungin results in rapid depletion of 
the cyst life cycle stage, which expresses β-1,3-glucan, but leaves the trophic burden 
intact (17, 24). 
Finally, in lieu of purified cysts, we will treat immune cells with various materials 
that are homologous to PAMPs on the surface of the cysts. Included in this list of 
surrogates are curdlan (a β-glucan preparation from Alcaligenes faecalis), zymosan (a 
Saccharomyces cerevisiae cell wall preparation consisting of β-glucans, mannans, 
mannoproteins and chitin), and depleted zymosan (zymosan that has been treated with 
hot alkali to denature proteins). 
 
Central Hypothesis: The life cycle stages of Pneumocystis murina have a differential 
interaction with immune cells. Our initial goal was to characterize the immune response 
generated in response to trophic forms, or a mixture of trophic forms and cysts. Multiple 
reports from Limper et al. indicated that β-1,3-D-glucan from the cyst wall was sufficient 
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to drive secretion of proinflammatory chemokines and cytokines by alveolar epithelial 
cells and dendritic cells (23, 103, 104, 106). Furthermore, β-1,3-D-glucan-treated 
dendritic cells promoted CD4+ T cell proliferation and Th1 polarization (23). Conversely, 
it was unclear which types of immune responses might be elicited by the trophic forms, 
which do not express β-glucan. To address this hypothesis, three aims were explored: 
 
Aim I: To determine if optimal innate and adaptive primary immune responses to 
Pneumocystis species are dependent on stimulation with the cyst life cycle stage. We 
initially hypothesized that infection of immunocompetent mice with trophic forms would 
lead to differential immune response compared to infection with mixed P. murina 
organisms due to the absence of β-glucan. Early data indicated that inoculation with 
trophic forms lead to the delayed initiation of innate and adaptive responses compare to 
inoculation with mixed P. murina organisms (Fig 3.1-6). Despite the absence of β-
glucan, trophic forms express multiple glycoproteins that have the potential to interact 
with pattern recognition receptors (20, 165). Therefore, if trophic forms induce a less 
robust immune response than the cyst, it is possible that trophic forms employ some 
mechanism(s) to evade or dampen innate responses to the potentially inflammatory 
PAMPs expressed on their surface. We address this Aim in Chapter 3. 
 
Aim II: To evaluate the role of trophic forms in the generation of protective 
adaptive immunity, as measured by clearance of infection. While Linke et al. 
demonstrate that depletion of cysts results in diminished inflammatory responses in the 
model of immune reconstitution inflammatory syndrome, it is unclear if trophic forms are 
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capable of eliciting any degree of an immune response. There is no evidence to suggest 
that Pneumocystis species have adaptive features associated with long-term immune 
escape, such as withdrawal to sites hidden from immune pressure. Indeed, infection of 
rodents with their respective Pneumocystis species results in clearance of the infection, 
albeit after several weeks. These data suggest that both trophic forms and cysts are 
susceptible to CD4+ T cell and B cell-mediated clearance. Since trophic forms may 
encounter immune cells and may be cleared by T cell and B cell-mediated responses, we 
hypothesize that trophic forms may, independently of the cyst stage, elicit immune 
responses. We address this Aim in Chapter 4. 
 
Aim III: To determine if trophic forms promote inflammation-mediated pneumonia 
in immunocompromised mice. While adaptive immunity is required for clearance of 
Pneumocystis infection, inflammation-mediated lung damage is deleterious in many 
models of PcP. Linke et al. propose that depletion of Pneumocystis cysts by β-1,3-glucan 
synthase inhibitors would reduce inflammation-induced lung damage in patients 
undergoing immune-reconstitution syndrome (24). RAG2-/- mice are not able to develop 
an adaptive response to Pneumocystis, and thus progress to PcP within 8 weeks post-
infection. We predict that treatment with the β-1,3-glucan synthase inhibitor 
anidulafungin would extend the life of the RAG2-/- host, as the trophic forms would elicit 
less inflammation-induced lung damage. We address this Aim in Chapter 4. 
 
Aim IV: To determine if trophic forms hamper the response to P. murina by 
preventing dendritic cell activation. The alveolar spaces of the uninfected host are 
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relatively free of immune cells. Clearance of Pneumocystis infection requires activation 
of alveolar macrophages, and the recruitment of CD4+ T cells and B cells into the lungs. 
Thus, dendritic cells, which extend their processes beyond the alveolar epithelium into 
the alveolar spaces, are in a prime position to raise the alarm against Pneumocystis 
infection. It is possible that the ability of trophic forms to broadly dampen immune 
responses is dependent on silencing this alarm. To prime protective T cell responses, 
dendritic cells must undergo activation and prepare to present antigen, costimulatory 
molecules, and inflammatory cytokines to T cells in the draining lymph nodes of the 
lungs. We hypothesize that Pneumocystis trophic forms may impair one or more steps 
involved in the communication between dendritic cells and T cells. We address this Aim 
in Chapter 5. 
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Figure 1-1 Proposed Pneumocystis life cycle. 
Asexual reproduction of trophic forms probably occurs during acute infection. Sexual 
reproduction probably occurs when haploid trophic forms conjugate to form a diploid 
precyst. The precyst matures through the early, intermediate and late phase to form a 
mature cyst which ultimately releases young trophic forms. 
 
Reproduced with permission from Skalski JH, Kottom TJ, Limper AH. 2015. 
Pathobiology of Pneumocystis pneumonia: life cycle, cell wall and cell signal 
transduction. FEMS Yeast Research 15: fov046. DOI: 10.1093/femsyr/fov046.  
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Figure 1-2 P. murina trophic forms and cysts. 
Brightfield images (60 X magnification, oil objective, Nikon Eclipse E600 microscope) 
of DiffQuik-stained P. murina (A) purified trophic forms and (B) mixture of trophic 
forms (arrowhead) and cysts (arrow). 
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Figure 1-3 C-type lectin receptor signaling. 
Engagement of DC-SIGN with fucose or highly-mannosylated structures induces 
acetylation of the NF-κB subunit p65 via the serine/threonine kinase Raf-1 (166). 
Mannose receptor (MR) is indicated in phagocytosis of Pneumocystis organisms (92). In 
human alveolar macrophages, nuclear translocation of canonical NF-κB molecules (p65, 
p50) and cytokine production have been shown to utilize MR (98, 167). Upon ligation 
with β-glucans, Syk associates with the ITAM motif within Dectin-1 to initiate 
downstream signaling through both the canonical and non-canonical NF-κB pathways. 
Dectin-2 and Mincle recognize α-mannans and require association with the FcRγ chain to 
initiate downstream signaling through the canonical NF-κB pathway. 
 
Reproduced with permission from Kurkjian CJ. 2013. Environmental and intrinsic factors 
influence alveolar macrophage function in the neonatal immune response to 
Pneumocystis. Available from ProQuest Dissertations & Theses Global (1513271303). 
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Chapter 2: Materials and Methods 
 
I. Materials 
A. Reagents 
Hanks Balanced Saline Solution (HBSS), Roswell Park Memorial Institute 1640 
(RPMI) medium, Penicillin/Streptomycin (P/S), gentamicin reagent solution, L-
glutathione, TrpLE Express cell dissociation buffer, Trypan blue, pHrodo Green 
Zymosan Bioparticles and Prolong Gold antifade reagent were purchased from Thermo 
Fisher Scientific (Waltham, MA).  
DDAO-SE was purchased from Molecular Probes, Invitrogen (Grand Island, NY). 
Dulbecco’s Phosphate Buffered Saline (PBS), albumin from bovine serum (BSA), 
DNase, Collagenase, glutathione, ethylenediaminetetraacetic acid (EDTA), formalin 
(neutral buffered, 10%), saponin, sodium azide (NaN3), ionomycin, brefeldin A, dimethyl 
sulfoxide (DMSO), 2-Mercaptoethanol (2-ME), Tween-20, and sulfuric acid (H2SO4) 
were purchased from Sigma-Aldrich (St. Louis MO).  
Heat-inactivated fetal bovine serum (HIFBS) was purchased from Atlas Biologicals 
(Fort Collins, CO). Methanol was purchased from BDH Chemicals (Poole Dorset, UK). 
MEM nonessential amino acid solution was purchased from ATCC (Manassas, VA). 
mGM-CSF was purchased from Peprotech (Rocky Hill, NJ). CD4 (L3T4) microbeads 
were purchased from (Miltenyi Biotec, San Diego, CA). DiffQuik was purchased from 
Siemens Healthcare Diagnostics, Inc. (Deerfield, IL). Foxp3 transcription factor staining 
kit and all ELISA kits were purchased from eBioscience (San Diego, CA). DNase easy 
kits were purchased from Qiagen (Germantown, MD). Transwell plates were purchased 
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from Corning Inc. (Corning NY). CFSE was purchased from Tonbo Biosciences (San 
Diego, CA). Direct-zol RNA miniPrep kit was purchased from Zymo Research (Irvine, 
CA). nCounter Mouse Immunology CodeSet was purchased from NanoString (Seattle, 
WA). 
 
B. Mice 
Six-week old BALB/cJ, C57BL/6, dectin-1 knockout (B6.129S6-Clec7atm1Gdb/J ), 
and mannose receptor knockout (MR-/-, B6.129P2-Mrc1tm1Mnz/J) mice were purchased 
from the Jackson Laboratory (Bar Harbor, ME) and bred in our animal facilities. Male 
and female pups were used in the neonatal experiments. Six-week old female BALB/cJ 
and C57BL/6 mice were purchased from the Jackson Laboratory and infected at eight 
weeks of age for either the adult experiments or to generate CD4+ T cells for the in vitro 
experiments. Uninfected adult female BALB/cJ, C57BL/6, dectin-1-/-, MR-/-, and 
B6.129P2 mice from the Jackson Laboratory were used to generate BMDCs for the in 
vitro experiments. Mice were maintained at the University of Kentucky Department of 
Laboratory Animal Resources (DLAR) under specific-pathogen-free conditions. 
C.129S6(B6)-Rag2tm1Fwa N12 (Rag2-/-) mice, originally from Taconic (Germantown, NY) 
were used to maintain a source of P. murina and were bred at DLAR in sterile 
microisolator cages with sterilized food and water. The University of Kentucky 
Institutional Animal Care and Use Committee approved all protocols regarding animal 
use. Femurs and tibias from Muc1-/- mice were generously provided by Dr. Sandra 
Gendler (Mayo Clinic, Scottsdale, AZ). 
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II. Methods 
C.  P. murina isolation 
Lungs were excised from P. murina-infected Rag2-/- mice and pushed through 
stainless steel mesh in HBSS containing 0.5% glutathione at pH 7.3. Cell debris was 
broken up by aspirating through 20 and 26-gauge needles, then removed by 
centrifugation at 100 X g for 3 min. Trophic forms were isolated by removing the 
supernatant following centrifugation at 400 X g for 7 min. This preparation results in 
greater than 99% pure trophic forms (168). The pellet from the 400 X g spin contained a 
mixed population of cysts and trophic forms, at a typical ratio of 10:1 trophic forms to 
cysts. Erythrocytes in the pellet were lysed with water, and organisms suspended in an 
equal volume of 2X phosphate-buffered saline (PBS). Organisms were incubated with 
200 U DNase at 37°C for 30 min. Clumps were broken up by aspirating through a 26-
gauge needle. The remaining cell debris was removed by centrifugation at 100 X g for 3 
min, followed by passage over a 70 µm filter. Aliquots of mixed P. murina organisms or 
purified trophic forms were diluted, and 100 µl aliquots were spun onto a 28.3 mm2 area 
of glass slides. Slides were fixed in methanol and stained with DiffQuik (as shown in Fig 
1.2). Organism numbers were determined microscopically using the 100X oil immersion 
objective of a Nikon microscope. 
Purified and separated Pneumocystis lifeforms were pelleted by centrifugation at 
1300 X g for 15 min, then resuspended in RPMI containing 10% HIFBS and 7.5% 
DMSO at a concentration of 107-108 Pneumocystis nuclei per 1ml media per cryovial. 
Frozen purified Pneumocystis was stored at -80C. As required for experiments, frozen 
purified Pneumocystis was thawed on ice and washed twice in HBSS with 1% P/S, 0.1% 
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gentamicin. Thawed P. murina was recounted (as described above) prior to inclusion in 
an experiment. It should be noted that the net effect of these centrifugation and wash 
steps would be expected to remove any matter with subcellular size. These washes, 
combined with the initial slow spin to remove lung debris, provide a reasonable degree of 
assurance that the trophic and mixed P. murina populations were free of any material that 
may confound the immunological assays employed in this dissertation. The visualization 
of the populations with DiffQuik stain (as seen in Fig 1.2) provides further assurance that 
the organisms were free of contamination from lung debris or bacteria. 
 
D. Infection of mice with P. murina 
Mice were lightly anesthetized with isoflurane to suppress the diver’s reflex. 
Neonatal mice (24-72 hours old) were inoculated intranasally with up to 106 trophic or 
mixed P. murina organisms in 10 µl HBSS containing 10 units/ml penicillin, 10 µg/ml 
streptomycin, and 1 µg/ml gentamicin. Adult mice (6 – 8 weeks old) were inoculated 
intratracheally with up to 107 trophic or mixed P. murina organisms in 100 µl HBSS 
containing antibiotics. The adult mice were placed on an upright support rack, and the 
inoculations were performed using a blunted intratracheal needle designed with a curve to 
accommodate the trachea. 
 
E. Adoptive transfer of CD4+ T cells 
Adult (8 weeks old) BALB/cJ mice were treated with saline or 1mg/kg 
anidulafungin (Pfizer, New York, NY) by the intraperitoneal route one day prior to 
infection and three times per week thereafter. Mice were anesthetized lightly with 
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isoflurane anesthesia to suppress the diver’s reflex and inoculated intratracheally with a 
dose of enriched trophic forms or mixed P. murina equivalent to 106 total nuclei in 100 µl 
HBSS containing 10 units/ml penicillin, 10 µg/ml streptomycin, and 1 µg/ml gentamicin. 
The mice were placed on an upright support rack, and the inoculations were performed 
using a blunted intratracheal needle designed with a curve to accommodate the trachea. 
Infected mice were euthanized at 14 days post-infection.  Tracheobronchial lymph nodes 
(TBLN) were collected from the infected mice followed by passage over a 70 µm filter. 
Erythrocytes were removed using hypotonic ammonium-chloride-potassium (ACK) 
lysing buffer (169). CD4+ T cells were isolated with mouse CD4+ T cell enrichment 
columns (positive selection, R&D Systems, Minneapolis, MN). CD4+ T cells were 
washed, resuspended, and split for phenotyping or adoptive transfer. Greater than 90% of 
recovered cells were CD4+ T cells, as determined by flow cytometry. 105 CD4+ T cells 
were adoptively transferred by the intravenous retro-orbital route to RAG2-/- mice 
(“recipients”). 
Three days after adoptive transfer, the recipient mice were treated with either 
1mg/kg anidulafungin or saline by the intraperitoneal route. This treatment continued 
three times per week throughout the course of the experiment. One day after the initiation 
of drug or saline treatment, the recipient mice were infected with a dose of enriched 
trophic forms or mixed P. murina organisms equivalent to 5 X 105 total nuclei. Animals 
were euthanized at 15 and 30 days post-infection. 
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F. Rechallenge with P. murina in CD4+ T cell-depleted mice 
Adult BALB/cJ mice were treated with 1mg/kg anidulafungin by the intraperitoneal 
route one day prior to intratracheal infection with 3 X 106 enriched trophic forms. 
Animals were treated with anidulafungin three times per week throughout the primary 
infection. Following clearance of the primary infection, anidulafungin treatment was 
stopped at day 34 post-infection to permit clearance of the drug prior to reinfection. At 
day 40 post-infection, 0.15 mg anti-CD4 antibody (clone GK1.5, Bio X Cell, Lebanon, 
NH) in 200 µl sterile saline was administered to deplete CD4+ T cells. The anti-CD4 
antibody treatment was administered every four days for the remainder of the study. One 
day after CD4+ T cell depletion, mice were treated with either anidulafungin or saline 
followed by re-infection with a dose of enriched trophic forms or mixed P. murina 
organisms equivalent to 5 X 106 total nuclei. The anidulafungin or saline treatment was 
administered three days per week for the remainder of the study. Animals were 
euthanized at day 15 post-infection. 
 
G. Isolation of cells from alveolar spaces, lungs, and lymph nodes 
Mice were exsanguinated under deep isoflurane anesthesia, and lungs were lavaged 
with 5 washes of HBSS containing 3 mM EDTA. Bronchial alveolar lavage fluid (BALF) 
was centrifuged to obtain cells, and cell-free supernatant from the first wash was frozen 
for subsequent cytokine assays. Right lung lobes were excised, minced, and digested in 
RPMI containing 3% heat-inactivated fetal calf serum, 1 mg/ml collagenase A, and 50 
U/ml DNase for 1 h at 37 °C. Digested lungs were pushed through 70 µm nylon mesh 
screens to obtain single-cell suspensions, and aliquots were taken for enumeration of P. 
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murina. Tracheobronchial lymph nodes (TBLN) were also excised and pushed through 
70 µm nylon mesh screens in HBSS. Erythrocytes were removed using hypotonic 
ammonium-chloride-potassium (ACK) lysing buffer. Cells were washed and counted by 
hemocytometer. 
 
H. Flow cytometric analysis for in vivo experiments 
BALF, lung digest, and TBLN cells were washed with PBS containing 0.1% bovine 
serum albumin and 0.02% NaN3 and stained with appropriate concentrations of 
fluorochrome-conjugated antibodies specific for murine surface proteins (anti-CD4 clone 
GK1.5, anti-CD8a clone 53-6.7, anti-CD19 clone 1D3, anti-CD44 clone MEM-85, anti-
CD62L clone MEL-14, anti-CD11c clone N418, anti-CD11b clone M1/70, and anti-
F4/80 clone BM8).Antibodies were purchased from BD Biosciences (San Jose, CA) or 
eBioscience (San Diego, CA). Expression of these molecules on the surface of the cells 
was determined by multiparameter flow cytometry using a LSRII flow cytometer (BD 
Biosciences). 50,000 events were routinely acquired and analyzed using FlowJo software 
(TreeStar, USA). 
 
I. Analysis of P. murina-specific IgG in serum 
Blood was collected from rechallenged mice following euthanasia at day 15 post-
rechallenge (n = 3 mice per group). Blood samples were centrifuged to pellet cells, and 
serum was collected and frozen at -80°C for later use. P. murina-specific 
immunoglobulin G (IgG) was measured by enzyme-linked immunosorbent assay 
(ELISA). A sonicate of P. murina trophic forms or mixed organisms (10 μg protein/ml) 
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was coated onto 96-well plates, and wells were blocked with 5% dry milk in HBSS 
containing 0.05% Tween-20. Sera were diluted and incubated on plates overnight. Serum 
collected from an uninfected mouse was used as a negative control. Plates were 
extensively washed, and bound IgG was detected using alkaline phosphatase-conjugated 
anti-mouse IgG (Sigma). Plates were washed and secondary antibodies detected using p-
nitrophenylphosphate at 1 mg/ml in diethanolamine buffer. Optical density was read at 
405 nm using a plate reader equipped with KC Junior software (Bio-Tek Instruments, 
Inc., Winnoski, VT). An OD of 0.1 was considered a cutoff value based on previous 
results from sera collected from uninfected mice. The OD of the negative control serum 
employed in these experiments remained below the 0.1 cutoff value. 
 
J. Enumeration of Pneumocystis in the lungs of mice 
Aliquots of lung homogenates were diluted in HBSS, and 100 µl aliquots were spun 
onto a 28.3 mm2 area of glass slides. Slides were fixed in methanol and stained with 
DiffQuik. Organism numbers were determined microscopically using the 100X oil 
immersion objective of a Nikon microscope. The number of P. murina trophic forms or 
cysts in 50 microscopic oil immersion fields was used to calculate fungal burden. Lung 
burden is expressed as the number of P. murina organisms per right lung lobe, and the 
limit of detection was Log10 3.12 nuclei per neonatal right lung lobe and Log10 3.42 
nuclei per adult right lung lobe. 
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K. Generation of BMDCs and CD4+ T cells for in vitro assays. 
BMDCs were generated from uninfected BALB/cJ, B6.129P2, dectin-1-/-, and  
MR-/- adult female mice. BMDCSs were produced by flushing cells from the bone 
marrow of the tibias and femurs of female adult mice with PBS + 5% heat-inactivated 
fetal bovine serum. Erythrocytes were removed using ACK lysing buffer (169). Cells 
were washed and resuspended in culture media containing RPMI with 10% heat-
inactivated FBS, 0.5 mM 2-mercaptoethanol, 1% MEM nonessential amino acid solution, 
100 units/ml penicillin, 100 μg/ml streptomycin, and 50 μg/ml gentamycin. Cells were 
plated in 100 mm Petri dishes at a cell density of 4 X 106 in 10 ml of culture media with 
20 ng/ml recombinant murine granulocyte-macrophage colony-stimulating factor. Plates 
were cultured at 37°C, 5.0% CO2. An additional 10 ml culture media with 20 ng/ml 
recombinant murine GM-CSF was added to cells after 24 h of growth. Every 48 h 
thereafter, non-adherent cells were removed and replaced with 10 ml of fresh media 
containing recombinant murine GM-CSF. Cells were cultured for nine to twelve days. 
BMDCs were collected by vigorously washing plates with media to remove loosely 
adherent cells. BMDCs were washed, resuspended, and split for phenotyping or cytokine 
assay. Greater than 80% of recovered cells were CD11c+. 
CD4+ T cells were generated by infecting adult BALB/cJ mice with 107 mixed P. 
murina organisms as described previously. TBLN were excised ten to fourteen days post-
infection and pushed through 70 µm nylon mesh screens in HBSS. Erythrocytes were 
removed using ACK. Cells were washed and counted. CD4 (L3T4) microbeads were 
used for positive selection of CD4+ cells. Greater than 90% of recovered cells were CD4+ 
T cells. 
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L. In vitro cytokine production assays. 
104 BMDCs and/or 5 X 104 CD4+ T cells in 96-well plates were stimulated with 10 
µg/ml curdlan (β-1,3-glucan from Alcaligenes faecalis), 20µg/ml zymosan 
(Saccharomyces cerevisiae cell wall), 20µg/ml depleted zymosan, 10µg/ml lipoteichoic 
acid (LTA), 100ng/ml lipopolysaccharides (LPS from Escherichia coli 0111:B4, purified 
by gel filtration to remove lipoproteins, per Sigma-Aldrich), 5 X 105 trophic forms and/or 
5 X 105 mixed P. murina at 37°C, 5.0% CO2 for 72 h in BMDC culture media. 
Supernatants were collected, centrifuged at 2700 X g for 1 min to remove organisms, and 
frozen for subsequent analysis of cytokine levels using IL-1β, IL-6, TNFα and IFN-γ 
ELISA. Trypan blue was used to evaluate viability of BMDCs following stimulation with 
10 µg/ml curdlan, 5 X 105 trophic forms and/or 5 X 105 mixed P. murina at 37 °C, 5.0% 
CO2 for 72 h in BMDC culture media. 
 
M. In vitro phagocytosis assays 
105 CFSE-labeled BMDCs were pre-incubated in chamber slides for one hour at 37 
°C, 5.0% CO2 in BMDC culture media. 2 X 105 DDAO-SE-labeled trophic forms or 2 X 
105 DDAO-SE-labeled mixed P. murina were incubated with the BMDCs for 60 min. 
Samples were washed three times in PBS, followed by fixation in 10% neutral buffered 
formalin for 10 min. Slides were washed in PBS, and coverslips were mounted with 
Prolong Gold. Slides were cured for 48 h at room temperature. Slides were examined for 
internalization of P. murina organisms by BMDCs using a Nikon A1RSi microscope and 
NIS-Elements software. A minimum of 100 cells were analyzed per group. 
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105 BMDCs were incubated in round-bottom polystyrene tubes or on chamber 
slides for one hour at 37 °C, 5.0% CO2 in BMDC culture media. 2 X 105 DDAO-SE-
labelled trophic forms, 2 X 105 DDAO-SE-labelled mixed P. murina, and/or 100µg/ml 
pHrodo Green-labeled zymosan bioparticles were incubated with the BMDCs for 60 min. 
These bioparticles are labeled with a pH-sensitive dye that fluoresces within the acidic 
environment of the phagosome. Samples were washed three times in PBS. For confocal 
microscopy, chamber slides were fixed in 10% neutral buffered formalin for 10 min at 
room temperature. Slides were washed in PBS, and treated with 300nM DAPI for 30 min. 
Slides were washed in PBS, and coverslips were mounted with Prolong Gold. Slides were 
cured for 48 hr at room temperature. Slides were examined with a Nikon A1RSi 
microscope and NIS-Elements software. A minimum of 100 cells were analyzed per 
group. For flow cytometry, samples in round-bottom polystyrene tubes were washed 
twice in cold PBS. Samples were resuspended in 300ul cold HBSS. The phagocytic 
capacity of the cells was determined by flow cytometry using a LSRII flow cytometer. 
1,000 dendritic cell events were acquired and analyzed using FlowJo software. 
 
N. In vitro MHC class II and CD40 assays 
105 BMDCs were stimulated with 20 µg/ml zymosan (Saccharomyces cerevisiae 
cell wall), 106 trophic forms and/or 106 mixed P. murina at 37 °C, 5.0% CO2 for 24 h in 
BMDC culture media. Adherent cells were collected from the plate using TrypLE 
expression dissociation reagent. Cells were washed with PBS containing 0.1% bovine 
serum albumin and 0.02% NaN3 and stained with appropriate concentrations of 
fluorochrome-conjugated antibodies specific for innate immune cells (anti-CD11c clone 
49 
 
N418, anti-Iad clone AMS-32.1, and anti-CD40 clone 3/23). Antibodies were purchased 
from eBioscience (San Diego, CA). Expression of these molecules on the surface of the 
cells was determined by multiparameter flow cytometry using a LSRII flow cytometer 
(BD Biosciences). 1,000 CD11c+ events were routinely acquired and analyzed using 
FlowJo software (TreeStar, USA). 
 
O. In vitro CD4+ T cell proliferation and polarization assays 
105 BMDCs and/or CFSE-labelled 5 X 105 CD4+ T cells were stimulated with 20 
µg/ml zymosan (Saccharomyces cerevisiae cell wall), 5 X 105 trophic forms and/or 5 X 
105 mixed P. murina at 37°C and in 5.0% CO2 for 6 days in BMDC culture media. Media 
was collected from the plates and spun at 400 X g for 7 min to separate cells from the 
supernatant. Supernatant was stored at -80°C for use in IFNγ, IL-13, and IL-17A cytokine 
ELISAs (eBioscience, San Diego CA). Adherent cells were collected from the plate using 
TrypLE Express dissociation reagent. Dissociated cells were combined with cell pellet 
from the plate media and washed in fresh culture media. 
Cells were washed in sterile PBS and stained with Fixable Viability Dye eFluor780 
(eBioscience, San Diego, CA). Cells were washed with PBS containing 0.1% bovine 
serum albumin and 0.02% NaN3 (PBA) and stained with PerCP-efluor710-conjugated 
anti-CD4 clone GK1.5. Cells were washed with PBA and resuspended in 300µl HBSS. 
CD4+ T cell proliferation was evaluated by multiparameter flow cytometry using a LSRII 
flow cytometer. 1,000 lymphocyte events were routinely acquired and analyzed using 
FlowJo software. 
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P. NanoString gene expression assay 
3 X 104 BMDCs in 96-well Stripwell plates were stimulated with 10 µg/ml curdlan 
(β-1,3-glucan from Alcaligenes faecalis), 1.5 X 106 trophic forms, or 1.5 X 106 mixed P. 
murina at 37 °C, 5.0% CO2 for 2, 4, and 8 h in BMDC culture media. Additional 
controls, including BMDCs treated with curdlan and trophic forms, were allowed to 
incubate for 72 h. The control supernatants were screened for IL-1β, IL-6, and TNFα 
cytokine production by ELISA, as described above. 
At the conclusion of the 2, 4, and 8 h timepoints, the appropriate Stripwell segments 
were removed from the plate structure. Strips were washed once with PBS. Cells were 
lysed in TriReagent and RNA was extracted with the Direct-zol RNA MiniPrep kit 
(Zymo Research, Irvine CA). The Direct-zol RNA MiniPrep kit permitted optimal 
hybridization of samples to the NanoString probes, presumably due to reduced 
contamination of chaotropic salts compared other RNA extraction protocols. 
RNA concentration was confirmed by using a NanoDrop machine, and purity was 
evaluated by using an Agilent 2100 Bioanalyzer. More than 50% of the RNA fragments 
from each sample were larger than 300 bp, satisfying the quality requirements for 
NanoString. The RNA integrity number (RIN) for all samples was above 8.0. 200 ng of 
each sample was sent to the Microarray Core at the University of Kentucky for 
NanoString processing. The NanoString nCounter Mouse Immunology kit was used to 
quantify the expression of 561 genes related to the murine immune response. Briefly, 
samples were hybridized to a panel of capture probes and reporter probes labeled with 
fluorescent barcodes. Hybridized samples were immobilized and aligned on the nCounter 
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cartridge. Reporter probes were read using the nCounter Analysis System, and counts 
were tabulated for each target transcript. 
Analysis and normalization of the raw NanoString data were conducted using 
nSolver Analysis Software 2.0. Raw counts were normalized to the internal positive 
controls and to the following housekeeping genes: Alas1, Eef1g, G6pdx, Gapdh, Gusb, 
Hprt, Oaz1, Polr1b, Polr2a, Ppia, Rpl19, Sdha, Tbp, Tubb5. Heat maps and principal 
component analysis were prepared with the nSolver Analysis Software 2.0. 
 
Q. Transwell contact assay 
1 X 105 BMDCs, 10 µg/ml curdlan, and/or 5 X 106 trophic forms were plated in the 
upper or lower compartments of Transwell plates with a polyester membrane with 0.4µm 
pores. Cells were incubated at 37°C in 5.0% CO2 for 72 h in BMDC culture media. 
Cytokine levels were analyzed as described above. To confirm that trophic forms did not 
cross the membrane, samples were centrifuged directly onto slides, DiffQuik stained, and 
50 fields were screened. 
Additional Transwell replicates were screened for P. murina DNA by quantitative 
PCR. Briefly, DNA was isolated from both the top and bottom compartments of the 
Transwell dishes using the Qiagen QIAamp Mini Kit. Presence of P. murina DNA was 
detected using primers designed to amplify a portion of the 18S rRNA gene of P. murina. 
Sequences of the primers are: forward 5’-GGGCTTCTTAGAGGGACTGTTGG-3’, 
reverse 5’-CGTGCGGCCCAGAACATCTA-3’ (IDT, Coralville, IA). The control 
plasmid for quantification of P. murina DNA contains the region of the 18S rRNA gene 
amplified by these primers (GenScript USA Inc., Piscataway, NJ). DNA was also isolated 
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from 104, 105 and 106 P. murina trophic forms. The quantitative PCR amplification was 
performed with DNA samples in triplicate for 39 cycles of 95°C for 5 seconds and 57°C 
for 30 seconds using a C1000 Thermal Cycler with a CFX96 real-time PCR detection 
system (Bio-Rad, Hercules, CA). The amount of trophic DNA calculated to have crossed 
from the Transwell insert to the bottom chamber would be equivalent to 2 X 103 
organisms. Pneumocystis trophic forms reside in a biofilm-like substance consisting of a 
conglomeration of DNA, β-glucan, and other sugars (14). It is possible that the trophic 
DNA detected across the Transwell represents shed DNA rather than intact organisms. 
Therefore, fewer than 2 X 103 trophic forms may have crossed the Transwell barrier. 
The number of organisms required to suppress cytokine expression in the Transwell 
system was determined by incubating 1 X 105 BMDCs, 10 µg/ml curdlan, and increasing 
numbers of trophic forms (ranging from 103 to 106 organisms) in the lower compartments 
of Transwell plates. Plates were incubated 37 °C, 5.0% CO2 for 72 h in BMDC culture 
media. Cytokine levels were analyzed as described above. 
 
R. Heat-killed trophic forms 
Trophic forms were heat-killed by incubation at 56 °C for 1 hr. Non-viability of the 
organisms was confirmed by inoculation of immunocompromised Rag2-/- mice. 104 
BMDCs were stimulated with 10 µg/ml curdlan, 5 X 105 trophic forms and/or 5 X 105 
heat-killed trophic forms at 37 °C, 5.0% CO2 for 72 h in BMDC culture media. Cytokine 
levels were analyzed as described above. 
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S. Statistical analysis. 
Analysis and normalization of the NanoString data were conducted using nSolver 
Analysis Software 2.0. Differences among the groups were identified by two-way 
ANOVA followed by pairwise comparisons using the Least Significant Difference 
Method. Five biological replicates were used per group. A change was deemed 
significant if the p-value was < 0.01. 
All other data were analyzed utilizing the SigmaStat statistical software package 
(SPSS Inc., Chicago, IL). Student’s t-test, one way or two way analysis of variance 
(ANOVA) was used to determine differences between groups, with Student-Newman-
Keuls or Holm-Sidak multiple comparisons post hoc tests. Kruskal-Wallis one-way 
ANOVA on ranks was used to analyze differences between groups when the data were 
nonparametric. Data were determined to be significantly different when the p-value was 
< 0.05. 
 
 
 
 
  
 
 
 
 
Copyright © Heather Marie Evans 2017  
54 
 
Chapter 3: Robust innate and adaptive immune responses to Pneumocystis murina 
are dependent on stimulation with the cyst life cycle stage, while the trophic forms 
suppress proinflammatory responses. 
 
The following chapter is modified from: Evans HM, Bryant GL, III, and Garvy BA. 
2016. The life cycle stages of Pneumocystis murina have opposing effects on the immune 
response to this opportunistic fungal pathogen. Infect Immun. 84:3195–3205. 
 
I. Introduction 
Prior research in the field has overwhelmingly focused on the immune response to 
infection with a mixture of the trophic and cystic life cycle stages. Certainly, such studies 
provide valuable information, as the typical immune response to Pneumocystis organisms 
is shaped in the context of infection with both trophic forms and cysts. However, a 
nuanced understanding of the role of the trophic and cystic life cycle stages in the 
development of the immune response to Pneumocystis infection may provide critical 
insights for vaccine development or identification of new drug targets. Recently, it was 
reported that treatment of mice with the β-1,3-D-glucan synthase inhibitor anidulafungin 
resulted in depletion of P. murina cysts (24). The mice were able to control the remaining 
trophic burden in the absence of an excessive inflammatory response, however, the 
details of how trophic forms are recognized and cleared are not known. 
Clearance of infection involving a mixture of Pneumocystis organisms is dependent 
on effective CD4+ T cell, B cell, and macrophage responses (1-4). In addition, failure to 
clear a mixture of Pneumocystis organisms leads to severe alveolar damage due to the 
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exaggerated inflammatory immune response (5). Both the neonatal lung environment and 
intrinsic immune cell deficits contribute to the delayed clearance of a mixture of P. 
murina organisms in neonatal mice (9-12). 
Dendritic cells are the principal antigen presenting cells in the lung. However, their 
role in initiating the adaptive response to Pneumocystis has been understudied. Previous 
work has demonstrated that dendritic cells respond to β-glucans derived from the 
Pneumocystis cell wall (23). Dendritic cells activated by Pneumocystis cell wall-derived 
β-glucans increase costimulatory molecule expression and drive T cell polarization 
towards a Th1-type response (23). The mechanism for dendritic cell recognition of 
Pneumocystis trophic forms, which do not express β-glucans, is unknown. 
Here, we demonstrate that both the adult and neonatal immune response to infection 
with P. murina trophic forms alone was less robust than the response to infection with a 
physiologically normal mixture of cysts and trophic forms. Infection with trophic forms 
alone resulted in reduced recruitment of activated CD4+ and CD8+ T cells into the lungs 
of both neonatal and adult mice compared to infection with a normal mixture of trophic 
forms and cysts. Infection with a mixture of P. murina organisms drove recruitment of 
nonresident innate immune cells into the lung parenchyma and alveolar spaces. In vitro, 
trophic forms suppressed production of the proinflammatory cytokines IL-1β, IL-6, and 
TNFα by bone marrow-derived dendritic cells (BMDCs) stimulated with β-glucan, 
zymosan, LTA, or LPS. In addition, trophic form-stimulated BMDCs failed to stimulate 
production of the Th1-type cytokine IFN-γ by CD4+ T cells. We report for the first time 
that the trophic forms of P. murina suppress proinflammatory responses induced by 
multiple PAMPs.  
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II. Results 
 
P. murina trophic forms encyst by day 14 post-infection in neonatal mice. 
Recent evidence indicates that cysts are the transmittable life cycle stage of 
Pneumocystis species (17). However, there is a paucity of data regarding how the 
immune system handles the trophic forms of the organisms. We previously published that 
alveolar macrophages from either adult or neonatal mice failed to translocate NFκB in 
response to trophic forms (9). Therefore, we first wanted to know how the immune 
response differed when cysts were absent early in the infection and how quickly after 
infection trophic forms transitioned to cysts. To evaluate the differential immune 
response to the life cycle stages, we infected wild-type neonatal mice with either pure 
trophic forms or a physiologically normal mixture of P. murina trophic forms and cysts 
(Fig 1.2). Neonatal mice infected with a normal mixture of P. murina organisms fail to 
mount adaptive immune responses until 21 days of age (9). This presents an opportunity 
to observe the growth of the life cycle stages of P. murina in the absence of protective 
responses.  
Trophic forms were detected at day 5 post-infection in the lungs of BALB/cJ 
neonates infected with 1 X 106 trophic forms or 1 X 106 mixed P. murina organisms (Fig 
3.1A). The mixed P. murina inoculum consisted of 9.01 X 105 trophic forms and 9.90 X 
104 cysts. Neonates infected with trophic forms had a higher trophic burden in the lungs 
at days 7 and 14 post-infection compared to mice infected with mixed P. murina (Fig 
3.1A). However, the trophic lung burdens were similar between the groups by day 21 
post-infection (Fig 3.1A-B). The cyst burden was below the limit of detection of Log10 
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3.12 organisms per lung during the first week post-infection in BALB/cJ neonates 
infected with either trophic forms or mixed P. murina (Fig 3.1C). Cysts were detected at 
day 14 post-infection in both groups. Neonates infected with trophic forms had a higher 
cyst burden in the lungs at day 14 post-infection compared to mice infected with mixed 
P. murina, but there was no statistically significant difference in the cyst burden between 
the groups by day 21 post-infection (Fig 3.1C). Neonates infected with trophic forms and 
mixed P. murina displayed no differences in the clearance of either trophic forms or cysts 
(Fig 3.1B and D). 
 
Cysts drive the early recruitment of activated T cells into alveolar spaces of neonatal 
mice. 
Based on previously published reports, we predicted that the absence of cysts in the 
inoculum of neonatal mice infected with trophic forms would yield a less robust response 
than infection with a normal mixture of trophic forms and cysts (24). Clearance of 
Pneumocystis organisms requires the generation of effective adaptive immune responses. 
We have previously shown that adaptive responses are not observed in 
immunocompetent neonatal mice until week 3 post-infection (9). To determine if the 
absence of cysts in the inoculum affects the neonatal adaptive immune response, T and B 
cells in the lungs of neonates infected with trophic forms were compared with those of 
neonates infected with a normal mixture of P. murina organisms. The numbers of 
activated CD44high CD62Llow CD4+ and CD8+ T cells in the alveolar spaces (represented 
by cells collected in the BALF) was significantly increased by week 3 post-infection in 
pups infected with organisms that included cysts in the inoculum compared to pups 
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infected with trophic forms (Fig 3.2A and C). No differences were observed in the 
numbers of T cells in the lung parenchyma (lung digest) (Fig 3.2B and D). These data 
indicate that the intensity of the early T cell response to P. murina in the alveolar spaces 
is dependent on the presence of cysts in the inoculum. The numbers of CD19+ B cells in 
the lungs did not differ in pups infected with mixed P. murina organisms compared to 
pups infected with trophic forms (Fig 3.2E). The numbers of activated T cells and CD19+ 
B cells in the alveolar spaces and lung parenchyma were equivalent between the groups 
at day 28 and 40 post-infection. 
To determine if the absence of cysts in the inoculum affects the neonatal innate 
immune response, the expansion or recruitment of alveolar or non-resident innate 
immune cells in neonatal mice infected with trophic forms was compared with that of 
neonates infected with a normal mixture of P. murina organisms. The recruitment of 
CD11c- CD11b+ non-resident innate immune cells to the alveolar spaces (BALF) by 
week 3 post-infection was higher in the mice infected with mixed P. murina organisms 
compared to trophic forms alone, but these differences were not statistically significant 
(Fig 3.2G). The numbers of CD11c+ CD11b+ innate immune cells increased by three 
weeks post-infection in the alveolar spaces of neonates infected with either trophic forms 
or mixed P. murina (Fig 3.2H). There were no differences in these responses at days 28 
and 40 post-infection (Fig 3.2G and H). 
 
P. murina trophic forms will encyst by day 7 post-infection in adult mice. 
Quantification of the fungal lung burden in neonatal mice demonstrates that the 
cysts were below the limit of detection during the first week post-infection with either 
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trophic forms or mixed P. murina organisms. To determine if similar kinetics would be 
observed in adults, we infected immunocompetent BALB/cJ adult mice with trophic 
forms or mixed P. murina organisms. Trophic forms were detected at day 5 post-
infection in the lungs of adults infected with trophic forms or mixed P. murina (Fig 3.3A, 
C). Cysts were first detected at day 7 post-infection in the lungs of adults infected with 
trophic forms or mixed P. murina (Fig 3.3B, D). The trophic and cystic lung burdens 
were similar between the groups at all timepoints, and peaked at day 14 post-infection 
(Fig 3.3A-D). The difference in the cyst burden at day 7 post-infection (Fig 3.3B) was 
not consistent in a repeat of the experiment (Fig 3.3D). The trophic and cystic lung 
burdens were below, or approaching, the limit of detection of Log10 3.42 organisms per 
lung by day 21 post-infection, indicating that there were no differences in the clearance 
of P. murina organisms by either group (Fig 3.3A-D). 
 
Cysts drive the early recruitment of T and B cells into the lungs of adult mice. 
To determine if cysts were required for the early recruitment of T and B cells into 
the lungs of immunocompetent adult mice, we infected BALB/cJ adult mice with either 
trophic forms or a normal mixture of P. murina organisms (Fig 3.4). The robust early 
recruitment of activated CD44high CD62Llow CD4+ and CD8+ T cells into the alveolar 
spaces (BALF) was dependent on the presence of cysts in the inoculum (Fig 3.4A-B). An 
increase in the numbers of activated CD4+ and CD8+ T cells was also observed at day 5 
post-infection in the lung parenchyma of mice infected with a mixture of trophic forms 
and cysts compared to mice infected with trophic forms alone (Fig 3.4A-B). Cysts in the 
inoculum also promoted the early recruitment of CD19+ B cells into the alveolar spaces 
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and an early increase in the number of CD19+ B cells in the TBLN (Fig 3.4C). T and B 
cell numbers in mice infected with trophic forms were similar or greater than those in 
mice infected with mixed P. murina as the mice approached clearance at week 3 post-
infection. 
 
Cysts promote the early infiltration of non-resident innate immune cells in adult 
mice. 
The recruitment of CD11c- CD11b+ non-resident innate immune cells to the 
alveolar spaces (BALF) and lung parenchyma (lung digest) of adult BALB/cJ mice by 
day 14 post-infection was higher in mice infected with cysts in the inoculum compared to 
trophic forms alone (Fig 3.5A). The numbers of CD11c+ CD11b+ innate immune cells 
increased during the first week post-infection in the alveolar spaces and parenchyma of 
adults infected with mixed P. murina (Fig 3.5B). The numbers of lung resident CD11c+ 
CD11b- innate immune cells increased in the lung parenchyma of adults infected with 
mixed P. murina at day 5 post-infection, but no statistically significant differences were 
observed in the alveolar spaces of the two groups (Fig 3.5C). Surface expression of the 
major histocompatibility complex class II molecule I-Ad was higher on both CD11c+ 
CD11b- and CD11c+ CD11b+ innate immune cells in the alveolar spaces of mice infected 
with mixed P. murina compared to mice infected with trophic forms alone (Fig 3.5D-E). 
These data indicate that the presence of cysts in the initial inoculum shapes the phenotype 
of the early innate immune response in adult mice. 
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Cysts drive the early production of IFN-γ in the alveolar spaces of adult mice. 
Th1-, Th2-, and Th17-type responses have all been associated with clearance of P. 
murina organisms (112, 114, 115). To determine if cysts promoted the early development 
of Th1-type responses in the lungs, we evaluated cytokine production following infection 
of BALB/cJ adult mice with either trophic forms or a normal mixture of P. murina 
organisms. The early production of IFN-γ in the BALF was higher in mice infected with 
cysts in the inoculum compared to trophic forms alone (Fig 3.6A). IFN-γ production in 
the lungs of mice infected with trophic forms remained low at all timepoints compared to 
mice infected with a mixture of P. murina organisms, despite the presence of cysts by 
day 7 post-infection (Fig 3.6A). In addition, the proportion of CD4+ T cells producing 
intracellular IFN-γ at day 7 post-infection was higher in the lungs of mice infected with 
mixed P. murina organisms compared to mice infected with trophic forms (Fig 3.6B). 
These data suggest that cysts are required in the inoculum for optimal Th1-type responses. 
 
Trophic forms suppress β-glucan-induced proinflammatory cytokine production by 
dendritic cells. 
β-glucan from the cell wall of Pneumocystis cysts has been previously shown to 
stimulate production of IL-1β, IL-6, and TNFα in dendritic cells and induce IFN-γ 
production in cocultured T cells (23). To evaluate whether trophic forms are able to 
stimulate proinflammatory cytokines, we measured IL-1β, IL-6, and TNFα production by 
bone marrow-derived dendritic cells (BMDCs) following stimulation with trophic forms, 
a normal mixture of P. murina organisms, and/or curdlan (Fig 3.7). Curdlan is a high-
molecular-weight β-1,3-glucan isolated from Alcaligenes faecalis, and is similar to the β-
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1,3-glucan that composes the P. murina cyst wall (15). IL-1β and IL-6 production was 
stimulated by 5 X 105 mixed P. murina organisms and 10 µg/ml curdlan, but not 5 X 105 
trophic forms (Fig 3.7A-B). These data demonstrate that cysts are required for production 
of IL-1β and IL-6 by BMDCs. Stimulation of BMDCs with curdlan induced IL-1β, IL-6, 
and TNFα production (Fig 3.7A-C). Conversely, our data indicate that trophic forms 
suppress curdlan-induced IL-1β, IL-6, and TNFα production by BMDCs in a dose-
dependent manner (Fig 3.7A-C). Interestingly, 106 trophic forms suppressed the IL-6 
production induced by 5 X 105 mixed P. murina organisms (Fig 3.7B), but were 
insufficient to induce suppression of IL-1β production (Fig 3.7A). In contrast to IL-1β 
and IL-6 production, TNFα production was stimulated by curdlan, but not trophic forms 
or mixed P. murina organisms (Fig 3.7C). Moreover, incubation of BMDCs with a high 
number of trophic forms or mixed P. murina organisms suppressed curdlan-induced 
production of TNFα (Fig 3.7C). This reduction in cytokine production was not due to a 
toxic effect on the BMDCs (Fig 3.8). 
The P. murina cell wall has been shown to contain more complex branching 
patterns, including β-1,6-glucan, than those contained in curdlan. The P. murina cell wall 
also includes mannosylated proteins. To evaluate the ability of trophic forms to suppress 
responses to a fungal cell wall, we measured cytokine production following stimulation 
with trophic forms, zymosan, and/or depleted zymosan (Fig 3.9). Zymosan is a protein-
carbohydrate preparation from the cell wall of Saccharomyces cerevisiae. Depleted 
zymosan is treated with hot alkali to prevent engagement of the toll-like receptors. 
Trophic forms suppressed zymosan and depleted zymosan-induced production of IL-1β, 
IL-6, and TNFα (Fig 3.9A-F). 
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Trophic forms suppress TLR2 and TLR4-induced proinflammatory cytokine 
production by dendritic cells. 
In addition to C-type lectin receptors such as dectin-1, Pneumocystis species have 
been shown to stimulate cytokine production by antigen presenting cells via Toll-like 
receptors (TLRs) 2 and 4 (156, 170). We measured IL-1β, IL-6, and TNFα production by 
BMDCs following stimulation with TLR2-agonist LTA, TLR4-agonist LPS and/or 
trophic forms (Fig 3.10). Stimulation of BMDCs with LTA or LPS induced IL-1β, IL-6, 
and TNFα production (Fig 3.10A-F). The addition of 5x105 trophic forms suppressed this 
cytokine response to LTA and LPS. 
 
The suppression of the response to curdlan is not mediated by mannose receptor. 
Carbohydrate PAMPs on the surface of fungi and other microorganisms may be 
recognized by C-type lectin receptors. Mannose receptor and dectin-1 have been 
implicated in the immune response to Pneumocystis species (69, 92, 98, 151, 157, 161). 
To evaluate the role of mannose receptor and dectin-1 in the response to trophic forms 
and β-glucan, we stimulated BMDCs deficient in those C-type lectin receptors with 
trophic forms, mixed P. murina organisms, and/or curdlan (Fig 3.11). Surprisingly, 
neither mannose receptor nor dectin-1 was required for IL-6 or TNFα production in 
response to mixed P. murina. IL-1β production in response to mixed P. murina was 
modestly dependent on dectin-1. As expected, mannose receptor was not responsible for 
the response to curdlan. Depletion of dectin-1 did not fully abolish the IL-6 and TNFα 
response to curdlan. It is possible that other receptors such as complement receptor 3 
(CD11b/CD18) or lactosylceramide may recognize curdlan (105, 106, 171-173). 
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Alternatively, the curdlan used in this project may have contained additional PAMPs 
beyond β-1,3-glucan. 
Regardless, our data demonstrate that neither mannose receptor nor dectin-1 was 
exclusively required for the trophic form-mediated suppression of IL-1β, IL-6, and TNFα 
production. In the absence of mannose receptor or dectin-1 there was a modest increase 
in IL-6 production in BMDCs treated with curdlan and trophic forms compared to wild-
type BMDCs. Together, these data demonstrate that dectin-1 does not contribute 
significantly to the IL-1β, IL-6, or TNFα response to mixed P. murina, but is involved in 
signaling β-glucan responses, though not exclusively. Furthermore, mannose receptor has 
only a minor role in the inhibitory effects of trophic forms on β-glucan stimulation of IL-
6 production. These data suggest that other pattern recognition receptors are involved in 
signaling both proinflammatory and suppressive functions of P. murina life forms. 
Finally, it should be noted that mixed P. murina organisms stimulated modest 
TNFα production by BMDCs from the C57BL/6 mouse strain background. TNFα 
production was not detected in response to mixed P. murina organisms when cells of a 
BALB/cJ background were used. Generally, cells from C57BL/6 mice exhibit a stronger 
Th1-type bias than cells from BALB/cJ mice. The immune response of C57BL/6 adult 
mice following inoculation with trophic forms or mixed P. murina organisms was similar 
to that observed in BALB/cJ mice (data not shown). Regardless, our data suggest that 
trophic form-mediated suppression of inflammatory responses is not limited to the 
BALB/cJ background. 
 
65 
 
Dendritic cells co-cultured with trophic forms fail to induce IFNγ production by 
CD4+ T cells. 
To evaluate whether dendritic cells are able to induce Th1-type responses when 
loaded with trophic forms, we stimulated BMDCs co-cultured with CD4+ T cells with 
either mixed P. murina or trophic forms. BMDCs loaded with mixed P. murina, but not 
trophic forms, stimulated IFN-γ production in CD4+ T cells (Fig 3.12). The addition of 
curdlan did not improve IFN-γ production in response to trophic forms (data not shown). 
These data demonstrate that cysts are required for effective Th1-type responses in vitro 
and are consistent with our findings in vivo that cysts drive the early T cell response to P. 
murina.  
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III. Discussion 
Our data confirm that cysts drive proinflammatory responses to infection with P. 
murina. Cysts promote the early recruitment of activated CD4+ and CD8+ T cells into the 
lungs of neonatal and adult mice. Cysts also promote the early recruitment of nonresident 
innate immune cells and CD19+ cells into the alveolar spaces of adult mice. Cysts in the 
inoculum stimulate the production of IFN-γ. Importantly, we found for the first time that 
trophic forms suppress β-glucan-, LTA-, and LPS-induced proinflammatory cytokine 
production by dendritic cells. Furthermore, dendritic cells cultured with trophic forms 
failed to stimulate production of IFN-γ by CD4+ T cells. Our data is consistent with the 
cyst life cycle stage driving proinflammatory responses that direct the early recruitment 
of innate and adaptive immune cells. However, the trophic life cycle forms dampen the β-
glucan and TLR-induced inflammation. This is a novel finding and suggests that the two 
life forms of Pneumocystis balance the immune response to the organisms. 
We have previously reported that there is a delay in the immune response to P. 
murina in neonatal mice compared to adults (9-12). Despite the delay, the immune 
response is sufficient to mediate clearance of P. murina organisms. This delayed response 
represents a balance between clearance of a pathogen and avoidance of inflammatory 
damage during postpartum development. Here, we report that cysts in the inoculum drive 
adaptive immune responses to P. murina in neonatal mice by day 21 post-infection. The 
fungal burden in neonates infected with trophic forms or mixed P. murina was similar by 
day 21 post-infection. These data suggest that the composition of the inoculum shapes the 
development of the immune response to P. murina organisms. 
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Redundant Th1-, Th2-, and Th17-type responses are associated with clearance of 
Pneumocystis organisms (1, 3, 4, 112, 114, 115). Here we report that cysts are required in 
the inoculum to stimulate the production of intracellular IFN-γ by CD4+ T cells in adult 
mice at day 7 post-infection. CD8+ T cells are not required for clearance of Pneumocystis 
organisms, but contribute to the production of proinflammatory cytokines, including IFN-
γ, that mediate effector responses (119). The concentration of extracellular IFN-γ in the 
alveolar spaces of adult mice infected with trophic forms did not change over the course 
of infection, despite an eventual increase in the cyst burden and the numbers of activated 
CD4+ and CD8+ T cells. This may suggest that trophic forms suppress Th1-type 
responses, which would be consistent with our in vitro data. 
Mice infected with trophic forms developed detectable cysts by day 7 in adult mice 
and day 14 post-infection in neonates. We were unable to discern in our models whether 
trophic forms are capable of inducing protective immune responses, or if the response to 
trophic forms is merely delayed. The reduced ability of trophic forms to stimulate IFN-γ 
expression does not preclude generation of protective responses, as there is redundancy in 
the types of T helper responses that can mediate clearance of Pneumocystis organisms 
(112, 114, 115). It has been previously reported (24), and our preliminary data using an 
echinocandin to prevent formation of cysts suggests, that infection with trophic forms is 
sufficient to generate protective CD4+ T cell and antibody responses (Chapter 4). 
Clearance of Pneumocystis organisms is also dependent on alveolar macrophage 
responses (2). Our data demonstrate that cysts drive increases in the numbers of CD11c+ 
CD11b+ lung resident innate immune cells. This population includes activated alveolar 
macrophages (9). We found that cysts promote MHC class II expression on the surface of 
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immune cells in the alveolar spaces. Decreased antigen presentation in the absence of 
cysts may have contributed to the less robust T cell response observed in mice infected 
with trophic forms. Additionally, cysts drive early infiltration of CD11c- CD11b+ innate 
immune cells into the lungs. This population consists of monocytes, small macrophages, 
and neutrophils. Neutrophils are not required for clearance, but their accumulation in the 
lungs correlates with disease severity in human Pneumocystis pneumonia patients (5, 
136). The CD11c- CD11b+ population may also include myeloid-derived suppressor cells 
(MDSCs). MDSCs are recruited into the lungs of immunocompromised rodents during 
PcP (140). MDSCs isolated from the lungs of mice with PcP suppress key effector cells, 
including CD4+ T cells and alveolar macrophages, and may directly contribute to lung 
injury (140, 141). The role of MDSCs in the lungs of immunocompetent hosts during 
Pneumocystis infection is unclear. 
Infection with trophic forms in the absence of cysts leads to the establishment of an 
immunosuppressive environment in the lungs that persists for up to one week following 
the formation of the cystic stage. If cysts are in the inoculum, the trophic form is unable 
to suppress inflammatory responses in the lungs as definitively. We would predict that 
infection with pure cysts, in the absence of trophic forms, would lead to accelerated 
inflammatory responses compared to infection with a mixture of organisms. 
Unfortunately, there is not a reliable method to isolate P. murina cysts in appreciable 
quantities. 
Other groups report difficulties in stimulating IL-1β, IL-6, and TNFα cytokine 
production by antigen presenting cells using unopsonized mixed P. murina organisms 
(161). We found that a multiplicity of infection of 50 mixed P. murina organisms to 1 
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BMDC was sufficient to induce IL-1β and IL-6 production. We attribute the necessity of 
this relatively high multiplicity of infection to the presence of trophic forms in the 
mixture, as our data demonstrate that trophic forms suppressed production of the β-
glucan-induced proinflammatory cytokines IL-1β, IL-6, and TNFα by BMDCs. A 
multiplicity of infection of 50 P. murina organisms per dendritic cell is composed of 
approximately 5 cysts capable of stimulating positive cytokine responses plus 45 trophic 
forms that will act to suppress these responses. Gene expression data demonstrate that 
BMDCs stimulated with trophic forms express less express IL-1β, IL-6 and TNF𝑎𝑎 
mRNA than cells stimulated with curdlan or mixed P. murina organisms (Chapter V). 
This suggests that the trophic forms suppress cytokine production rather than cytokine 
secretion. 
Interestingly, mixed P. murina organisms failed to induce TNFα in BMDCs in our 
model. TNFα production is associated with protection against P. murina, and its 
production has been reported in BMDCs following stimulation with β-glucan extracted 
from the cell wall of the cyst life cycle stage (23). We propose that trophic forms, which 
comprise approximately 90% of the organisms in mixed P. murina infection, are 
sufficient to suppress production of TNFα by BMDCs that would otherwise be induced 
by β-glucan on the surface of the cysts. Consistent with this contention, we found that 
trophic forms inhibited cytokine production by curdlan-stimulated BMDCs. 
C-type lectin receptors are transmembrane proteins that bind carbohydrates (144). 
Activation triggers phagocytosis, as well as signaling cascades that culminate in the 
activation of antigen presenting cells and the production of inflammatory cytokines. 
Dendritic cells have been shown to respond to P. carinii cyst wall β-glucans via dectin-1 
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(23). Dectin-1 is required for the generation of an effective response to Pneumocystis 
infection (69). Previous work has shown that mannose receptor binds glycoprotein A on 
the cell surface of Pneumocystis organisms, triggering phagocytosis, reactive oxygen 
species production, and NF-κB-mediated production of IL-8 (92, 98, 157). Here, we 
demonstrate that neither dectin-1 nor mannose receptor were exclusively required for the 
production of IL-1β, IL-6, and TNFα by BMDCs in response to P. murina. Our data 
suggest redundancy in the receptors that recognize cysts and trophic forms. 
Conversely, some C-type lectin receptors may suppress proinflammatory responses. 
Engagement of the C-type lectin receptor mincle by the fungal skin pathogen Fonsecaea 
monophora was shown to suppress proinflammatory responses induced by dectin-1-
mediated signaling (159). Zhang et al. demonstrated that blockage or knockdown of 
mannose receptor on rat alveolar macrophages resulted in elevated TNFα production in 
response to unopsonized mixed Pneumocystis organisms (161). Here, we demonstrate 
that the deletion of mannose receptor on dendritic cells resulted in a modest decrease in 
the ability of trophic forms to suppress the production of IL-6 in response to β-glucan, 
indicating that suppression is mediated through mechanisms other than mannose receptor. 
We are currently examining whether mincle could mediate the suppressive activity of 
trophic forms as was found for F. monophora. 
Our data indicate that trophic forms suppress cytokine responses to the TLR2 
agonist LTA and the TLR4 agonist LPS. In one paper, mice with mutant TLR4 were 
shown to have reduced IL-10, IL-12p40, and MIP-2 in the BALF of Pneumocystis 
infected mice and enhanced levels of TNF and IL-6 with no difference in clearance of the 
organisms (170). In addition, dectin-1 acts synergistically with TLR2 and TLR4 to 
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promote cytokine production following stimulation with curdlan (174). Simultaneous 
inhibition of dectin-1-, TLR2-, and TLR4-mediated signals may permit the trophic forms 
to broadly dampen the proinflammatory response and protect the colonization of 
Pneumocystis organisms in the immunocompetent host. Suppression of zymosan and 
depleted zymosan-stimulated cytokine production provides evidence that trophic forms 
can broadly dampen the response to carbohydrate and protein agonists. 
The inflammatory potential of the cysts in the face of a 10-fold excess of 
suppressive trophic forms should not be understated. The ability of trophic forms to 
suppress cytokine production is dose-dependent, and our data suggest that slight changes 
in the ratio of trophic forms to cysts may shift the balance between suppression and 
stimulation. Increasing the trophic form to cyst ratio from 10:1 to 12:1 (by the addition of 
105 trophic forms) is sufficient for the trophic forms to begin to reduce the IL-6 response 
to the mixed population. Our in vivo data indicate that the cyst burden remains low during 
the first week post-infection, but that cysts in the inoculum drive the initial inflammation. 
The rapid establishment of an immunosuppressive trophic population may be critical to 
avoid preemptive detection and clearance in immunocompetent hosts. Conversely, 
immunocompromised mice with severe pneumonia experience a final burst of trophic 
growth, in which the ratio of trophic forms to cysts reaches as high as 30:1 (unpublished 
observation). This population shift may prolong the life of the immunocompromised host 
by dampening inflammation, and may extend the window of opportunity for the 
transmission of cysts to additional hosts. 
The inoculation with trophic forms employed within this paper does not mimic the 
natural route of infection, as cysts are the transmittable life cycle stage of Pneumocystis 
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species (17). Consistent with our goal, our approach allows conclusions to be formed 
about the differential immune responses generated to the life cycle stages of 
Pneumocystis species. Recently, it was reported that treatment of immune-reconstituted 
mice with the β-1,3-D-glucan synthase inhibitor anidulafungin results in depletion of 
cysts, with the remaining trophic burden stimulating a much reduced inflammatory 
response (24). Anidulafungin belongs to a drug class known as the echinocandins, which 
have been used in combination with other antifungals in the treatment of Pneumocystis 
pneumonia in human patients (83). Linke et al., propose that depletion of cysts would 
reduce inflammation-induced lung damage in patients (24). Our data corroborates this 
suggestion, and highlight the need for a greater understanding of the response to the 
trophic stage. We propose that depletion of the immunostimulatory cysts in the presence 
of the immunosuppressive trophic forms may hamper the ability of immunocompromised 
patients or infants to control the infection. However, the net outcome may be positive, as 
lung damage during Pneumocystis pneumonia is predominately due to the inflammatory 
immune response. 
In summary, our data indicate that cysts are the primary form of Pneumocystis 
responsible for provoking adult and neonatal immune responses to infection with P. 
murina. These responses include infiltration of nonresident innate immune cells and the 
recruitment of CD19+ B cells and activated CD4+ and CD8+ T cells. Cysts are required to 
stimulate the production of IFN-γ by CD4+ T cells in vitro, and in the alveolar spaces of 
immunocompetent adult mice. We found that trophic forms suppress β-glucan-induced 
proinflammatory cytokine production by dendritic cells. We propose that the suppression 
of immune responses by the trophic forms promotes the colonization of Pneumocystis in 
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immunocompetent hosts and may be beneficial to immunocompromised hosts by 
dampening the inflammatory responses that contribute to lung pathology during PcP. 
This differential immune response to Pneumocystis trophic forms and cysts is most 
certainly a leading contributor to the success of the organisms as human pathogens. 
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Figure 3-1 Cysts are undetectable during the first week post-infection in BALB/cJ 
neonates infected with P. murina trophic forms. 
Neonatal (24-72 h old) mice were infected i.n. with 106 trophic forms or mixed P. murina 
organisms. Trophic (A, B) and cystic (C, D) lung burden in the right lung lobes was 
determined by enumeration of organisms on DiffQuik stained slides under a microscope. 
Data represent the mean ±SD of 3-4 mice per group and are representative of 2 separate 
experiments. The limit of detection was Log10 3.12 nuclei per neonatal right lung lobe. 
Two way ANOVA with Holm-Sidak post-hoc test was used to compare mean trophic 
form or cyst number between the groups, *p ≤ 0.05.  
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Figure 3-2 Cysts promote the recruitment of activated T cells in the BALF by day 21 
post-infection in neonates. 
 
Neonatal (24-72 h old) BALB/cJ mice were infected i.n. with 106 trophic forms or mixed 
P. murina organisms. Flow cytometry was used to phenotype activated CD44high 
CD62Llow CD4+ T cells (A, B), activated CD44high CD62Llow CD8+ T cells (C, D), and 
CD19+ B cells (E, F) in the BALF and lung digest. Flow cytometry was used to 
phenotype CD11c- CD11b+ (G) and CD11c+ CD11b+ (H) non-lymphocytes with high 
granularity and size from the BALF. Data represent the mean ±SD of 3-4 mice per group 
and are representative of 2 separate experiments. T tests were used to compare mean total 
cell number between the groups at individual timepoints, *p ≤ 0.05. 
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Figure 3-3 Cysts are undetectable before day 7 post-infection in BALB/cJ adults 
infected with P. murina trophic forms. 
 
Adult mice were infected i.t. with 5 X 106 trophic forms or mixed P. murina organisms. 
Trophic (A, C) and cystic (B, D) lung burdens from two separate experiments were 
determined by enumeration of organisms on DiffQuik stained slides under a microscope. 
Data represent the mean ±SD of 5 mice per group. The limit of detection was Log10 3.42 
nuclei per adult right lung lobe. T tests were used to compare the mean fungal burden 
between the two groups at individual timepoints, *p ≤ 0.05. 
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Figure 3-4 Infection with the cyst life cycle stage drives recruitment of T and B cells 
into the lungs of adult mice. 
 
BALB/cJ adult mice were infected i.t. with 5 X 106 trophic forms or mixed P. murina 
organisms. Flow cytometry was used to phenotype activated CD4+ T cells (A), activated 
CD8+ T cells (B), and CD19+ B cells (C) in the BALF, lung digest, and TBLN. 
Activation of T cells was evaluated by CD44 and CD62L expression. Data represent the 
mean ±SD of 5 mice per group and are representative of 2 separate experiments. T test 
was used to compare mean total cell number between the groups at individual timepoints, 
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.  
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Figure 3-5 Cysts promote the early increase in CD11c+ CD11b+ innate immune cells 
and infiltration of CD11c- CD11b+ innate immune cells into the alveolar spaces and 
lung parenchyma of adult mice. 
 
BALB/cJ adult mice were infected i.t. with 5 X 106 trophic forms or mixed P. murina 
organisms. Flow cytometry was used to phenotype CD11c- CD11b+ (A), CD11c+ CD11b+ 
(B) and CD11c+ CD11b- (C) non-lymphocytes with high granularity and size from the 
BALF and lung digest. Flow cytometry was used to compare expression of the MHC 
class II molecule I-Ad on CD11c+ CD11b- (D) and CD11c+ CD11b+ (E) cells in the 
BALF. Data represent the mean ±SD of 5 mice per group and are representative of 2 
separate experiments. T tests were used to compare mean total cell number between the 
groups at individual timepoints, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.  
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Figure 3-6 Cysts stimulate production of the proinflammatory Th1-type cytokine 
IFN-γ in the lungs BALB/cJ adult mice. 
 
Adult mice were infected i.t. with 5 X 106 trophic forms or mixed P. murina organisms. 
IFN-γ cytokine production in the supernatant of the first BALF wash was quantified by 
ELISA (A). Flow cytometry was used to evaluate intracellular IFN-γ expression in CD4+ 
cells in the lung digest at day 7 post-infection (B). Data represent the mean ±SD of 5 
mice per group and are representative of 2 separate experiments. T tests were used to 
compare BALF IFN-γ levels between the groups at individual timepoints (A) and to 
compare the percentage of CD4+ T cells expressing IFN-γ between the groups (B), **p ≤ 
0.01. 
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Figure 3-7 Cysts, but not trophic forms, stimulate production of the 
proinflammatory cytokines IL-1β and IL-6 by BMDCs in vitro. 
 
BMDCs from adult BALB/cJ mice were incubated with 5 X 105 trophic forms or 5 X 105 
mixed P. murina organisms for 72 h. Curdlan was included as a positive control for 
cytokine production. IL-1β (A), IL-6 (B), and TNFα (C) cytokine production was 
quantified by ELISA. Data represent the mean ±SD of 3 biological replicates per group 
and are representative of at least 2 separate experiments. One way ANOVA with Student-
Newman-Keuls post-hoc test was used to compare supernatant cytokine concentration 
between the groups, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, n.s., not statistically significant.  
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Figure 3-8 Incubation of BMDCs with trophic and cystic forms of P. murina does 
not impact cell viability. 
 
BMDCs from adult BALB/cJ mice were incubated with 5 X 105 trophic forms, 5 X 105 
mixed P. murina organisms, 10µg/ml curdlan or curdlan and trophic forms for 72 h. 
Trypan blue staining was used to determine the percentage of viable BMDCs. Data 
represent the mean ±SD of 3 biological replicates per group and are representative of 2 
separate experiments. One way ANOVA with Student-Newman-Keuls post-hoc test was 
used to compare the percent of viable BMDCs between the groups, n.s., not statistically 
significant.  
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Figure 3-9 Trophic forms suppress the zymosan- and depleted zymosan-stimulated 
production of proinflammatory cytokines by BMDCs. 
 
BMDCs from adult BALB/cJ mice were incubated with 5 X 105 trophic forms, 20µg/ml 
zymosan (A-C) and/or 20µg/ml depleted zymosan (D-F). IL-1β (A, D), IL-6 (B, E), and 
TNFα (C, F) cytokine production was quantified by ELISA. Data represent the mean 
±SD of 3 biological replicates per group and are representative of 3 separate experiments. 
One way ANOVA with Student-Newman-Keuls post-hoc test was used to compare 
supernatant cytokine concentration between the groups, **p ≤ 0.01, ***p ≤ 0.001.  
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Figure 3-8 Trophic forms suppress LTA- and LPS-mediated cytokine production. 
 
BMDCs from adult BALB/cJ mice were incubated with 5 X 105 trophic forms, 10µg/ml 
LTA (A-C), and/or 100ng/ml LPS (D-F) for 72 h. IL-1β (A, D), IL-6 (B, E), and TNFα 
(C, F) cytokine production was quantified by ELISA. Data represent the mean ±SD of 3 
biological replicates per group and are representative of three separate experiments. One 
way ANOVA with Student-Newman-Keuls post-hoc test was used to compare 
supernatant cytokine concentration among the groups when the data were parametric (D, 
E), ***p ≤ 0.001. Kruskal-Wallis one-way ANOVA on ranks was used to compare 
differences among the groups when the data were nonparametric (A, B, C, F), *p ≤ 0.05.  
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Figure 3-9 The response to trophic forms and cysts is not exclusively dependent on 
the C-type lectin receptors dectin-1 and mannose receptor. 
 
BMDCs from wildtype C57BL/6 littermate controls, MR-/-, and dectin-1-/-adult mice were 
incubated with 5 X 105 trophic forms or 5 X 105 mixed P. murina organisms for 72 h. 
Curdlan was included as a positive control for cytokine production. IL-1β (A), IL-6 (B), 
and TNFα (C) cytokine production was quantified by ELISA. Data represent the mean 
±SD of 3 biological replicates per group and are representative of 3 separate experiments. 
Kruskal-Wallis one-way ANOVA on ranks was used to compare differences among the 
groups when the data were nonparametric, *p ≤ 0.05.  
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Figure 3-10 Cysts, but not trophic forms, stimulate production of the 
proinflammatory Th1-type cytokine IFN-γ by CD4+ T cells in vitro. 
 
CD4+ T cells and BMDCs from adult BALB/cJ mice were incubated with trophic forms 
or mixed P. murina organisms for 72 h. IFN-γ cytokine production was quantified by 
ELISA. Data represent the mean ±SD of 3 biological replicates per group and are 
representative of 3 separate experiments. One way ANOVA with Student-Newman-Keuls 
post-hoc test was used to compare supernatant IFN-γ concentration between the groups, 
**p ≤ 0.01, n.s., not statistically significant. 
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Chapter 4. The trophic life cycle stage of Pneumocystis species induces protective 
adaptive responses without inflammation-mediated progression to pneumonia. 
 
I. Introduction 
There are few reports that address how Pneumocystis trophic forms and cysts shape 
the development of the in vivo immune response. Previous studies demonstrate that 
dendritic cells treated with β-1,3-glucan from the cyst wall drive Th1/Th17-type CD4+ T 
cell responses (23, 88). However, the clearance of Pneumocystis organisms from the host 
lung is dependent on a broad range of effector responses, including CD4+ T cell, B cell, 
and macrophage activity (1-4). Furthermore, Th2 and Th17-type CD4+ T cell responses 
may be generated in response to Pneumocystis infection, and clearance of the infection 
may be mediated by any of the T helper phenotypes within the Th1/Th2/Th17 paradigm 
(24, 111-115). 
In Chapter 3, we report that Pneumocystis trophic forms suppressed the production 
of proinflammatory cytokines IL-1β, IL-6, and TNFα by dendritic cells stimulated with a 
range of PAMPs, including β-glucan, LPS, LTA, zymosan, and depleted zymosan (168). 
Immunocompetent mice inoculated with purified trophic forms failed to initiate early 
innate and adaptive immune responses compared to mice inoculated with a mixture of 
trophic forms and cysts. Despite these delays, the mice inoculated with trophic forms 
were able to clear the infection within a similar period of time as the mice inoculated with 
mixed organisms. However, the rapid turnover of trophic forms into cysts in these 
previous experiments precludes the formation of conclusions regarding which life cycle 
stage(s) initiate the immune responses that led to clearance. 
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Basic research into the interactions between this fungal pathogen and the host 
immune response has the potential to inform novel approaches to reduce morbidity and 
mortality due to Pneumocystis pneumonia. In this Chapter, we sought to determine if 
trophic forms were capable of stimulating protective CD4+ T cell and B cell responses to 
P. murina infection. Conversely, immune-mediated damage is a major consequence of 
Pneumocystis pneumonia. Therefore, we explored the role of trophic forms in the 
development of Pneumocystis pneumonia. These models employed the inoculation of 
immunocompetent mice with an enriched population of trophic forms coupled with 
treatment with a β-1,3-glucan synthesis inhibitor, anidulafungin, to prevent encystment. 
Here, we demonstrate that the trophic stage of P. murina is sufficient to provoke 
CD4+ T cell- and antibody-mediated responses leading to clearance of infection, but not 
progression to PcP. The adoptive transfer of CD4+ T cells generated in the presence of 
trophic forms was sufficient to mediate the clearance of both trophic forms and cysts 
from the lungs of RAG2-/- mice. In addition, primary infection with trophic forms was 
sufficient for the development of antibody-mediated secondary responses leading to 
clearance of both trophic forms and cysts following reinfection. Recent studies 
demonstrate that protective immunization against Pneumocystis infection is a feasible 
goal, even in the context of SIV-induced immunosuppression or CD4+ T cell depletion 
(175, 176). Here, our data suggest that trophic form-mediated immune suppression of 
innate responses does not impede the development of protective secondary adaptive 
responses. Conversely, our data suggest that the depletion of the cyst life cycle stage may 
be sufficient for protection against the inflammation-mediated pathology associated with 
PcP.  
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II. Results 
 
Trophic forms are sufficient to provoke CD4+ T cell-mediated clearance of infection. 
Here, we employ an adoptive transfer model to evaluate the role of trophic forms in 
the generation of protective CD4+ T cell responses. Briefly, we treated 
immunocompetent, wild-type mice (“donors”) with the β-1,3-glucan synthesis inhibitor 
anidulafungin followed by infection with 106 purified trophic forms. The mice were 
treated with anidulafungin i.p. three times per week to prevent formation of the cystic 
stage, as initially described by Linke et al (24). A control group of mice were treated with 
saline and infected with a mixture of 106 P. murina trophic forms and cysts. The mixed 
P. murina inoculum consisted of 10 trophic forms to 1 cyst. CD4+ T cells were isolated 
from the TBLN 14 days post-infection by positive selection. CD4+ T cells were 
adoptively transferred by the retro-orbital route to RAG2-/- mice (“recipients”). Recipient 
mice were treated with either anidulafungin or saline i.p. followed by infection with 5 X 
105 trophic forms or mixed organisms, respectively. Animals were euthanized at 15 and 
30 days post-infection. 
As expected, cysts were below the limit of detection in recipient mice treated with 
anidulafungin (Fig 4.1A). Mice that received trophic form-stimulated CD4+ T cells 
followed by infection with trophic forms had more trophic forms in the lungs at day 15 
post-infection compared to all other groups (Fig 4.1A). However, all of the recipient mice 
infected with trophic forms cleared their trophic burden by day 30 post-infection, while 
only one of four mice infected with mixed organisms cleared the infection by day 30 
post-infection. A higher number of activated CD4+ T cells were also observed at day 15 
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post-infection in the lung parenchyma of the group that received trophic form-stimulated 
CD4+ T cells followed by infection with trophic forms compared to all other groups (Fig 
4.1B). These differences were resolved by day 30 post-infection, and no differences in 
the numbers of activated CD4+ T cells in the alveolar spaces (BALF) or TBLN were 
observed among the groups. These data indicate that trophic forms are sufficient to drive 
protective CD4+ T cell responses capable of mediating the clearance of trophic 
organisms. 
 
Trophic forms promote early CD4+ T cell-mediated IFNγ production in 
response to infection with trophic forms in the absence of cysts. 
Previous experiments by our lab suggest that co-culture of BMDCs with trophic 
forms is not sufficient for stimulation of IFNγ production by CD4+ T cells (Chapter 3). 
However, adoptive transfer of CD4+ T cells from trophic form-infected donors led to 
increased expression of IFNγ at day 15 post-infection in the alveolar spaces of recipient 
mice infected with trophic forms compared to adoptive transfer of CD4+ T cells from 
mixed P. murina-infected donors into recipient mice infected with mixed P. murina. (Fig 
4.2). Statistically significant differences were not observed amongst the groups in regards 
to TNFα, IL-13, and IL-17A production in the alveolar spaces (Fig 4.2). These data 
indicate that CD4+ T cells generated in the presence of trophic forms are capable of 
mediating proinflammatory responses following adoptive transfer. 
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Trophic forms are sufficient to induce B cell-mediated clearance of P. murina 
infection. 
Immunocompetent mice inoculated with purified trophic forms display delayed 
accumulation of B cells into the lungs compared to mice inoculated with a mixture of 
trophic forms and cysts (168). B cells are required for clearance of primary P. murina 
infection (3, 4). Here, we used a reinfection model with concurrent depletion of CD4+ T 
cells to evaluate the role of trophic forms in the generation of protective B cell responses. 
We treated immunocompetent, wild-type mice with the β-1,3-glucan synthesis inhibitor 
anidulafungin, followed by infection with 3 X 106 purified trophic forms. Animals were 
treated with anidulafungin three times per week throughout the primary infection. 
Following clearance of the primary infection, anidulafungin treatment was stopped, and 
anti-CD4 antibody was administered to deplete CD4+ T cells (Fig 4.3A). Mice were then 
treated with either anidulafungin or saline, and re-infected with 5 X 106 purified trophic 
forms or mixed P. murina organisms, respectively. Animals were euthanized at day 15 
post-infection. 
The memory B cell response to trophic forms was sufficient to drive the P. murina 
trophic forms and cysts burdens below the limit of detection (Log10 3.42) by day 15 post-
infection (Fig 4.3B). No differences in the numbers of CD19+ B cells in the alveolar 
spaces, lung parenchyma, and TBLN were observed between the mice rechallenged with 
trophic forms or mixed organisms (Fig 4.3C). Likewise, no differences were observed in 
the expression of the costimulatory molecules CD80 and CD86 on the surface of B cells 
(data not shown). Differences in the numbers of activated CD8+ T cells in the BALF, 
lung parenchyma, and TBLN were not observed between the groups (data not shown). 
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These data indicate that trophic forms are sufficient to induce B cell-mediated clearance 
of trophic forms and cysts. 
 
Serum antibody from trophic form- or mixed P. murina-infected mice binds mixed 
P. murina at higher titer than purified trophic forms. 
Pneumocystis-specific antibody is protective against secondary infection, even in 
the absence of CD4+ T cells (112, 121, 177). To test the specificity of the antibody 
produced in our B cell rechallenge model, serum was collected at day 15 post-
rechallenge. The titer of serum IgG against sonicated mixed P. murina organisms was 
1:5000, compared to a titer of 1:1000 against an equal protein concentration of sonicated 
trophic forms (Fig 4.4). A similar trend was observed when serum IgG was probed 
against an equal organism concentration of sonicated trophic forms vs mixed P. murina 
organisms (data not shown). The source of the serum (mice rechallenged with trophic 
forms vs mixed organisms), did not have an impact on the titer against trophic forms nor 
mixed organisms (Fig 4.4). These data are comparable to the anti-trophic form and anti-
mixed organism titers of serum collected from immunocompetent mice following 
primary infection with mixed organisms (data not shown). These data suggest that serum 
antibody from P. murina-infected mice binds purified trophic forms with a lower affinity 
or avidity than cysts. 
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Trophic forms promote early antibody-mediated innate responses to infection with 
trophic forms in the absence of cysts. 
B cells may enhance innate immunity to Pneumocystis organisms via antibody-
mediated opsonization of the fungal organisms and by the production of cytokines and 
other signals to maximize antifungal responses (3, 178-180). Here, innate immune cells 
were phenotyped and quantified at day 15 post-infection in the lungs of CD4-depleted 
mice rechallenged with trophic forms or mixed P. murina (Fig 4.5). A 2-fold increase in 
activated macrophages and lung dendritic cells (CD11c+ CD11b+ innate immune cells) 
was observed at day 15 post-infection in the alveolar spaces of mice rechallenged with 
trophic forms (Fig 4.5). Differences in the numbers of immature alveolar macrophages 
and lung dendritic cells (CD11c+ CD11b-), and non-resident innate immune cells (CD11c- 
CD11b+) were not observed between the groups (Fig 4.5). These data suggest differences 
in the kinetics of the macrophage or dendritic cell response following clearance of the 
secondary infection with trophic forms compared to mixed P. murina organisms.  
 
Infection with trophic forms in the absence of cysts is not sufficient for progression 
to PcP in immunocompromised mice. 
Pneumocystis pneumonia (PcP) is characterized by inflammation-mediated alveolar 
damage. Previously, we have shown that trophic forms suppress the production of pro-
inflammatory cytokines by BMDCs (Chapter 3) and alveolar macrophages (multiple 
members of the Garvy lab, data not shown). Here, we evaluate the role of the trophic 
forms in the development of PcP using mice deficient in T and B cells. We hypothesized 
that infection with trophic forms in the absence of cysts would delay the onset of 
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inflammation-mediated PcP. Treatment of immune-reconstituted mice with the β-1,3-
glucan synthase inhibitor anidulafungin results in depletion of Pneumocystis murina cysts 
(17). RAG2-/- mice were treated with anidulafungin or saline, followed by infection with 
2 X 106 purified trophic forms (Fig 4.6). Anidulafungin or saline treatment was 
maintained through the experiment. Saline-treated control mice were euthanized at day 
72 post-infection due to symptoms of advanced PcP, including severe weight loss (Fig 
4.6A). In contrast, mice treated with anidulafungin had no overt symptoms of PcP, and 
continued to gain weight through the end of the study at day 120 post-infection (Fig 
4.6A). The lungs of saline-treated control mice contained 8 X 107 trophic forms and 5 X 
106 cysts at day 72 post-infection (Fig. 4.6B). No cysts were detected in the lungs of the 
anidulafungin-treated mice at day 120 post-infection (Fig 4.6B). A small population of 4 
X 105 trophic organisms remained in the lungs of the anidulafungin-treated mice (Fig 
4.6B). 
T cells and B cells are required for clearance of P. murina organisms (1, 3, 4). In 
the absence of adaptive immunity, infection with mixed P. murina organisms induces 
non-protective inflammatory responses, including recruitment of innate immune cells 
(133, 134). We compared the innate immune responses in the alveolar spaces (BALF) 
and lung parenchyma of the saline- and anidulafungin-treated mice following euthanasia 
at day 72 and day 120 post-infection, respectively (Fig 4.6C-E). A direct comparison 
between the groups is not advisable due to the difference in study endpoints. Rather, the 
following data are presented as a snapshot of the lungs at the time of euthanasia. An 
average of 119 pg/ml TNFα was detected in the BALF of the saline-treated mice at day 
72 post-infection, while the lavage of anidulafungin-treated mice contained an average of 
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17 pg/ml TNFα at day 120 post-infection (Fig 4.6C). The majority of the cells in the 
alveolar spaces and lung parenchyma of saline-treated mice were CD11c- CD11b+ non-
resident innate immune cells (Fig 4.6D). The bulk of cells within this population were 
F4/80low neutrophils (Fig 4.6E). In contrast, most of the cells in the alveolar spaces of the 
anidulafungin-treated groups were CD11c+ CD11b- immature macrophages or dendritic 
cells (Fig 4.6D), and the majority of the CD11c- CD11b+ non-resident cells were 
F4/80high, indicating recruitment of monocytes or macrophages rather than myeloid-
derived suppressor cells (MDSCs) or neutrophils (Fig 4.6E). These data indicate that 
cysts are required for the development of inflammatory responses associated with 
Pneumocystis pneumonia. Additionally, trophic forms are able to survive in 
immunocompromised lungs for extended periods of time in the absence of cysts and 
without being able to complete their life cycle.  
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III. Discussion 
The data reported here confirm that the trophic stage of P. murina is sufficient to 
induce CD4+ T cell- and antibody-mediated responses leading to clearance of infection, 
but not progression to Pneumocystis pneumonia. We have previously reported that cysts 
are required for robust early innate and adaptive immune responses, including 
recruitment of CD4+ T cells and B cells into the alveolar spaces (168). While the 
magnitude of the early response was reduced in the animals inoculated with trophic forms 
alone, both the mice inoculated with trophic forms and the mice inoculated with mixed P. 
murina cleared the infection by 30 days post-inoculation (168). Previously we found that 
mice infected with trophic forms developed detectable cysts by day 7 in adult mice and 
day 14 post-infection in neonates (168). Because of this, we were unable to discern 
whether trophic forms failed to induce protective immune responses, or if the response to 
trophic forms was merely delayed. Here, we used the β-1,3-glucan synthase inhibitor 
anidulafungin to evaluate the adaptive and innate immune responses stimulated by 
trophic forms in the absence of cysts. 
Both CD4+ T cells and B cells are required for clearance of P. murina during 
primary infection, but either CD4+ T cells or antibody are sufficient for clearance during 
secondary infection (1, 3, 4, 121, 124, 181). We report here that adoptive transfer of 
CD4+ T cells from trophic form- or mixed P. murina-infected animals was sufficient to 
mediate clearance of trophic forms in recipient mice. However, adoptive transfer of CD4+ 
T cells from trophic form- or mixed P. murina-infected animals was sufficient to mediate 
clearance of mixed P. murina in only one mouse among the group of four animals by day 
30 post-infection. We have previously reported that transfer of CD4+ T cells from mixed 
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P. murina-infected animals is sufficient to mediate clearance of mixed P. murina 
organisms in RAG1-/- mice (124). Therefore, we predicted that mixed P. murina-
stimulated CD4+ T cells would eventually mediate clearance of the infection, given 
sufficient time.  
While macrophages are required for clearance of Pneumocystis organisms, these 
cells are not competent to resolve the infection in the absence of adaptive immunity (1-4). 
Here, a control population of RAG2-/- mice was infected with mixed Pneumocystis 
organisms and treated with saline, but were not given CD4+ T cells. As expected, this 
group contained a relatively high average fungal burden of 9.89 X 106 trophic forms and 
8.69 X 105 cysts at day 30 post-infection, with an average of 11.4 trophic forms to cysts 
(data not shown). This population reconfirms that the adoptive transfer of CD4+ T cells is 
required for the control of fungal growth. In addition, this control population 
demonstrates that while the majority of the CD4+ T cell recipient mice failed to clear the 
mixed P. murina organisms by day 30 post-infection, the adoptive transfer of CD4+ T 
cells was sufficient to limit fungal growth. This observation is consistent with our 
prediction that the transfer of P. murina-stimulated CD4+ T cells would eventually 
mediate clearance of the mixed P. murina infection, given sufficient time. Furthermore, 
we and others have reported clearance of mixed P. murina infection following adoptive 
transfer of CD4+ T cells in similar models. 
Intriguingly, our data suggest that the CD4+ T cell-mediated clearance of trophic 
forms during secondary infection occurs more rapidly in the absence of cysts. This 
phenomenon occurs independently of the composition of the priming infection. Our 
previous evidence indicates that cysts enhance, rather than inhibit the inflammatory 
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response (168). Therefore, we suggest that the more efficient clearance of trophic forms 
observed in the absence of cysts may be due to slower growth kinetics of trophic forms in 
the absence of cysts. Linke et al. demonstrate that anidulafungin does not limit the 
expansion of trophic forms during the first two weeks of treatment (24). However, our 
long-term anidulafungin model (Fig 4.6) demonstrates poor expansion of the trophic 
population due to the prolonged absence of the cyst stage. In the absence of 
anidulafungin, a single mature cyst produces eight progeny which develop into trophic 
forms. Clearance of the trophic population by immune cells may be accelerated in the 
absence of this source of nascent trophic forms. 
Previously reported data demonstrate that cysts are required for robust numbers of 
activated CD4+ T cells within the alveolar spaces and lung parenchyma of infected 
animals (168). However, we report here that the adoptive transfer of trophic form-
stimulated CD4+ T cells leads to increased numbers of activated CD4+ T cells in the lung 
parenchyma of recipient mice at day 15 post-infection compared to transfer of CD4+ T 
cells from mixed infection. It is noteworthy that fewer CD4+ T cells were harvested from 
the draining lymph nodes of the wild-type donor mice infected with trophic forms 
compared to mixed P. murina infection (data not shown). However, the adoptive transfer 
of equal numbers of CD4+ T cells reveals that these CD4+ T cells are fully capable of 
mediating clearance. 
Our previous data indicated that inoculation with trophic forms leads to fewer IFN-
γ-producing CD4+ T cells and suboptimal IFN-γ concentrations in the alveolar spaces 
compared to inoculation with mixed P. murina (168). Furthermore, trophic form-
stimulated BDMCs failed to produce TNFα, IL-1β, and IL-6 in response to various other 
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stimuli, and failed to induce IFNγ production during co-culture with CD4+ T cells (168). 
Conversely, the data reported here shows that trophic forms are sufficient to drive CD4+ 
T cell-mediated TNFα, IFN-γ, and IL-13 production in vivo. These data suggest that 
stimulation with trophic forms does not skew the immune response away from Th1 or 
Th2-type responses. While Th17 responses are critical for control of many fungal 
infections, including candidiasis, a mixed T helper response is observed in response to 
Pneumocystis infection. This mixed response appears to be largely redundant, as Th1-, 
Th2-, and Th17-type responses have all been associated with clearance of P. murina 
organisms (24, 111-115). Cumulatively, our data suggest that trophic forms suppress the 
development of innate immunity, and thus delay the initiation of adaptive responses 
(168), but trophic forms do not have a direct suppressive effect on CD4+ T cells in vivo. 
We have reported that cysts are required for an early increase in B cells in the lungs 
of infected mice (168). However, here we report that primary infection with trophic 
forms is sufficient to induce antibody-mediated clearance of P. murina trophic forms and 
cysts during secondary infection. No differences in B cell count were observed in the 
animals rechallenged with trophic forms or mixed P. murina. Rechallenge of CD4+ T 
cell-depleted mice with trophic forms promoted increased numbers of activated 
macrophages and dendritic cells (CD11c+ CD11b+) in the alveolar spaces compared to 
mice rechallenged with mixed P. murina. However, these data were generated by a single 
timepoint following clearance (day 15), and differences between the groups may be due 
to the kinetics of clearance, rather than differences in the magnitude of the response.  
Intriguingly, serum antibody bound sonicated mixed P. murina antigen at higher 
titer than trophic antigen. This phenomenon was observed even in serum from 
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anidulafungin-treated animals that had never developed cysts. Previous studies suggest 
that there is significant overlap in the glycoproteins, including glycoprotein A (gpA, 
alternatively, major surface glycoprotein, MSG), on the surface of trophic forms and 
cysts (20, 165). Our data suggest that serum antibody raised against trophic forms binds 
conserved material on the cyst life cycle stage. We also observe that serum antibody 
collected during primary infection in immunocompetent mice bound cysts at higher titer 
than trophic form, as confirmed by fluorescent microscopy (data not shown). These data 
indicate that treatment of trophic forms or cysts with anidulafungin was not responsible 
for the decreased titer of serum antibody against trophic antigen. Rather, these 
observations again suggest that there may be differences in the identity or quantity of the 
antigenic material present on the trophic forms and cysts. Alternatively, trophic forms 
may modulate the T helper response, resulting in the reduction or elimination of a subset 
of IgG isotypes, leading to a net reduction of total IgG, but not necessarily a reduction in 
protection. Regardless, our data indicate that while serum antibody binds mixed P. 
murina antigen at higher titer than trophic forms, antibody-mediated responses are 
sufficient for clearance of both trophic forms and cysts. 
While the initiation of innate and adaptive responses is required for clearance of 
Pneumocystis organisms in immunocompetent hosts, the non-specific provocation of 
inflammation leads to immune-mediated damage in immunocompromised hosts that 
progress to Pneumocystis pneumonia (133, 134). It has been previously reported that 
treatment of immune-reconstituted mice with the β-1,3-glucan synthase inhibitor 
anidulafungin results in depletion of cysts and a reduced inflammatory response (24). 
Here, we report that long-term anidulafungin treatment of trophic form-infected RAG2-/- 
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mice results in the carriage of a relatively small population of trophic forms without 
progression to pneumonia. Control RAG2-/- mice developed cysts and progressed to 
pneumonia characterized by weight loss, and recruitment of neutrophils into the lungs. In 
contrast, the majority of innate immune cells within the alveolar spaces of anidulafungin-
treated mice were immature alveolar macrophages and lung dendritic cells. 
Linke et al., propose that depletion of cysts would reduce inflammation-induced 
lung damage in patients, and our data further corroborates this suggestion (24). However, 
our data highlight the need for a greater understanding of the impact of trophic forms on 
inflammatory responses and host health. While no overt symptoms of pneumonia were 
detected in our anidulafungin-treated mice, it has been reported that trophic forms induce 
direct damage to alveolar epithelial cells due to attachment to the host cell membrane 
(132). Further studies should evaluate the effect of a chronic infection with trophic forms 
on the health of alveolar epithelium. 
In our model, the fungal lung burden of RAG2-/- mice with severe pneumonia may 
consist of as many as 1 X 108 trophic forms. It is unclear why the expansion of trophic 
forms was limited in RAG2-/- mice during long-term treatment with anidulafungin. 
Cushion et al, demonstrate that a short-term course of β-1,3-glucan synthase inhibitor 
therapy does not hamper expansion of trophic forms (17, 24). However, the extended 
time course of our study suggests that cysts enhance the growth of the trophic forms. 
It is thought that the formation of the cyst requires sexual reproduction, and it is 
possible that the growth of the fungus is severely limited when the trophic forms are 
restricted to asexual reproduction (13). Meiosis followed by multiple rounds of mitosis 
within the maturing cyst results produces eight progeny, which develop into trophic 
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forms. In the absence of this rapid expansion of organisms via sexual reproduction, it is 
possible that innate immune cells may kill enough of the trophic forms to limit the 
growth of the population, but not enough to clear the organisms from the lungs. 
Alternatively, a signal or product from the cyst or cyst-stimulated host cells may be 
required for expansion of trophic forms. Trophic forms are found clustered within a 
biofilm-like substance that includes material from previously ruptured cysts (14). 
Depletion of cysts may deprive the trophic forms of this protective shelter, and may 
permit killing of trophic forms by innate immune cells. 
Whatever the mechanism, it is interesting that in an immunosuppressed 
environment the trophic population persists in the absence of cysts. This indicates that 
long-term exposure to trophic forms is insufficient to promote widespread activation of 
lung immune cells, including macrophages, in the absence of signals from T cells and B 
cells. Furthermore, this may suggest that trophic forms also suppress the production of 
proinflammatory signals, including cytokines, by alveolar epithelial cells. In Chapter 5, 
we will demonstrate that dendritic cells are capable of phagocytosing trophic forms. It is 
possible that, in the absence of the cyst, the trophic population may be limited by random 
encounters with phagocytes. These encounters may result in the destruction of individual 
trophic forms, but may serve to suppress the activation of the immune cell and thereby 
protect the trophic population as a whole. It should also be noted that the long-term 
carriage of trophic forms results in the infiltration of a population of CD11c- CD11b+ 
cells that are overwhelmingly F4/80high. This suggests that trophic forms do not mediate 
immune suppression by recruiting F4/80low myeloid-derived suppressor cells. 
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These observations emphasize the need for an improved understanding of the life 
cycle of Pneumocystis species, and the role of the trophic and cystic lifeforms in the 
development of protective vs detrimental immune responses. The data presented herein 
suggest that disruption of cyst development (and, thus the elimination of the progeny 
from sexual reproduction), limits the growth of Pneumocystis trophic form and prevents 
the development of Pneumocystis pneumonia. Future studies should evaluate the 
consequences of long-term carriage of trophic populations within the host lung. 
Relatively few human populations suffer from an immunodeficient state as pronounced 
as that modeled in the RAG2-/- mice, thus, additional animal models of 
immunodeficiency may be employed to identify patient populations capable of clearing 
this small population of trophic forms. In these populations, treatment with anidulafungin 
or other echinocandins may remove the threat of immune-mediated lung damage, while 
providing an opportunity for the host to develop a more modest, yet effective immune 
response to the trophic population, as Linke et al. demonstrated in their model of immune 
reconstitution syndrome (24). 
We have previously reported that infection with trophic forms in the absence of 
cysts leads to the delayed initiation of innate and adaptive responses against 
Pneumocystis infection (168). Despite these delays, we found here that the trophic stage 
of P. murina is sufficient to induce CD4+ T cell- and antibody-mediated responses 
leading to clearance of infection, but not progression to Pneumocystis pneumonia, as 
defined by severe weight loss and infiltration of innate immune cells into the lungs. 
These data suggest that immune evasion by the trophic forms may hinge on the 
suppression of the initiation of the innate immune response. The development of adaptive 
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immunity may represent a “point of no return” at which the trophic forms are no longer 
able to escape clearance. 
Manipulation of the immune response to trophic forms and cysts may provide 
new options for the treatment and prevention of Pneumocystis infection, while a failure to 
consider these differential responses may hamper future efforts. Here, our data indicate 
that trophic forms elicit adaptive responses, but do not provoke the non-protective 
inflammation characteristic of Pneumocystis pneumonia. Further evaluation of the 
antigenic determinants on trophic forms and cysts may elicit a vaccine that provides 
protection while limiting immune-mediated damage, including immune reconstitution 
syndrome. 
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Figure 4-1 Infection with trophic forms is sufficient to provoke CD4+ T cell-
mediated clearance of P. murina trophic forms. 
 
CD4+ T cells were adoptively transferred from trophic form or mixed Pneumocystis-
infected BALB/c mice (donors) to RAG2KO mice (recipients). Recipient mice were 
challenged with trophic forms or mixed Pneumocystis organisms. Both donor and 
recipient mice were treated with anidulafungin or saline throughout the study to maintain 
trophic or mixed Pneumocystis burdens, respectively. Fungal lung burdens (A) in the 
right lung lobes were determined by enumeration of organisms on DiffQuik stained slides 
under a microscope. Flow cytometry was used to phenotype activated CD44high CD62Llow 
CD4+ T cells (B) in the BALF, lung digest, and TBLN. Data represent the mean ±SD of 4 
mice per group and are representative of 2 separate experiments. Kruskal-Wallis one-way 
ANOVA on ranks with Student-Newman-Keuls post-hoc test was used to compare 
differences among the groups at individual timepoints when the data were nonparametric 
(A). Two-way ANOVA with Student-Newman-Keuls post-hoc test was used to compare 
cell numbers where the data were parametric (B), *p ≤ 0.05.  
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Figure 4-2 Transfer of CD4+ T cells from trophic form-infected mice promotes 
increased production of IFNγ in recipient mice challenged with trophic forms, 
compared to challenge with mixed Pneumocystis organisms. 
 
CD4+ T cells were adoptively transferred from trophic form or mixed Pneumocystis-
infected BALB/c mice (donors) to RAG2KO mice (recipients). Recipient mice were 
challenged with trophic forms or mixed Pneumocystis organisms. Both donor and 
recipient mice were treated with anidulafungin or saline throughout the study to maintain 
trophic or mixed Pneumocystis burdens, respectively. TNFα, IFNγ, IL-13, and IL-17A 
concentrations in the supernatant of the first BALF wash were quantified by ELISA. Data 
represent the mean ±SD of 4 mice per group and are representative of 2 separate 
experiments. Two-way ANOVA with Student-Newman-Keuls post-hoc test was used to 
compare cytokine expression, *p ≤ 0.05.  
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Figure 4-3 Infection with trophic forms is sufficient to provoke antibody-mediated 
clearance of P. murina trophic forms and cysts. 
 
BALB/c adult mice were infected i.t. with trophic forms. Mice were treated with 
anidulafungin one day prior to infection, and three times per week thereafter until d35 
post-infection. Anti-CD4 antibody was administered at d40 post-infection to deplete 
CD4+ T cells. The depletion of CD4+ T cells was confirmed by flow cytometry three days 
after treatment with the first dose of anti-CD4 monoclonal antibody (A). Treatment with 
anidulafungin or saline resumed one day prior to rechallenge with trophic forms or mixed 
P. murina organisms, respectively. The depletion of CD4+ T cells was confirmed by flow 
cytometry on lung homogenate at d43 (A). Animals were euthanized 15 days after 
rechallenge. Fungal lung burdens (B) in the right lung lobes were determined by 
enumeration of organisms on DiffQuik stained slides under a microscope. The limit of 
detection was Log10 3.42 organisms per adult right lung lobe. Flow cytometry was used to 
phenotype CD19+ B cells (C) in the BALF, lung digest, and TBLN. Data represent the 
mean ±SD of 3 mice per group and are representative of 2 separate experiments. T tests 
were used to compare mean fungal burden or total cell number between the groups, *p ≤ 
0.05.  
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Figure 4-4 Serum antibody collected from trophic form or mixed P. murina-infected 
mice binds trophic forms at lower titer than mixed P. murina. 
 
BALB/c adult mice were infected i.t. with trophic forms. Mice were treated with 
anidulafungin one day prior to infection, and three times per week thereafter until d35 
post-infection. Anti-CD4 depleting antibody was administered at d40 post-infection. 
Treatment with anidulafungin or saline resumed one day prior to rechallenge with trophic 
forms or mixed P. murina organisms, respectively. Animals were euthanized 15 days 
after rechallenge, and serum antibody was collected. ELISAs were performed on serum 
to determine the level of trophic form- or mixed Pneumocystis-specific IgG. Serum was 
probed against equal protein concentrations of sonicated trophic or mixed P. murina 
antigen. Data are expressed as the optical density at 405 nm. Data represent the mean 
±SD of 3 mice per group and are representative of 2 separate experiments. Kruskal-
Wallis one-way ANOVA on ranks with Student-Newman-Keuls post-hoc test was used 
to compare mean optical density at 405nm between trophic antigen and mixed antigen 
groups at individual dilutions, *p ≤ 0.05. 
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Figure 4-5 The antibody-mediated secondary response to trophic forms promotes an 
increase in CD11c+ CD11b+ innate immune cells in the alveolar spaces. 
 
BALB/c adult mice were infected i.t. with trophic forms. Mice were treated with 
anidulafungin one day prior to infection, and three times per week thereafter until d35 
post-infection. Anti-CD4 depleting antibody was administered at d40 post-infection. 
Treatment with anidulafungin or saline resumed one day prior to rechallenge with trophic 
forms or mixed P. murina organisms, respectively. Animals were euthanized 15 days 
after rechallenge. Flow cytometry was used to phenotype CD11c+ CD11b-, CD11c+ 
CD11b+ and CD11c- CD11b+ non-lymphocytes with high granularity and size from the 
BALF and lung digest. Data represent the mean ±SD of 3 mice per group and are 
representative of 2 separate experiments. T tests were used to compare mean total cell 
number between the groups, **p ≤ 0.01.  
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Figure 4-6 Cysts are required for progression to pneumonia in 
immunocompromised mice infected with P. murina. 
 
RAG2KO mice were treated with anidulafungin or saline, followed by infection with 2 X 
106 purified trophic forms. Anidulafungin or saline treatment was maintained through the 
experiment. Saline-treated control mice were euthanized at day 72 post-infection due to 
symptoms of advanced PcP. Mice treated with anidulafungin were euthanized at day 120 
post-infection. The change in average body weight was recorded (A). Fungal lung 
burdens (B) in the right lung lobes were determined by enumeration of organisms on 
DiffQuik stained slides under a microscope. TNFα concentrations in the supernatant of 
the first BALF wash were quantified by ELISA (C). Flow cytometry was used to 
phenotype CD11c+ CD11b-, CD11c+ CD11b+ and CD11c- CD11b+ non-lymphocytes with 
high granularity and size from the BALF and lung digest (D). CD11c- CD11b+ cells were 
further phenotyped by flow cytometry on the basis of F4/80 expression (E). Data 
represent the mean ±SD of 3 mice per group and are representative of 2 separate 
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experiments. T tests were used to compare body weight between the groups at individual 
timepoints, *p ≤ 0.05.  
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Chapter 5: The trophic life cycle stage of the opportunistic fungal pathogen 
Pneumocystis murina hinders the ability of dendritic cells to stimulate CD4+ T cell 
responses 
 
The following chapter is modified from: Evans HM, Simpson A, Shen S, Stromberg AJ, 
Pickett CL and Garvy BA. 2017. The trophic life cycle stage of the opportunistic fungal 
pathogen Pneumocystis murina hinders the ability of dendritic cells to stimulate CD4+ T 
cell responses. Infect Immun. In press. doi:10.1128/IAI.00396-17. 
 
I. Introduction 
In Chapter 3, we have reported that the life cycle stages of Pneumocystis murina 
have opposing effects on the immune response (168). The immune response to infection 
with P. murina trophic forms alone was less robust than the response to infection with a 
physiologically normal mixture of cysts and trophic forms. Infection with trophic forms 
alone resulted in reduced numbers of CD11c+ innate immune cells in the lungs, as well as 
reduced recruitment of activated CD4+ and CD8+ T cells, compared to infection with a 
normal mixture of trophic forms and cysts. In vitro, trophic forms suppressed production 
of the proinflammatory cytokines by dendritic cells stimulated with broad range of fungal 
and bacterial PAMPs. In addition, trophic form-stimulated BMDCs failed to stimulate 
production of the Th1-type cytokine IFN-γ by CD4+ T cells. 
In this Chapter, we sought to further characterize the dendritic cell response to 
trophic forms. Dendritic cells are the principal antigen presenting cells in the lung. 
However, their role in initiating the adaptive response to Pneumocystis has been 
understudied. Previous reports indicate that β-glucan from the cyst wall is sufficient to 
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induce dendritic cell-mediated proliferation and polarization of Th1/Th17-type CD4+ T 
cells(23, 88). The mechanism for dendritic cell recognition of Pneumocystis trophic 
forms, which do not express β-glucan, is unknown. Both stages express surface 
glycoproteins and mannoproteins that may serve as pathogen-associated molecular 
patterns (PAMPs) that could be recognized by receptors on host cells (7-9). However, the 
breath of the suppression observed in Chapter 3 suggests that, despite the availability of 
PAMPs, trophic forms induce poor activation of dendritic cells. In contrast, the data 
presented in Chapter 4 indicate that trophic forms are sufficient to promote CD4+ T cell 
responses. 
We sought to further evaluate the effects of trophic forms on dendritic cell 
activation and antigen presentation. The failure of trophic forms to stimulate key 
proinflammatory cytokines (Chapter 3) encouraged us to use the NanoString gene 
expression assay to evaluate the dendritic cell response to trophic forms compared to a 
mixed population of trophic forms and cysts. NanoString is an array capable of analyzing 
the relative expression of a predefined panel of target genes. Herein, we employed the 
NanoString nCounter Mouse Immunology CodeSet to evaluate the expression of 561 
immunity-related mouse transcripts in dendritic cells treated with trophic forms or a 
mixed population of trophic forms and cysts. This technique painted a focused portrait of 
the dendritic cell response to trophic forms. The NanoString assay more directly 
addressed our research focus than other, more extensive, methods of gene expression 
analysis such as RNASeq. 
The NanoString assay was a powerful tool to demonstrate the broad failure of 
dendritic cells to become activated in response to trophic forms. We demonstrate that P. 
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murina trophic forms hinder the ability of dendritic cells to serve in their essential role as 
stimulators of CD4+ T cell responses by reducing the capacity of dendritic cells to 
produce proinflammatory cytokines, present antigen, and express costimulatory 
molecules. Treatment of dendritic cells with trophic forms induced a less robust pattern 
of expression of immunity-related genes than treatment with a mixture of P. murina 
trophic forms and cysts. In addition, treatment with trophic forms reduced the ability of 
dendritic cells to increase surface expression of MHC class II and CD40 in response to 
stimulation with mixed P. murina organisms or zymosan. These defects in the expression 
of MHC class II and costimulatory molecules corresponded with a reduced capacity for 
trophic form-loaded dendritic cells to stimulate CD4+ T cell proliferation and 
polarization.  
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II. Results 
 
P. murina trophic forms induce a suppressive pattern of gene expression in dendritic 
cells. 
Pneumocystis trophic forms suppress the production of proinflammatory cytokines 
by dendritic cells stimulated with multiple PAMPs (168). These PAMPs are recognized 
by a range of pattern recognition receptors that mediate diverse signaling pathways 
within the cell, including, in the case of IL-1β, inflammasome activation. These data 
suggest that P. murina trophic forms have a broadly suppressive effect on dendritic cells. 
To evaluate the activity of dendritic cells in response to trophic forms, we employed a 
target gene expression array to analyze the dendritic cell response to P. murina trophic 
forms based on the expression of 561 immunity-related mouse transcripts (NanoString 
nCounter Mouse Immunology CodeSet). BMDCs from adult BALB/cJ mice were 
incubated with trophic forms or mixed P. murina organisms at a dendritic cell to fungal 
cell ratio of 1:50. Controls included untreated BMDCs and BMDCs treated with 10 
µg/ml of the β-glucan curdlan. Curdlan is a high-molecular-weight β-1,3-glucan isolated 
from Alcaligenes faecalis, and is similar to the β-1,3-glucan that composes the P. murina 
cyst wall (182, 183). Curdlan is employed in these experiments as a reductive positive 
control for β-glucan-induced signaling in BMDCs. RNA was extracted after 2, 4, and 8 
hr, and analyzed with the preassembled NanoString panel. Raw NanoString data are 
hosted at doi:10.1128/IAI.00396-17 (Data Set S1). Raw counts were normalized to 
internal reference transcripts and housekeeping genes. 
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The normalized data illustrate that trophic forms induced a broader pattern of 
reduced gene expression in dendritic cells, compared to stimulation with a normal 
mixture of cystic and trophic forms (“mixed Pc”), or the β-glucan curdlan (Fig 5.1A-D). 
The heat map shown in Fig 5.1A depicts the relative values of the 561 transcripts for 
each sample (n = 5) within each treatment group, at 8 h post-treatment. Data are shown as 
the relative gene expression value compared to the unstimulated control. A large portion 
of the immunity-related genes were induced by treatment with curdlan, but 
downregulated by treatment with trophic forms (Fig 5.1A). Stimulation with a mixture of 
P. murina organisms did not induce total gene expression as robustly as the positive 
control, curdlan (Fig 5.1A). However, stimulation with mixed P. murina organisms did 
lead to upregulation of a greater number of genes than stimulation with trophic forms 
alone (Fig 5.1A). Intriguingly, stimulation with trophic forms and mixed P. murina 
organisms led to the upregulation of several genes whose expression was not induced by 
curdlan (Fig 5.1A, C).  
Experimental data shown in Fig 5.1B represent the principle component analysis-
based clustering of the samples within each group after 8 h of treatment. Principle 
component analysis plots the data in terms of the directions where the data has the most 
variance (the mathematically-defined “principal components”). Here, each of the groups 
formed distinct clusters, indicating a unique pattern of gene expression following each 
treatment. Experimental data shown in Fig 5.1C-D represent genes upregulated or 
downregulated in the treated groups relative to the untreated control. Differences were 
identified by two-way ANOVA followed by pairwise comparisons using the Least 
Significant Difference Method. A change was deemed significant if the p value was 
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<0.01. Notably, BMDCs treated with trophic forms also increased the expression of a 
subset of genes relative to unstimulated cells. Of the 561 immunity-related transcripts, 
stimulation with trophic forms induced the statistically significant upregulation of 154 
genes (Fig 5.1C) and the downregulation of 130 genes (Fig 5.1D) relative to the 
unstimulated control. 121/154 (78.6%) of the genes upregulated (Fig 5.1C) by 
stimulation with trophic forms and 93/130 (71.5%) of the genes downregulated (Fig 
5.1D) by treatment with trophic forms were also upregulated or downregulated 
(respectively) in the mixed P. murina- and curdlan-treated groups. The pattern of gene 
expression in response to mixed P. murina organisms (a mixture of 10 trophic forms to 1 
β-glucan expressing cyst) was similar to the phenotypes induced by either trophic forms 
or curdlan with few unique genes either up- or down-regulated (Fig 5.1C-D). The data 
shown in Fig 5.1 demonstrate that trophic forms induced a unique pattern of gene 
expression in regards to both the identity of gene transcript, and the magnitude of the 
change in expression. In contrast, treatment with mixed P. murina organisms induced a 
pattern of gene expression that represents an intermediate phenotype between the 
comparatively less robust pattern of gene expression that is induced by trophic forms and 
the highly inflammatory pattern that is induced by the β-glucan curdlan. 
 
Trophic forms induce the expression of genes encoding chemokines and complement 
proteins. 
As noted in Fig 5.1C, stimulation with trophic forms induced the statistically 
significant upregulation of 154 genes compared to the unstimulated control. The data 
shown in Fig 5.2A include all of the genes in the NanoString panel with a statistically 
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significant (p < 0.01) four-fold or greater increase in expression between BMDCs treated 
with trophic forms compared to unstimulated BMDCs. Several genes on this list are 
related to the complement system or encode chemokines. Notably, many of these genes, 
including the genes encoding complement system transcripts, are more highly expressed 
in cells treated with trophic forms compared to stimulation with curdlan or a mixture of 
P. murina organisms. 
The data in Fig 5.2B-C represent all genes encoding regulators of inflammation (B) 
or immunity-related transcription factors (C) with a statistically significant (p < 0.01) 
two-fold or greater increase in expression between BMDCs treated with trophic forms 
compared to unstimulated BMDCs. While we have previously reported that trophic forms 
fail to induce translocation of NFκB in alveolar macrophages and trophic forms suppress 
the production of IL-1β, IL-6, and TNFα protein by dendritic cells, these data indicate 
that dendritic cells are responsive to the trophic forms (9, 168). Furthermore, treatment of 
dendritic cells with trophic forms induces a distinct pattern of gene expression compared 
to stimulation with curdlan and mixed P. murina. 
 
Muc1 is not required for trophic form-mediated suppression of cytokine responses. 
A striking finding in our gene expression data is that the expression of Muc1 is 50-
fold greater in BMDCs treated with trophic forms compared to the unstimulated control 
(Fig 5.2A). In contrast, stimulation of BMDCs with mixed P. murina organisms or 
curdlan induced a 10-fold increase in Muc1 expression compared to the unstimulated 
control (Fig 5.2A). Muc1 encodes a transmembrane mucin-like glycoprotein that is 
associated with suppression of TLR-mediated signaling in alveolar epithelial cells (184). 
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In addition to CLRs such as dectin-1, Pneumocystis species have been shown to stimulate 
cytokine production via TLR2 and TLR4 (156, 170). We previously published that 
Pneumocystis trophic forms suppressed the production of proinflammatory cytokines by 
dendritic cells stimulated with the TLR2 agonist LTA and the TLR4 agonist LPS. To 
evaluate the role of Muc1 in trophic form-mediated suppression of TLR signaling, we 
measured cytokine production by Muc1-deficient BMDCs following stimulation with 
trophic forms, mixed P. murina organisms, curdlan, LPS, and/or LTA (Fig 5.3). Trophic 
form-mediated suppression of IL-6 was similar in wild-type and Muc1-/- BMDCs. 
 
Stimulation with trophic forms leads to attenuated expression of multiple cytokine 
genes compared to treatment with a mixture of trophic forms and cysts. 
Dendritic cells are the principal antigen presenting cells in the lung, and are critical 
for optimal B cell and T cell activation in response to pathogens (reviewed in (84)). 
Immature lung dendritic cells reside in the alveolar interstitium, where they project their 
dendritic extensions through the epithelial-tight junctions into the alveolar spaces. 
Encounters with antigen promote a complex maturation process that prepares the 
dendritic cell to serve as an antigen-presenting cell. We previously published that 
Pneumocystis trophic forms suppressed the production of proinflammatory cytokines IL-
1β, IL-6, and TNFα by dendritic cells stimulated with multiple PAMPs (168). A principle 
aim of the gene expression array was to identify the extent of the suppressive impact of 
trophic forms on dendritic cells. 
Data shown in Fig 5.4A represent the relative gene expression at 8 h post-
stimulation of every cytokine included in the preassembled panel. Gene expression is 
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displayed as the log2 value of the quotient of the treated value divided by the untreated 
value. Stimulation with trophic forms led to the expression of the vast majority of the 
cytokine genes included in the panel. However, the magnitude of this upregulation was 
attenuated compared to treatment with mixed P. murina organisms or curdlan. For 
example, treatment with trophic forms increased the expression of transcripts encoding 
IL-1β and IL6. However, this upregulation was not as great as that observed in cells 
stimulated with mixed P. murina or curdlan (Fig 5.4A). In addition, IL-1β and IL-6 
protein were not detectable in the supernatant of dendritic cells stimulated with purified 
trophic forms (Fig 5.5). Treatment with trophic forms failed to induce gene and protein 
expression of TNFα (Fig 5.4A and Fig 5.5). Mixed P. murina and curdlan both induced 
expression of the transcript encoding TNFα. However, as previously reported, stimulation 
with curdlan but not mixed P. murina induced protein expression of TNFα (168). 
 
Trophic forms induce less robust expression of multiple transcription factors and 
positive regulators of inflammation compared to treatment with a mixture of 
trophic forms and cysts. 
Data shown in Fig 5.4B represent genes that encode positive regulators of 
inflammation whose expression was significantly different (greater than 2-fold 
difference, p<0.01) between the cells treated with trophic forms and mixed P. murina 
organisms at 8 h. Notably, treatment with trophic forms in the absence of cysts lead to 
less robust expression of a wide range of mediators of inflammation, including the genes 
encoding the dendritic cell maturation marker SLAMF1, compared to stimulation with a 
mixed population of trophic forms and cysts. Data shown in Fig 5.4C represent genes 
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that encode immunity-associated transcription factors whose expression was significantly 
different (greater than 2-fold difference, p<0.01) between the cells treated with trophic 
forms and mixed P. murina organisms at 8 h. Conventional dendritic cells (cDCs) may be 
divided into two broad subsets: CD8α+ CD103+ cDC1s, which promote Th1 polarization 
and CD11b+ cDC2s, which promote Th2 or Th17-type responses (185-190). Treatment 
with trophic forms reduced the expression of the transcripts encoding the cDC1-
associated transcription factors Batf3 and Irf8 and the expression of the cDC2-associated 
transcription factor Irf4 below the basal level of expression. In contrast, stimulation with 
mixed P. murina organisms enhanced the expression of each of these markers. 
 
Suppression of the cytokine response is not dependent on trophic form viability, but 
is partially dependent on direct contact between trophic forms and dendritic cells. 
Pneumocystis trophic forms suppress the production of proinflammatory cytokines 
IL-1β, IL-6, and TNFα by dendritic cells stimulated with multiple PAMPs (Fig 5.5 and 
(168)). We report here that trophic forms are capable of suppressing the expression of 
multiple immunity related genes (Fig 5.1 and 5.4) below the basal level of expression. 
To determine if suppression requires live participation by the trophic forms, we tested the 
ability of heat-killed (Fig 5.6A-C) or sonicated (Fig. 5.6D-F) trophic forms to prevent 
IL-1β, IL-6, and TNFα cytokine production in BMDCs treated with curdlan. Live, heat-
killed, and sonicated trophic forms suppressed cytokine production, indicating that troph-
mediated suppression is not dependent on the viability of trophic forms. Surprisingly, 
while intact mixed P. murina organisms induce IL-1β and IL-6 production, these data 
indicate that sonicated mixed P. murina organisms suppressed these responses. These 
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data suggest that intact cysts are required for stimulation of cytokine production, and, in 
the absence of this stimulation, the trophic material is able to suppress the response to 
other PAMPs. 
Immunosuppression by the trophic forms could be mediated by a secreted factor or 
by direct contact between the trophic forms and the BMDCs. We measured curdlan-
induced IL-1β, IL-6, and TNFα cytokine production by BMDCs separate from trophic 
forms by Transwell polyester inserts with 0.4µm pores (Fig 5.6G-I). Direct contact 
between the trophic forms and BMDCs was not required for a reduction in IL-1β or 
TNFα cytokine production (Fig 5.6G-H). Intriguingly, direct contact was required for the 
suppression of IL-6 protein production (Fig 5.6I). 
A relatively small amount of P. murina DNA was detected in the lower Transwell 
compartment, and quantitative PCR indicated that up to 2 X 103 trophic forms (or 
equivalent trophic DNA) may have crossed the Transwell membrane (data not shown). 
However, the addition of greater than 106 trophic forms was required to see the level of 
suppression that was observed in the Transwell system (Fig 5.7). In addition, a portion of 
the supernatant from the lower compartments was cytospun onto slides and examined 
under a microscope (limit of detection = 102 organisms, data not shown). No trophic 
forms were observed, further confirming that a significant proportion of the trophic forms 
did not cross the membrane. These controls indicate that the suppression of TNFα and IL-
1β observed in Fig 5.6G-I was due to material shed from trophic forms, rather than the 
passage of whole trophic forms through the Transwell membrane. 
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Trophic forms suppress the expression of multiple factors related to antigen 
presentation, including MHC class II and the costimulatory molecule CD40. 
We have previously reported that infection of wild-type mice with trophic forms 
induces less expression of MHC class II on the surface of CD11c+ CD11b- and CD11c+ 
CD11b+ cells within the lungs compared to infection with mixed P. murina organisms 
(168). This effect was consistent through two weeks post-infection. The reduced capacity 
of BMDCs to express MHC class II correlated with less robust CD4+ T cell recruitment 
and proliferation in the lungs of mice infected with trophic forms compared to mixed P. 
murina organisms (168).  
The preassembled NanoString panel included several genes related to antigen 
presentation (Fig. 4A). Gene expression is displayed as the log2 value of the quotient of 
the treated value divided by the untreated value. These data indicate that trophic forms 
suppress the expression of multiple antigen-presentation genes below the basal level of 
expression. Ciita encodes the class II transactivator, a master regulator of genes related to 
MHC class II expression. The expression of Ciita is 10-fold lower in BMDCs treated 
with trophic forms compared to the unstimulated control (Fig 5.8A). In contrast, 
stimulation with mixed P. murina led to a 3-fold decrease in Ciita expression compared 
to the unstimulated control, while treatment with curdlan did not significantly alter the 
expression of Ciita (Fig. 4A). Data shown in Fig 5.8B represent the relative expression of 
genes encoding costimulatory molecules. Treatment of BMDCs with trophic forms 
induces lower levels of expression of the transcripts encoding the costimulatory 
molecules CD40, CD80, CD86, PD-L1 and PD-L2 than stimulation with mixed P. 
murina organisms. 
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Flow cytometry was used to evaluate protein expression of MHC class II (Fig 5.8C-
E) and CD40 (Fig 5.8D-F) on the surface of BMDCs treated for 24 hours with trophic 
forms, mixed P. murina organisms, and/or zymosan. Zymosan is a protein-carbohydrate 
preparation from the cell wall of Saccharomyces cerevisiae, and, unlike curdlan, zymosan 
may be processed and presented as protein antigen. Treatment of BMDCs with mixed P. 
murina organisms and/or zymosan resulted in increased surface expression of MHC class 
II and CD40 compared to the basal level. Treatment with trophic forms failed to induce 
surface expression of MHC class II and CD40. Addition of trophic forms to BMDCs 
treated with P. murina organisms or zymosan inhibited the expression of MHC class II 
and CD40. These data indicate that trophic forms suppress the expression of MHC class 
II and the costimulatory molecule CD40 on the surface of dendritic cells. Maturation of 
dendritic cells is characterized by an initial burst in antigen presentation and MHC class 
II expression followed by a reduction in additional antigen processing and presentation. 
However, surface expression of peptide-MHC class II complexes is highly stable in 
mature dendritic cells, with a reported half-life of 31 hours observed in dendritic cells 
stimulated with LPS (191). Therefore, the observed reduction in MHC class II surface 
expression after 24 hours of stimulation suggests that treatment with trophic forms 
impedes the maturation of dendritic cells. 
 
Pretreatment of dendritic cells with trophic forms reduces allogenic CD4+ T cell 
proliferation in a mixed lymphocyte reaction. 
In order to determine the significance of reduced MHC class II on BMDCs treated 
with trophic forms, a mixed lymphocyte reaction was used in which T cell proliferation is 
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dependent on detection of allogenic MHC class II, but not specific antigen. To test the 
effect of trophic forms on allogenic CD4+ T cell proliferation, BMDCs generated from 
Iad-expressing BALB/cJ mice were pretreated with trophic forms or mixed P. murina 
organisms for one hour (Fig 5.9A). CFSE-stained splenocytes from uninfected Iab-
expressing C57BL/6 mice were then added to the wells and co-cultured for 6 days. Flow 
cytometry was used to evaluate the proliferation of C57BL/6 CD4+ T cells (Fig 5.9A). 
Pretreatment of allogeneic BMDCs with trophic forms, but not mixed P. murina 
organisms reduced CD4+ T cell proliferation and IFNγ production in the mixed 
lymphocyte reaction (Fig 5.9A). These data are consistent with trophic forms suppressing 
MHC class II expression, resulting in the inability of the pretreated dendritic cells to 
stimulate antigen-independent allogenic T cell proliferation in a mixed lymphocyte 
reaction. 
 
Trophic form-loaded dendritic cells stimulate less robust CD4+ T cell responses. 
CD4+ T cell responses are required for the clearance of P. murina (1). We have 
previously reported that BMDCs loaded with mixed P. murina, but not trophic forms, 
stimulate IFN-γ production by CD4+ T cells in vitro (168). To evaluate whether dendritic 
cells are able to present antigen and induce CD4+ T cell responses when loaded with 
trophic forms, we broadened our analysis to include proliferation and other T helper 
cytokines (Fig 5.9B-E). BMDCs loaded with mixed P. murina, but not trophic forms, 
stimulated proliferation in CFSE-labeled CD4+ T cells (Fig 5.9B). To confirm that 
trophic forms are phagocytosed by BMDCs, confocal microscopy was used to 
demonstrate that DDAO-SE-labeled trophic forms were internalized (Fig 5.10A). 
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Furthermore, confocal microscopy (Fig 5.10B-C) and flow cytometry (Fig 5.10D-E) 
confirmed that stimulation of dendritic cells with trophic forms does not reduce the 
ability of dendritic cells to phagocytose pHrodo Green-label zymosan bioparticles, which 
fluoresce in low pH. 
BMDCs loaded with mixed P. murina stimulated higher production of the Th1-type 
cytokine IFNγ, the Th2-type cytokine IL-13, and the Th17-type cytokine IL-17A by CD4+ 
T cells compared to stimulation with trophic forms alone (Fig 5.9C-E). However, 
stimulation with trophic forms did induce greater production of IL-13 than the 
unstimulated control (Fig 5.9D). These data indicate that while cysts are required for 
robust proliferation of CD4+ T cells and production of cytokine in vitro, BMDCs loaded 
with trophic forms are capable of driving modest Th2-type T cell polarization. P. murina 
organisms did not stimulate CD4+ T cell proliferation and cytokine production in the 
absence of BMDCs (data not shown), indicating that these responses are dependent on 
antigen presentation by BMDCs.  
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III. Discussion 
We have previously reported that the cyst life cycle stage drives proinflammatory 
responses that direct the early recruitment of innate and adaptive immune cells. Infection 
of adult mice with Pneumocystis trophic forms in the absence of cysts leads to the 
establishment of an immunosuppressive environment in the lungs that persists for up to 
one week following the formation of the cystic stage (168). If cysts are in the inoculum, 
the trophic form is unable to suppress inflammatory responses in the lungs as effectively. 
We have reported that the trophic life cycle forms dampen β-glucan and TLR-induced 
inflammation compared to stimulation with a mixture of trophic forms and cysts (168). 
Here, our data confirm that P. murina trophic forms hinder the ability of dendritic cells to 
serve in their essential role as stimulators of CD4+ T cell responses by reducing the 
capacity of dendritic cells to produce proinflammatory cytokines, present MHC class II, 
and express costimulatory molecules. 
We did not define the factor(s) expressed by the trophic forms that induce 
suppression. However, experiments were presented that have begun to define the nature 
of these factors. Intriguingly, suppression of the dendritic cell cytokine response was not 
dependent on trophic form viability and was only partially dependent on direct contact 
between trophic forms and dendritic cells. It is plausible that either secreted proteins or 
shed glycosylated proteins such as glycoprotein A (gpA, or major surface glycoprotein, 
MSG) are responsible for trophic-form mediated suppression. Direct contact between 
trophic forms and BMDCs was required for suppression of IL-6, but not IL-1β protein 
production, while TNFα suppression was partially dependent on direct contact. This data 
may suggest that multiple factors from the trophic forms are responsible for the broad 
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suppression of the production of inflammatory cytokines by dendritic cells. Alternatively, 
it is possible that the amount of suppressive material that crossed into the lower 
compartment is less than the amount that is present when BMDCs are co-cultured with 
trophic forms in the lower well. The dose-response curve in Fig 3.7 suggests that 
suppression of IL-1β requires the addition of fewer trophic forms compared to the 
suppression of IL-6. Therefore, it is possible that the Transwell assay employed here 
represents a scenario in which sufficient suppressive material has reached the BMDC to 
inhibit IL-1β, but not IL-6, production. Further studies should evaluate the dose-response 
of BMDCs treated with increasing amounts of material from the trophic forms.  
Dendritic cell activation is dependent on the expression of a wide range of 
transcription factors and signaling mediators related to inflammatory responses. Here, we 
report that trophic forms induced a differential pattern of gene expression in dendritic 
cells compared to treatment with a normal mixture of trophic forms and cysts. Treatment 
of dendritic cells with trophic forms induced a less robust pattern of expression of several 
immunity-related genes than treatment with a mixture of P. murina trophic forms and 
cysts. We previously published that Pneumocystis trophic forms suppressed the 
production of proinflammatory cytokines IL-1β, IL-6, and TNFα by dendritic cells 
stimulated with multiple PAMPs, including β-glucan, LPS, LTA, zymosan, and depleted 
zymosan (168). Here, we demonstrate that transcript levels of these proinflammatory 
cytokines were lower in dendritic cells treated with trophic forms compared to mixed P. 
murina. These data suggest that the cyst life cycle is required for robust cytokine 
production by dendritic cells. 
128 
 
Treatment of BMDCs with trophic forms induced the expression of several genes 
encoding complement components. The complement protein C3 is not required for 
clearance of P. murina infection (123). However, it has been proposed that the 
accumulation of complement components during PcP contributes to immune-mediated 
lung damage (192). Anaphylatoxins (complement peptides C3a, C4a, and C5a) are 
formed during the complement cascade, and may promote neutrophil recruitment (193, 
194). It is unclear if complement components contributed to the differential immune 
response that we observed following inoculation with trophic forms or mixed P. murina 
organisms (Chapter 3). 
Stimulation of BMDCs with trophic forms also induced the expression of several 
genes that encode chemokines. This list is comprised of chemokines that are 
chemoattractant for a range of leukocytes, including monocytes, dendritic cells, 
neutrophils, NK cells, T cells, and B cells. However, our in vivo data suggest that 
inoculation with trophic forms results in delayed recruitment of leukocytes into the host 
lungs (Chapter 3). Our anidulafungin-treated RAG2-/- model demonstrates that the long-
term carriage of a trophic population results in the infiltration of a population of CD11c- 
CD11b+ cells that are predominately F4/80high (Fig 4.6). This suggests that trophic forms 
promote the recruitment of monocytes or macrophages rather than F4/80low neutrophils or 
myeloid-derived suppressor cells. Neutrophils are not required for clearance, but their 
accumulation in the lungs correlates with disease severity in human Pneumocystis 
pneumonia patients (5, 136). Further work is required to determine which chemokine 
proteins are present in the host lung during infection with trophic forms or mixed P. 
129 
 
murina organisms, and to identify the cell populations recruited in response to trophic 
infection of immunocompetent hosts. 
The data in Fig 5.2B-C represent all genes encoding regulators of inflammation (B) 
or immunity-related transcription factors (C) with a statistically significant (p < 0.01) 
two-fold or greater increase in expression between BMDCs treated with trophic forms 
compared to unstimulated BMDCs. While we have previously reported that trophic forms 
fail to induce translocation of NFκB in alveolar macrophages and trophic forms suppress 
the production of IL-1β, IL-6, and TNFα protein by dendritic cells, these data indicate 
that dendritic cells are responsive to the trophic forms (9, 168). Furthermore, treatment of 
dendritic cells with trophic forms induces a distinct pattern of gene expression compared 
to stimulation with curdlan and mixed P. murina. 
Trophic forms induce differential regulation of several genes related to 
inflammation and transcription compared to stimulation with mixed P. murina. These 
genes encompass diverse signaling pathways, including genes encoding members of the 
interferon regulatory factors (IRF) and STAT families. Here, we show that treatment with 
trophic forms suppressed the expression of Batf3 and Irf8, which mediate the 
development of Th1-promoting CD8α+ CD103+ conventional DCs (cDC1). The 
expression of Irf4, which mediates the development of Th2/ Th17-promoting CD11b+ 
cDCs (cDC2) was also suppressed by treatment with trophic forms but induced by 
treatment with mixed P. murina. These data suggest that trophic forms may broadly 
suppress the development of multiple dendritic cell subsets, and are consistent with the 
failure of trophic form-stimulated dendritic cells to induce robust production of T helper 
cytokines compared to stimulation with mixed P. murina. It should be noted, however, 
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that the BMDCs employed in these experiments more closely resemble monocyte-derived 
dendritic cells and are not true conventional dendritic cells, which require Flt3L for 
differentiation (195, 196). The ability of trophic forms to suppress Batf3, Irf8, and Irf4 
expression in Flt3L-dependent conventional dendritic cells has not been evaluated. 
Some fungal pathogens, including Candida spp and H. capsulatum, may prevent 
phagosomal maturation and acidification (197-199). However, our data indicate that 
stimulation with trophic forms or a mixed P. murina does not reduce the phagocytic 
capacity of the dendritic cell. Rather, our data confirm that treatment with trophic forms 
reduces the ability of dendritic cells to present antigen. Treatment with trophic forms 
reduced the ability of dendritic cells to increase surface expression of MHC class II and 
CD40 in response to stimulation with mixed P. murina organisms or zymosan (a 
Saccharomyces cell wall preparation). Our data indicate that this suppression occurred at 
the level of transcription, as treatment with trophic forms led to downregulation of 
several genes associated with MHC class II processing and expression, including the 
gene encoding the master class II transactivator, Ciita. Treatment with trophic forms also 
resulted in lower expression of the genes encoding the costimulatory molecules CD40, 
CD80, and CD86, as well as the immune regulatory molecules PD-L1, and PD-L2 
compared to treatment with a mixture of organisms that contained cysts. These defects in 
the expression of MHC class II and costimulatory molecules corresponded with a reduced 
capacity for trophic form-loaded dendritic cells to stimulate CD4+ T cell proliferation and 
polarization. Intriguingly, suppression of the dendritic cell cytokine response was not 
dependent on trophic form viability, nor on direct contact between trophic forms and 
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dendritic cells. It is possible that this will also be true for expression of MHC class II, 
however, these experiments are ongoing. 
Modulation of the T helper phenotype of the inflammatory response is a common 
strategy employed by infectious fungi for immune evasion (200). In addition to 
presentation of antigen, activated dendritic cells produce cytokines that influence the 
polarization of the T helper response. Shifts in this balance may elicit an inefficient 
adaptive response. For example, the generation of a Th2-type response to the fungal 
commensal Candida albicans inhibits Th1 responses, and promotes pathogen survival by 
decreasing phagocyte activation (201). However, while Th1 or Th17 responses are critical 
for control of many fungal infections, including candidemia, a mixed T helper response is 
observed in response to Pneumocystis infection. This mixed response appears to be 
largely redundant, as Th1-, Th2-, and Th17-type responses have each been associated with 
clearance of P. murina organisms (24, 111-115). Broad suppression of cytokine 
production by trophic forms may be necessary to overcome this redundancy and delay the 
activation of adaptive immunity against P. murina. 
Here, the data indicate that dendritic cells loaded with trophic forms stimulate 
production of the Th2-type cytokine IL-13, but not production of the Th1-type cytokine 
IFNγ or the Th17-type cytokine IL-17A. These data indicate that trophic forms may 
polarize the immune response towards a weak Th2-type response, while suppressing Th1 
and Th17-type responses. However, the effectiveness of this response in the absence of 
CD4+ T cell proliferation is unclear. In addition, it is unclear how trophic forms, which 
suppress IL-6 protein production and fail to induce expression of the genes encoding IL-
2, IL-4, and IL-13 as robustly as stimulation with mixed P. murina organisms, promote 
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Th2 polarization. The CD4+ T cells used in this experiment were generated from the 
draining lymph nodes of mixed P. murina-infected donor mice. We expect that this 
population included P. murina-specific Th2 CD4+ T cells (113, 115), which may have 
continued to produce IL-13, but not proliferate in the presence of trophic form-loaded 
dendritic cells. The failure of trophic forms to induce Th1 and Th17 CD4+ T cell 
polarization is consistent with the attenuated expression of the genes encoding IL-1β, IL-
2, IL-6, IL-12, and IL-12β compared to stimulation with mixed P. murina organisms. 
In addition, trophic forms are capable of inducing the expression of the genes that 
encode the transcription factors T-bet (Tbx21) and Gata3 (Fig. 5.2), which mediate Th1 
and Th2-type responses, respectively. T-bet expression in dendritic cells is required for 
effective polarization of Th1 T cells (202-204). GATA3 expression in BMDCs is required 
for production of the Th2-type cytokines IL-13 and IL-5 (205). This indicates that the 
failure of trophic forms to induce robust Th1 and Th2-type responses is not due to direct 
suppression of the transcription of these master regulators. 
Tolerogenic dendritic cells promote anergic or regulatory T cell responses by 
secreting IL-10, TGFβ, and IL-2 and expressing the inhibitory molecules PD-L1 and PD-
L2. However, our data indicate that treatment of dendritic cells with trophic forms results 
in lower levels of gene expression of each of these tolerogenic markers than treatment 
with a mixture of trophic forms and cysts. Therefore, trophic forms are not likely to 
induce a classical tolerogenic phenotype in dendritic cells. Rather, our data indicate that 
treatment with trophic forms broadly reduces the ability of the dendritic cell to provide 
activation signals to the CD4+ T cells. 
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In summary, our data indicate that the trophic life cycle stage of Pneumocystis 
limits the ability of dendritic cells to stimulate CD4+ T cell polarization and proliferation 
by reducing the expression of MHC class II, costimulatory molecules, and 
proinflammatory cytokines. These defects may be traced back to reduced levels of gene 
expression of each of these factors, compared to dendritic cells stimulated with a 
physiologically normal mixture of trophic forms and cysts. We propose that the 
suppression of immune responses by the trophic forms promotes the colonization of 
Pneumocystis in immunocompetent hosts. This differential immune response to 
Pneumocystis trophic forms and cysts is most certainly a leading contributor to the 
success of the organisms as human pathogens. 
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Figure 5-1 Exposure of BMDCs to P. murina trophic forms induces a distinct 
pattern of gene expression. 
 
3 X 105 BMDCs from adult BALB/cJ mice were incubated with 1.5 X 106 trophic forms 
or 1.5 X 106 mixed P. murina organisms. Controls included untreated BMDCs and 
BMDCs treated with 10µg/ml of the β-glucan curdlan. Cells were lysed after 2, 4, or 8 h 
of incubation. RNA was extracted. Gene expression analysis was carried out using a 
preassembled Nanostring Codeset that measures expression of 561 immunity-related 
mouse transcripts (nCounter Mouse Immunology kit). Analysis and normalization of the 
raw NanoString data were conducted using nSolver Analysis Software 2.0. Raw counts 
were normalized to internal positive controls and reference transcripts. A heat map (A) 
was generated to display the treated expression value relative to the untreated value. 
Principle component analysis (B) was used to compare the pattern of gene expression 
among the untreated and treated groups following 8 h of incubation. Genes upregulated 
(C) or downregulated (D) in the treated groups relative to the untreated control were 
identified by log transformed two way ANOVA followed by pairwise comparisons using 
the Least Significant Difference Method. Five biological replicates were used per group. 
A change was deemed significant if the p value was <0.01.  
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Figure 5-2 Trophic forms induce the expression of genes encoding chemokines and 
complement proteins. 
 
The relative gene expression after 8 h of treatment was calculated as the log2 value of the 
quotient of the treated expression value divided by the untreated expression value. The 
data in Fig 5.2A represent genes in the NanoString panel with a statistically significant (p 
< 0.01) four-fold or greater increase in expression between BMDCs treated with trophic 
forms compared to unstimulated BMDCs. The data represent all genes encoding 
regulators of inflammation (B) or immunity-related transcription factors (C) with a 
statistically significant (p < 0.01) two-fold or greater increase in expression between 
BMDCs treated with trophic forms compared to unstimulated BMDCs. Differences in 
expression between the groups were identified by log transformed two way ANOVA 
followed by pairwise comparisons using the Least Significant Difference Method. Five 
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biological replicates were used per group. Genes with differences in expression with p < 
0.01 between BMDCs treated with trophic forms vs unstimulated cells are denoted *, 
trophic forms vs mixed P. murina organisms are denoted †, and trophic forms vs curdlan 
are denoted ‡. 
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Figure 5-3 Muc1, a negative regulator of TLR-mediated signaling, is not required 
for trophic-form mediated suppression. 
 
1 X 104 BMDCs from Muc-/- and wild-type BALB/cJ mice were incubated with 5 X 105 
trophic forms, 5 X 105 mixed P. murina organisms, 10µg/ml curdlan, 100ng/ml LPS, and 
10µg/ml LTA for 72 h. IL-6 production was quantified by ELISA. Data represent the 
mean ±SD of 3 biological replicates per group and are representative of 2 separate 
experiments. Kruskal-Wallis one-way ANOVA on ranks was used to compare 
differences among the Muc1-/- BMDCs treated with a stimulus (mixed Pc, curdlan, LPS, 
or LTA) compared to a combination of stimulus with trophic forms, *p < 0.05.  
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Figure 5-4 Trophic forms induce less robust expression of genes encoding multiple 
cytokines, positive regulators of inflammation, and transcription factors compared 
to treatment with a mixture of trophic forms and cysts. 
 
The relative gene expression after 8 h of treatment was calculated as the log2 value of the 
quotient of the treated expression value divided by the untreated expression value. All 
cytokine genes in the preassembled NanoString panel are graphed (A). The data in Fig 
5.4B-C represent all genes encoding regulators of inflammation (B) or immunity-related 
transcription factors (C) with a statistically significant two-fold or greater difference in 
expression between BMDCs treated with trophic forms vs mixed P. murina organisms. 
Differences in expression between the groups were identified by log transformed two 
way ANOVA followed by pairwise comparisons using the Least Significant Difference 
Method. Five biological replicates were used per group. A change was deemed 
significant if the p value was <0.01. Genes with differences in expression with p < 0.01 
between BMDCs treated with trophic forms vs unstimulated cells are denoted *, trophic 
forms vs mixed P. murina organisms are denoted †, and trophic forms vs curdlan are 
denoted ‡.   
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Figure 5-5 Cysts, but not trophic forms, stimulate production of the 
proinflammatory cytokines IL-1β and IL-6 by BMDCs in vitro. 
 
BMDCs from adult BALB/cJ mice were incubated with 3 X 104 trophic forms or 3 X 104 
mixed P. murina organisms for 72 h. Curdlan was included as a positive control for 
cytokine production. TNFα (A), IL-1β (B), and IL-6 (C) cytokine production was 
quantified by ELISA. Data represent the mean ±SD of 3 biological replicates per group 
and are representative of 2 separate experiments. One way ANOVA with Student-
Newman-Keuls post-hoc test was used to compare supernatant cytokine concentration 
between the groups, **p ≤ 0.01, ***p ≤ 0.001, n.s., not statistically significant.  
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Figure 5-6 Suppression of the cytokine response is not dependent on trophic form 
viability, but is partially dependent on direct contact between trophic forms and 
dendritic cells. 
 
1 X 104 BMDCs (A-F) from BALB/cJ mice were incubated with 5 X 105 trophic forms, 5 
X 105 heat-killed trophic forms, 5 X 105 sonicated trophic forms, 5 X 105 sonicated 
mixed P. murina organisms, and/or 10µg/ml curdlan for 72 h. 1 X 105 BMDCs (G-I) 
from BALB/cJ mice were incubated with 5 X 106 trophic forms and/or 10µg/ml curdlan 
for 72 h in a Transwell culture plate. TNFα (A, D, G), IL-β (B, E, H), and IL-6 (C, F, I) 
cytokine production was quantified by ELISA. Data represent the mean ±SD of 3 
biological replicates per group and are representative of 2 separate experiments. One-way 
ANOVA with Student-Newman-Keuls post-hoc test was used to compare differences 
among the groups where the data were parametric (A-D, G-I), *p ≤ 0.05, ** p ≤ 0.01, 
***p ≤ 0.001, n.s., not statistically significant. Kruskal-Wallis one-way ANOVA on 
ranks was used to compare differences among the groups where the data were 
nonparametric (E-F), *p ≤ 0.05.  
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Figure 5-7 A ratio of 10 trophic forms to 1 BMDC is required to for suppression of 
cytokine expression. 
 
1 X 105 BMDCs were incubated with 10 µg/ml curdlan, and increasing numbers of 
trophic forms for 72 h. TNFα (A), IL-1β (B), and IL-6 (C) cytokine levels in the 
supernatant were quantified by ELISA. Data represent the mean ±SD of 3 biological 
replicates per group and are representative of 2 separate experiments. One way ANOVA 
with Student-Newman-Keuls post-hoc test was used to compare cytokine concentrations 
among the groups, *p ≤ 0.05, n.s., not statistically significant.  
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Figure 5-8 Trophic forms suppress the expression of multiple factors related to 
antigen presentation, including MHC class II and the costimulatory molecule CD40. 
 
The data in Fig 5.8A-B represent genes in the NanoString panel encoding transcripts 
related to antigen-processing and presentation (A) or costimulatory molecules (B) with a 
statistically significant (p < 0.01) two-fold or greater increase in expression between 
BMDCs treated with trophic forms compared to unstimulated BMDCs. The relative gene 
expression after 8 h of treatment was calculated as the log2 value of the quotient of the 
treated expression value divided by the untreated expression value. Genes with 
differences in expression with p < 0.01 between BMDCs treated with trophic forms vs 
unstimulated cells are denoted *, trophic forms vs mixed P. murina organisms are 
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denoted *, trophic forms vs mixed P. murina organisms are denoted †, and trophic forms 
vs curdlan are denoted ‡. Flow cytometry was used to evaluate surface expression of 
MHC class II (C, E) and CD40 (D, F) on the surface of BMDCs following 24 hours of 
treatment with trophic forms, mixed P. murina, and/or the fungal cell wall preparation 
zymosan. Flow cytometry data represent the mean ±SD of 3 biological replicates per 
group and are representative of 2 separate experiments. One way ANOVA with Student-
Newman-Keuls post-hoc test was used to compare the surface expression of MHC class 
II or CD40 protein among the groups, *p ≤ 0.05, ** p ≤ 0.01, ***p ≤ 0.001.  
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Figure 5-9 Trophic forms reduce dendritic cell-dependent proliferation of CD4+ T 
cells. 
 
Treatment with trophic forms reduces CD4+ T cell proliferation in response to co-culture 
with allogeneic BMDCs in a mixed lymphocyte reaction (A). BMDCs generated from 
BALB/cJ mice were pre-treated with trophic forms or mixed P. murina organisms for one 
hour. CFSE-stained splenocytes from uninfected C57BL/6 mice were then added to the 
wells and co-cultured for 6 days. Flow cytometry was used to identify the CD4+ T cells 
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and evaluate their proliferation (A). BMDCs stimulated with trophic forms induce less 
proliferation and cytokine protein expression in CD4+ T cells than cells stimulated with 
mixed P. murina (B-E). BMDCs and CFSE-stained CD4+ T cells from adult BALB/cJ 
mice were incubated with trophic forms or mixed P. murina for 6 days. Flow cytometry 
was used to evaluate proliferation of CD4+ T cells (B). ELISA was used to evaluate the 
concentrations of the cytokines IFNγ (A, C), IL-13 (D) and IL17A (E) in the supernatant. 
Data represent the mean ±SD of 3 biological replicates per group and are representative 
of at least two separate experiments. Cytokine data in the absence of One-way ANOVA 
with Student-Newman-Keuls post-hoc test was used to compare the percentage of 
proliferating CD4+ T cells or supernatant cytokine concentration among the groups, *p ≤ 
0.05, ** p ≤ 0.01, ***p ≤ 0.001, n.s., not statistically significant.  
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Figure 5-10 Trophic forms do not have a negative impact on the phagocytic capacity 
of dendritic cells. 
 
CFSE-stained BMDCs from BALB/cJ mice were incubated with DDAO-SE-stained 
trophic forms or mixed P. murina organisms for one hour in a chamber slide (A). Cells 
were fixed in neutral buffered formalin, and confocal microscopy was used to identify 
internalized trophic forms (A). The z-stacks demonstrate that BMDCs internalize DDAO-
SE-labeled trophic forms (A). BMDCs were incubated with pHrodo Green zymosan 
bioparticles and/or DDAO-SE-stained trophic forms or mixed P. murina organisms for 
one hour in chamber slides (B-C) or FACS tubes (D-E). The chamber slides were fixed 
in neutral buffered formalin, and stained with DAPI (B-C). Confocal microscopy was 
used determine the percentage of BMDCs that had phagocytosed the pH-sensitive 
pHrodo Green zymosan bioparticles based on at least 100 events per group (B-C). Flow 
cytometry was used to determine the percentage of BMDCs that had phagocytosed the 
pHrodo Green zymosan bioparticles based on at least 1000 events per group (D). The 
geometric mean fluorescence intensity (MFI) in the FITC channel of the zymosan+ 
BMDCs was calculated for each group (E). Data represent the mean ±SD of 3 biological 
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replicates per group and are representative of 2 separate experiments. One way ANOVA 
with Student-Newman-Keuls post-hoc test was used to compare supernatant cytokine 
concentration between the groups, n.s., not statistically significant (p > 0.05).  
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Chapter 6: Discussion 
 
I. Summary 
Pneumocystis species are opportunistic fungal pathogens that cause severe 
pneumonia in immunocompromised hosts, including HIV/AIDS patients and patients 
undergoing chemotherapy or immunosuppressive therapy. Failure to clear Pneumocystis 
organisms leads to inflammation-mediated alveolar damage (5). Prior research in the field 
has overwhelmingly focused on the immune response to infection with a mixture of the 
trophic and cystic life cycle stages. Certainly, such studies provide valuable information, 
as the typical immune response to Pneumocystis organisms is shaped in the context of 
infection with both trophic forms and cysts. However, such studies do not provide a 
nuanced understanding of the distinct roles of the trophic and cystic life cycle stages in 
the development of the immune response to Pneumocystis infection. Here, our goal is to 
explore the biology of the immune response to these life cycle stages. 
Tropic forms are proposed to represent the asexual stage, and are single-nucleated 
organisms that are typically found in clusters surrounded by a biofilm-like substance 
consisting of a conglomeration of DNA, β-glucan, and other sugars (13, 14). Cysts are 
ascus-like structures formed by mitosis, and consist of multiple nuclei surrounded by a 
fungal cell wall. β-1,3 glucan and β-1,6 glucan serve as the structural components of the 
cyst wall (13, 15, 16). β-glucan is not detected on the surface of trophic forms (15, 17). 
Both stages express surface glycoproteins and mannoproteins that may serve as 
pathogen-associated molecular patterns (PAMPs) that could interact with receptors on 
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phagocytic cells (18-20). Neither life form produces the classical fungal components 
ergosterol, chitin or α-glucans (21, 22). 
Ultrastructural studies revealed that the trophic forms tightly adhere to the luminal 
surface of alveolar epithelial cells via microprotusions or invaginations of the trophic 
plasma membrane (64). This interaction is a risky endeavor for the trophic forms, as 
alveolar epithelial cells are capable of producing proinflammatory cytokines. In addition, 
this interaction with the alveolar epithelium places the trophic forms at risk for detection 
by immature lung dendritic cells, which project their dendritic extensions through the 
epithelial-tight junctions into the alveolar spaces. This encounter has the potential to 
induce dendritic cell activation and migration to the draining lymph nodes, where the cell 
may present antigen to lymphocytes. The involvement of dendritic cells is critical to the 
recruitment of T and B cells into the airway lumen, particularly as these spaces are 
largely free of lymphocytes prior to infection. Essentially, this slow-growing obligate 
parasite has adopted a niche that places it in constant danger of swiftly initiating the 
adaptive immune responses that will clear the organisms from the lungs. 
Herein, we show that the life cycle stages of Pneumocystis murina differ in their 
interactions with the host immune response (Chapter 3). Infection with a normal mixture 
of trophic forms and cysts elicits proinflammatory responses, including early infiltration 
of T and B cells into the airways. Conversely, the trophic forms of Pneumocystis murina 
suppress the proinflammatory response to multiple pathogen-associated molecular 
patterns (PAMPs), including β-glucan. Depletion of cysts in immunocompromised 
RAG2-/- hosts resulted in a trophic burden that grew slowly over a six month period, but 
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did not induce overt symptoms associated with PcP, such as weight loss and infiltration 
of innate immune cells into the lungs (Chapter 4). 
While cysts are required for robust pro-inflammatory responses, including the early 
recruitment of immune cells into the airways, infection with trophic forms in the absence 
of cysts is sufficient to drive protective CD4+ T cell and B cell responses (Chapter 4). 
Remarkably, our data indicate that CD4+ T cells generated in the absence of cysts 
promote faster clearance of infection than CD4+ T cells generated in the presence of 
mixed P. murina organisms (Chapter 4). We do not report evidence of a direct 
suppressive effect of trophic forms on CD4+ T cells or B cells. 
Rather, our data indicate that trophic forms broadly inhibit the ability of dendritic 
cells to fulfill their role as antigen-presenting cells by reducing the expression of 
cytokines, MHC class II, and costimulatory molecules (Fig 6.1 and Chapter 5). These 
data suggest that immune evasion by the trophic forms may hinge on the suppression of 
the initiation of the innate immune response, including the inhibition of dendritic cell 
communication with CD4+ T cells. The rapid establishment of a trophic population may 
be critical for this fungal pathogen to evade innate immune cells and avoid preemptive 
clearance of the transmittable, yet inflammatory cyst stage. However, the development of 
adaptive immunity to Pneumocystis may represent a “point of no return” at which the 
trophic forms are no longer able to escape clearance (Chapter 3). 
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II. Significance 
This dissertation represents a major advancement in understanding the interactions 
between the host immune response and the life cycle stages of Pneumocystis species. Past 
research into the host response to Pneumocystis infection has overwhelmingly focused on 
the sum of the response to a fungal burden that includes a mixture of trophic forms and 
cysts. However, the capacity of the trophic forms to suppress innate immunity provides a 
compelling reason for decades of Pneumocystis research to be revaluated in the context 
of differential interactions between the life cycle stages and the host immune response. 
 
1. The role of trophic form-mediated suppression during natural infection 
Due to technical restrictions, we have not evaluated the immune response to 
purified or enriched cysts. However, the data that we have generated regarding the broad, 
immunosuppressive capabilities of the trophic forms suggest a corollary: the cysts are 
highly inflammatory. Namely, the net inflammation conditions generated in response to 
mixed P. murina organisms likely necessitates that the cyst must overcome the 
suppressive capabilities of the trophic forms at physiologically normal ratio of 1 cyst per 
10 trophic forms. 
The inflammatory potential of the cyst in the face of a 10-fold excess of trophic 
forms raises questions regarding the relevance of trophic suppression during the tenancy 
of the host lung. Here, we demonstrate that trophic form-mediated suppression modulates 
the early kinetics of the immune response, and that this delay persists for one week after 
the emergence of a population of cysts (Fig 3.3). Despite this delay, the immune response 
is able to clear the infection within the same period of time as observed in the group 
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inoculated with mixed P. murina organisms. It should be noted that this dissertation 
provides no direct evidence that trophic form-mediated suppression increases the fungal 
burden or delays clearance. 
To address these concerns, we encourage the reader to consider the ecological niche 
of these ubiquitous fungal species. Pneumocystis species have evolved a life cycle 
characterized by transient infection of immunocompetent hosts. These species appear to 
occupy a niche somewhere in the gray area between “parasite” and “commensal.” We 
propose that trophic form-mediated suppression is a host defense that has evolved, and 
has been maintained by selection, within Pneumocystis species. If this is true, it would be 
expected that a mixed Pneumocystis population arising from the natural route of infection 
would benefit from trophic form-mediated suppression. To this effect, we would predict 
that the inhibition of trophic form-mediated suppression during mixed P. murina 
infection would accelerate the clearance of this population. Conversely, it may be 
unreasonable to expect that trophic forms, in the absence of cysts, further delay clearance 
(Chapter 3). 
We further propose that there may be other benefits to trophic form-mediated 
suppression. Inoculation with enriched trophic forms was not sufficient to increase the 
fungal burden or delay clearance. However, trophic form-mediated suppression may 
serve in other ways to enhance the fitness of the mixed population. Immune suppression 
by the trophic forms may improve the early niche within the host lung by dampening the 
consequences of inflammation, including the limitation of extracellular nutrient 
availability and the release of antimicrobial products, surfactant, and reactive nitrogen or 
oxygen species. It is also plausible that inflammatory signals may limit the ability of 
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Pneumocystis organisms to scavenge nutrients directly from alveolar epithelial cells. 
Alternatively, we demonstrate that trophic forms inhibit cytokine production in response 
to a broad range of PAMPs, including bacterial productions such as LPS and LTA. It is 
possible that trophic forms promote the maintenance of a tolerogenic state within the lung 
during coinfection of Pneumocystis species with bacteria or additional fungal species. 
The ultimate aim of trophic form-mediated suppression may not be to delay 
clearance per se, but to enhance the transmission of cysts to a new host. To this effect, we 
consistently observe a large burst of trophic growth during the first week post-infection 
(as seen in Fig 3.3) resulting in a trophic form to cyst ratio in excess of 20:1. Based on 
the work presented in this dissertation, it seems plausible that this energy-intensive 
expansion of the trophic population may be necessary to preserve favorable conditions 
within the alveolar spaces, and thus protect the health of the transmittable cysts. 
 
2. Significance for the development of treatments and vaccines 
Protective adaptive responses are required for clearance of Pneumocystis organisms 
from the lungs, while, in the absence of protective responses, inflammation-mediated 
lung damage causes much of the pathology associated with Pneumocystis pneumonia. 
The differential effect of trophic forms and cysts on the host response, therefore, has the 
potential to shape both positive and negative outcomes associated with Pneumocystis 
infection. Manipulation of this differential response may provide new options for the 
treatment and prevention of Pneumocystis infection, while a failure to consider this 
differential response may hamper future efforts. Here, our data indicate that trophic forms 
elicit adaptive responses, but do not provoke the non-protective inflammation 
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characteristic of Pneumocystis pneumonia. Further evaluation of the antigenic 
determinants on trophic forms and cysts may elicit a vaccine that provides protection 
while limiting immune-mediated damage.  
In Chapter 4, we demonstrate that, the absence of the cyst stage, a small trophic 
population was maintained in the lungs of RAG2-/- mice without overt evidence of 
disease. While further studies are required to evaluate the effects of a low trophic burden 
on the host lung, we report no evidence of the inflammatory conditions associated with 
Pneumocystis pneumonia, including infiltration of immune cells and accumulation of 
proinflammatory cytokines in the BALF. These observations suggest that the depletion of 
the cyst stage may provide beneficial treatment options in at-risk patients, particularly 
those that retain some means of clearing the remaining trophic forms. These patient 
populations would include those recovering from drug- or virus-induced 
immunosuppression. The potential benefit of cyst-targeted anti-fungal therapies is 
highlighted by a report from Linke et al. which demonstrates that treatment of rodents 
with echinocandins reduces inflammation in a model of immune reconstitution syndrome 
(24). It is our hope that the data presented in this dissertation encourage additional 
research regarding the influence of trophic forms and cysts on the detrimental 
proinflammatory response that is characteristic of Pneumocystis pneumonia. 
 
3. Pathogen-associated immunosuppression 
The identification of the mechanism(s) of trophic form-mediated suppression has 
the potential to provide highly valuable data for both basic science and translational 
medicine. The characterization of the suppressive material may suggest a list of 
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homologous materials expressed by other fungi or, perhaps, other kingdoms of life. These 
associations may generate hypotheses regarding the mechanism of interaction between 
the suppressive material and the host cell. Such efforts have the potential to enhance our 
understanding of immune evasion by a ubiquitous fungal parasite that causes devastating 
opportunistic infections in immunocompromised hosts. 
Furthermore, our data demonstrate that co-culture with trophic forms broadly 
suppresses the ability of dendritic cells to produce proinflammatory cytokines in response 
to multiple PAMPs, including LPS, LTA, and zymosan. In addition, we have observed a 
similar degree of cytokine suppression in J774 macrophages and alveolar macrophages 
(Garvy lab, unpublished data). The identification of the mechanism(s) involved in 
suppression may provide pathways or effectors that may be manipulated or mimicked to 
develop novel anti-inflammatory therapies. Excessive production of proinflammatory 
cytokines, including IL-1, IL-6, and TNFα, contribute to damage during disease states 
such as sepsis or influenza-associated cytokine storm (206, 207). Future studies involving 
trophic form-mediated suppression may identify mechanisms to reduce cytokine 
production without compromising host immunity. 
 
III. Limitations 
This dissertation suffers from the universal limitations surrounding Pneumocystis 
research. Chief among these restrictions is the lack of a long term ex vivo culture system 
for Pneumocystis organisms. The inability of P. jirovecii to live outside of a human host 
has limited research on this medically important parasite and opportunistic pathogen. Rat 
and mouse models have driven critical advances in understanding the immune responses 
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to P. carinii and P. murina, respectively. The transmission of Pneumocystis organisms 
and the progression of disease, including the development of interstitial pneumonia, in 
immunocompromised rodents appear to be homologous to that experienced in humans. 
Patients with specific immunodeficiencies, including defects in immune cell populations, 
signaling pathways, and cytokines, have provided evidence regarding the components of 
the immune response that are essential for clearance of Pneumocystis organisms. These 
observations have been substantiated by a large body of research exploring the immune 
response to Pneumocystis in rodent models. 
The complexity of immune cell subsets within the lungs also places limitations on 
the scope of this dissertation. Dendritic cells are relatively rare within uninfected tissues. 
cDCs may represent only 1-2% of the total cells within a single-cell suspension from the 
lungs (208). Furthermore, while some common markers to distinguish dendritic cells, 
such as CD11c, are applicable in the spleen, the lung is populated by other populations of 
CD11c+ immune cells subsets that defy basic attempts at identification and isolation. For 
example, Lancelin and Guerrero-Plata report that positive selection of a single-cell 
preparation from the lungs yields a mixed population dominated by CD11chi MHC-IIlo 
macrophages (>70%) (208). Cell sorting for CD11chi MHC-IIhi cells resulted in a 
population consisting of >96% pure dendritic cells, with a typical yield of 5 X 104 cDC 
per lung (208). 
Dendritic cells are relatively rare within tissues, with the exception of the spleen 
and thymus. Several protocols have been developed to generate primary dendritic cells 
from bone marrow, permitting researchers to reduce the numbers of animals (and 
research effort) required to perform dendritic cell studies. Here, we have employed the 
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methodology developed by Lutz et al. (209). Briefly, bone marrow from the tibias and 
femurs of adult mice was cultured for nine to twelve days in complete culture media 
containing recombinant murine granulocyte-macrophage colony-stimulating factor (GM-
CSF). Every 48 h thereafter, non-adherent cells (including monocytes) were removed and 
replaced with fresh media with additional GM-CSF. BMDCs were collected by 
vigorously washing the plates with media to remove loosely adherent cells. In our hands, 
greater than 80% of recovered cells were CD11c+, and up to 6 X 107 BMDCs may be 
generated from the bone marrow of a single mouse. 
However, recent studies have challenged the identity of the BMDCs employed in 
this model. It has become appreciated that culture of BMDCs with bone marrow yields a 
mixed population of dendritic cells derived from monocytes and common dendritic cell 
precursors (210, 211). Neither population may be said to represent bona fide conventional 
dendritic cells, which require Flt3L for differentiation (195, 196).  
It should also be noted that the culture of bone marrow derived cells does not lead 
to the development of a pure population of dendritic cells. Others have determined that 
the bone marrow precursors of both dendritic cells and macrophages develop into 
CD11c+ MHC-II+ cells in the presence of GM-CSF (210, 211). Both subsets undergo 
activation in response to LPS, while the dendritic cell subset alone is capable of inducing 
CD4+ T cell responses to OVA antigen (211). The protocol employed here was developed 
by Lutz et al. to enrich for CD11c+ dendritic cells (209). It is unclear if this protocol 
limits the contamination of CD11c+ MHC-II+ macrophages. While it has been reported 
that the addition of Flt3L to the culture media reduces the development of macrophages, 
it should be noted that Flt3L promotes the expansion of a small population of monocytes 
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in addition to conventional dendritic cells (195, 196). Helft et al. suggest that the practice 
of culturing bone marrow-derived dendritic cells remains a viable model for exploring 
basic cell function. However, the authors caution researchers to consider the impact of 
heterogeneous bone marrow-derived populations in their assays. Current protocols for the 
development of bone marrow-derived dendritic cells reduce, but do not eliminate, the 
complexity of the heterogeneous cell populations found in vivo. 
 
IV. Future directions 
This dissertation has provided significant answers regarding the role of the life 
cycle stages of Pneumocystis species in the development of host immunity. It is our hope 
that this work encourages future research into the biology of Pneumocystis organisms and 
host-pathogen interactions. Perhaps the greatest unanswered questions of this project are: 
(1) identification of the trophic form-associated factor(s) that induce suppression and (2) 
identification of the dendritic cell regulatory mechanisms involved in the suppressive 
response. 
 
4. Identification of the suppressive factor(s): 
This dissertation does not identify the suppressive factor(s) on the trophic forms 
that induce suppression. However, we have carried out a few preliminary studies 
regarding this mechanism. Here, we demonstrate that suppression of the cytokine 
response is not dependent on trophic form viability, nor direct contact between trophic 
forms and dendritic cells (Chapter 5). Live, heat-killed, and sonicated trophic forms 
suppressed cytokine production by β-glucan-treated BDMCs, indicating that suppression 
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is not dependent on the viability of trophic forms. Surprisingly, while intact mixed P. 
murina organisms induce IL-1β and IL-6 production, these data indicate that sonicated 
mixed P. murina organisms suppressed these responses. These data suggest that intact 
cysts are required for stimulation of cytokine production, and, in the absence of this 
stimulation, the trophic material is able to suppress the response to other PAMPs. 
Alternatively, it is possible that trophic forms directly reduce the inflammatory potential 
of the cyst by masking or digesting PAMPs on the cyst surface. 
Immunosuppression by the trophic forms could be mediated by a secreted factor or 
by direct contact between the trophic forms and the BMDCs. Direct contact between the 
trophic forms and BMDCs was not required for a reduction in IL-1β or TNFα cytokine 
production (Chapter 5). Intriguingly, direct contact was required for the suppression of 
IL-6 protein production (Chapter 5). These experiments suggest that the suppressive 
effect of trophic forms does not require intact or living organisms, and indicate that 
suppression of dendritic cell responses is partially induced by some material, less than 0.4 
micron in size, that is passively released from trophic forms. 
However, it should be noted that these experiments only examined the suppression 
of IL-1β, IL-6, and TNFα supernatant concentrations. The effects of heat-killing, 
sonication or separation on trophic-form mediated suppression of other dendritic cell 
responses (including antigen presentation) have not been evaluated. The inability of 
trophic forms to suppress IL-6 production in the Transwell system suggests that multiple 
factors may be required for suppression of certain responses. 
The suppressive factor(s) may be a protein or polysaccaharide that is shed from the 
surface of the trophic forms. Future work in our laboratory will seek to characterize the 
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suppressive factor using mass spectrometry. Sonication of trophic forms produces a 
mixture of biomolecules that is too complex for characterization by mass spectrometry. 
Proper sample preparation for mass spectrometry will require us to reduce the complexity 
of the sample. Various methods, including treatment with proteinases and glucanases, 
will be used to digest specific categories of proteins or polysaccharides. Alternatively, 
proteins may be isolated from the bulk sonicate on the basis of size. The goal will be to 
characterize by mass spectroscopy the least complex material that retains the suppressive 
abilities of whole trophic forms. 
 
5.  Identification of the immediate host cell targets of suppression: 
Here, we have characterized the suppressive phenotype of dendritic cells stimulated 
with trophic forms. However, we have not identified the precise mechanism by which 
trophic forms induce this broad suppressive phenotype. It is possible, for example, that 
trophic forms induce broad changes in gene expression by manipulating histone 
modification within the dendritic cell. Alternatively, trophic forms may target one or a 
handful of genes controlling dendritic cell maturation. 
Tolerogenic dendritic cells promote anergic or regulatory T cell responses by 
secreting IL-10, TGFβ, and IL-2 and expressing the inhibitory molecules PD-L1 and PD-
L2. However, our data indicate that treatment of dendritic cells with trophic forms results 
in lower levels of gene expression of each of these tolerogenic markers than treatment 
with a mixture of trophic forms and cysts. Therefore, trophic forms are not likely to 
induce a classical tolerogenic phenotype in dendritic cells. Rather, our data indicate that 
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treatment with trophic forms broadly reduces the ability of the dendritic cell to provide 
activation signals to the CD4+ T cells. 
The results of the NanoString assay were compared against systems biology 
databases (InnateDB and others) via tools such as pathway analysis. This analysis 
assisted in the identification of the antigen presentation genes differentially regulated in 
trophic form-treated cells (Chapter 5). However, such analyses have not yet proved 
fruitful in the identification of the master regulatory factor(s) targeted by the trophic 
forms. A large body of research has recently been produced regarding the mechanisms 
involved in the maturation and polarization of dendritic cells. However, the interactions 
connecting many of the proteins within the dendritic cell regulome remain unidentified. 
As these gaps in our understanding are filled, obvious candidates for the trophic target 
may emerge. In the meantime, more classical approaches may provide fruitful leads. For 
example, the identification of the suppressive material from the trophic form may permit 
future studies (such as co-immunoprecipitation assays) to search for interactions with the 
host cell. 
Recent evidence suggests that fungal pathogens may manipulate interactions with 
C-type lectin receptors to suppress proinflammatory responses. Engagement of the C-
type lectin receptor mincle by the fungal skin pathogen Fonsecaea monophora was 
shown to suppress the proinflammatory Th1- and Th17-type immune responses induced 
by dectin-1-mediated signaling (159). Opposing roles for dectin-2 and mincle have been 
observed in the recognition of Fonsecaea pedrosoi (160). We are currently examining 
whether mincle could mediate the suppressive activity of trophic forms, as was found for 
F. monophora (159). 
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Mycobacterium tuberculosis provides an additional example of pathogen-mediated 
manipulation of C-type lectin receptor responses. Pecora et al. have reported that M. 
tuberculosis inhibits MHC class II transactivator (Ciita) expression, MHC class II 
molecule expression, and antigen presentation on macrophages. Lung dendritic cells 
infected with M. bovis BCG express less MHC class II on their surface than uninfected 
dendritic cells from the same lung (212). M. tuberculosis uses terminal mannosylated 
oligosaccharides to bind mannose receptor and DC-SIGN on host macrophages (213). 
Internalization via these receptors suppresses, rather than triggers, inflammatory 
responses in macrophages and dendritic cells. Specifically, the C-type lectin receptor DC-
SIGN internalizes M. tuberculosis by binding mannosylated lipoarabinomannan, or 
ManLAM, on the bacterial cell wall. However, binding of ManLAM by the C-type lectin 
receptor DC-SIGN inhibits M. tuberculosis or LPS-induced dendritic cell maturation. The 
terminal mannosylation of M. tuberculosis oligosaccharides may mimic the structures 
present on host mannoproteins. 
Here, we demonstrate that the deletion of mannose receptor on dendritic cells 
resulted in a modest decrease in the ability of trophic forms to suppress the production of 
IL-6, but not TNFα and IL-1β, indicating that suppression is mediated through 
mechanisms other than mannose receptor (Chapter 3). Future experiments may evaluate 
the role of additional mannose-recognizing receptors in the suppression of 
proinflammatory signaling, MHC class II expression, and induction of CD4+ T cell 
responses.  
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Other compelling questions, with accompanying speculation, include: 
1. How inflammatory are the cysts? 
Here, we do not evaluate the immune response to pure cysts. However, our data 
suggest that stimulation with a 10 to 1 mixture of trophic forms to cysts was sufficient to 
induce inflammatory responses in the dendritic cell (Chapter 5). The inflammatory 
potential of the cyst to induce a signal over trophic form-mediated suppression should be 
evaluated. Previous work has demonstrated that dendritic cells activated by Pneumocystis 
cyst cell wall-derived β-glucans increase costimulatory molecule expression and drive T 
cell polarization towards a Th1-type response (23). Despite repeated efforts, we have not 
identified a reliable method to purify cysts from the lungs of mice. However, other 
groups have enriched Pneumocystis cysts from the lungs of infected rats, which are 
infected with a higher fungal burden than mice. Future studies could evaluate the immune 
response to purified P. carinii cysts from rats, or may continue to evaluate the response to 
purified Pneumocystis cell wall fragments. 
 
2. Does the ratio of trophic forms to cysts influence the host immune response 
during the course of infection? 
Our data suggest that slight shifts in the ratio of trophic forms to cysts may result in 
differential immune responses. For example, the addition of trophic forms to a mixed 
population to create a net ratio of 20 trophic forms to one cyst reduces the expression of 
IL-6 by BMDCs (Chapter 3). The in vivo effects of such shifts have not been studied, 
but such research may provide intriguing details regarding the life cycle of the fungus 
within its host. Over the course of infection, Pneumocystis organisms may be found at a 
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typical ratio of 10 trophic forms to 1 cyst. However, this is not a steady state: cysts are 
the transmittable life cycle stage, yet a large burst of trophic forms are observed during 
the first week post-infection (Chapter 3). It is possible that this rapid transition may 
delay recognition of inflammatory PAMPs by dendritic cells in the lung, and may prevent 
preemptive clearance. 
Furthermore, a fungal burden of 20 to 30 trophic forms per cyst is consistently 
found in the lungs of immunocompromised mice exhibiting severe symptoms of 
Pneumocystis pneumonia. It is possible that inflammatory signals within the lungs 
promote a shift in the population towards an increase in suppressive trophic forms over 
inflammatory cysts. This shift could extend the life of the host, albeit at the cost of 
favoring the production of the non-transmittable trophic forms over the formation of 
cysts. 
 
3. What impact does the differential response to Pneumocystis life forms have 
on the outcome of the infection in various models of disease? 
Our data indicate that infection with trophic forms delays the initiation of innate 
and adaptive immune responses. Future studies should consider the role of trophic form-
mediated suppression in models of various types of immunodeficiency. We found that 
depletion of cysts from the lungs of RAG2-/- mice results in the formation of a small 
trophic population that does not cause overt symptoms of Pneumocystis pneumonia, 
including weight loss (Chapter 4). Linke et al., demonstrate that depletion of cysts 
reduced inflammation in a murine model of immune reconstitution inflammatory 
syndrome (24). However, the range of patients at risk for pneumocystis pneumonia 
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includes those suffering from a wide range of immunodeficiencies. Does trophic form-
mediated suppression increase the risk of developing PcP, or, in the event of PcP, does 
this suppression reduce inflammation-mediated lung damage in patients undergoing 
chemotherapy, or corticosteroid treatment? Is suppression of dendritic cell responses 
more successful in hosts with deficient B cell responses, such as those treated with anti-
CD40 antibody therapy? What is the role of trophic form-mediated suppression in 
HIV/AIDs patients before and after the initiation of HAART? Here, we demonstrate that 
infection with purified trophic forms leads to a delay in the initiation of immune 
responses in neonatal mice compared to an infection with a mixture of organisms 
(Chapter 3). What is the impact of trophic form-mediated suppression within the 
developing lungs of a neonatal host? It is possible that the trophic forms reduce 
inflammation-mediated lung damage in the lungs of immunocompromised hosts. 
However, trophic form-mediated suppression may permit the fungal population to expand 
in the absence of immune pressure. This may prove detrimental if the host develops or 
regains the ability to respond to the infection, as the increased fungal burden may worsen 
inflammation-mediated lung damage. Future studies will be required to explore these 
possibilities. 
 
4. What mechanisms overcome trophic form-mediated immune suppression? 
Here, we demonstrate that trophic forms are sufficient to induce protective CD4+ T 
cell and B cell responses leading to clearance of infection (Chapter 4). However, our 
data indicate that the initiation of these immune responses is delayed if cysts are absent in 
the inoculum (Chapter 3). Furthermore, we demonstrate that trophic form-loaded 
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dendritic cells are unable to prime CD4+ T cell responses in vitro. The populations of 
immune cells involved in overcoming this delay are unknown. It is possible that trophic 
forms may not suppress other innate cells as definitively as dendritic cells. For example, 
alveolar epithelial cells, macrophages, or neutrophils may be more adept than dendritic 
cells at producing proinflammatory cytokines in the presence of trophic forms. The 
generation of a local inflammatory environment may promote dendritic cell maturation 
and activation, leading to presentation of antigen in the draining lymph nodes and the 
initiation of immune responses. 
Research from other members of the Garvy lab indicates that trophic forms also 
suppress the ability of J774 and alveolar macrophages to express cytokines in response to 
mixed P. murina organisms. However, macrophages produce proinflammatory cytokines 
at an infectious dose of 10 mixed P. murina organisms per phagocyte, compared to the 50 
to 1 dose required to yield production of IL-1β and IL-6 by dendritic cells. In our hands, 
macrophages, but not dendritic cells, produce TNFα in response to mixed P. murina 
organisms. These data suggest that macrophages may either be more responsive to the 
cysts or less susceptible to suppression than dendritic cells. However, it should be noted 
that in Chapter 4, the long-term carriage of trophic forms in RAG2-/- mice (which lack B 
cells and T cells) failed to promote a substantial accumulation of TNFα in the BALF. 
Conversely, B cells may contribute to the initial activation of antigen-presenting 
cells in the lungs. Opata et al. demonstrate that B cells must be present during the first 
few days post-infection for effective priming of CD4+ T cell responses to mixed P. 
murina infection. This effect occurred independently of antibody production, indicating 
that B cells provide additional cues for T cell activation (124). B cells are a key source of 
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TNFα during the response to mixed Pneumocystis infection (125). Future studies may 
characterize the role of B cells in the activation of CD4+ T cells and effector cells in 
response to trophic forms. 
 
V. Conclusions 
Here, we propose that trophic forms broadly inhibit the ability of dendritic cells to 
fulfill their role as antigen-presenting cells by reducing the expression of cytokines, MHC 
class II, and costimulatory molecules. These data correspond with suboptimal CD4+ T 
cell proliferation and polarization in vitro, and delayed CD4+ T cell responses in vivo. 
The data presented herein provide compelling evidence for decades of Pneumocystis 
research to be revaluated in the context of interactions between the life cycle stages and 
the host immune response. The differential immune response to the life cycle stages of 
Pneumocystis shapes both the induction of protective responses and the development of 
inflammation-associated pathology. Manipulation of this balance may provide new 
options for the management and prevention of Pneumocystis infection, while a failure to 
consider this differential response may hinder future efforts. Further exploration of the 
interaction between trophic forms and the host may enhance our basic understanding of 
the pathways involved in immune activation and suppression. These pursuits may also 
fuel the discovery of novel anti-inflammatory therapies capable of broadly dampening 
cytokine production and antigen presentation. 
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Figure 6-1 Model of trophic form-mediated suppression of dendritic cell function. 
 
Trophic forms inhibit multiple components involved in antigen presentation by dendritic 
cells, including secretion of inflammatory cytokines and expression of MHC class II and 
costimulatory molecules on the cell surface. Furthermore, trophic forms suppress the 
expression of multiple genes related to activation and maturation in dendritic cells. 
Dendritic cells silenced by trophic forms are unable to induce CD4+ T cell responses in 
vitro. This corresponds with delayed innate and adaptive responses in vivo.  
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Appendix A: List of Abbreviations 
AIDS  Acquired immune deficiency syndrome 
BMDC  Bone marrow-derived dendritic cells 
CLR   C-type lectin receptor 
COPD  Chronic obstructive pulmonary disease 
ELISA  Enzyme-linked immunosorbent assay 
GM-CSF  Granulocyte-macrophage colony-stimulating factor 
HAART  High active antiretroviral therapy 
HIV   Human immunodeficiency virus 
IFNγ   Interferon gamma 
IG   Immunoglobulin 
IκB   NFκ-B inhibitor 
IL   Interleukin 
IRIS   Immune reconstitution inflammatory syndrome 
IT   Intratracheal 
ITAM  Immunoreceptor tyrosine activation motif 
J774   Macrophage cell line derived from murine tumor 
LPS   Lipopolysaccharides 
LTA   Lipoteichoic acid 
PAMP  Pathogen-associated molecular pattern 
MHC class II Major histocompatibility class II 
MIP   Macrophage inflammatory protein 
MR   Mannose receptor 
NFAT  Nuclear factor of activated T-cells 
NF-κB  Nuclear factor-κ light chain enhancer of activated B cells 
NLR   NOD-like receptor 
Pc   Pneumocystis 
PcP   Pneumocystis Pneumonia 
PRR   Pattern recognition receptor 
ROS   Reactive oxygen species 
SCID  Severe combined immune deficiency 
SIDS   Sudden infant death syndrome 
TGFβ  Transforming growth factor β 
Th   T helper 
TIR   Toll/interleukin-1 receptor 
TLR   Toll-like receptor 
TMP-SMX Trimethoprim-sulfamethoxazole 
TNFα  Tumor necrosis factor α 
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